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 Abstract  
 
Abstract 
Nontyphoidal Salmonella (NTS) are a major cause of fatal bacteremia in Africa. 
Developing a vaccine requires an improved understanding of the relevant mechanisms 
of immunity. Antibodies are important for protection against NTS in both man and 
mouse, and a potentially important role for antibody in cell-free complement-mediated 
bactericidal activity against Salmonella in Africans has been reported. We demonstrated 
that although BALB/c, C3H and C57BL/6 mice produced antibody responses to 
immunisations with an African invasive S. Typhimurium isolate and laboratory strains of 
S. Typhimurium, their sera failed to effect antibody-dependent complement-mediated 
killing against the African S. Typhimurium isolate. Supplementation with human 
complement showed that the lack of serum-killing was due to the weaker complement 
activity of mouse serum. Therefore, the protective effect of antibodies could be 
underestimated by the mouse model. 
 
To investigate the possibility that lack of serum-killing of NTS in the mouse influences 
bacterial spread from the blood, we created an in vitro model of Salmonella infection in 
human blood. Phagocytosis overlapped Salmonella survival in serum which allowed a 
proportion of Salmonellae to escape from complement-fixing bactericidal antibodies. 
However, remaining Salmonellae were deposited with membrane attack complex C5b-9 
and killed. While Salmonella serum-susceptibility varied with growth conditions and 
bacterial growth phase, serum had at least a bacteriostatic effect. Antibody-dependent 
complement-mediated bactericidal activity could stop sustained and fatal bacteremia 
developing in vivo. Antibodies alone might halt fatal development of the salmonellosis in 
the absence of a strong cellular immune response. The data is consistent with clinical 
descriptions of IFNγ-deficient patients who suffer from serious extra-intestinal, yet non-fatal 
NTS disease. 
 Abstract  
 
The description of inhibitory anti-O-antigen (OAg) antibodies in a subset of HIV-infected 
patients cast doubt on the suitability of OAg as a vaccine agent. We used a range of invasive 
African Salmonella isolates, laboratory Salmonella strains and Salmonella LPS mutants to 
adsorb human serum in order to investigate the targets of bactericidal complement-fixing 
antibodies. Adsorption with wild type Salmonellae produced an effective serovar-specific 
removal of both antibodies and bactericidal activity, without adversely affecting the activity of 
complement. In contrast, mutants that lacked OAg failed to remove Salmonella serovar-
specific antibodies and killing against their parent strains. S. Typhimurium and S. Enteritidis 
OAg chimera strains, expressing either native or heterologous OAg (O:4 or O:9) 
demonstrated that OAg, and not serovar, was the principal determinant of the ability of 
Salmonellae to remove specific antibodies and serum-killing. These data indicate that anti-
OAg antibodies are major effectors of complement-mediated killing of invasive African 
nontyphoidal Salmonella by normal human serum. This supports the development of an OAg 
based vaccine. 
 
We used transmission electron microscopy to explore the mechanism of inhibition in some 
HIV-infected sera. Consistent with viable counts from serum bactericidal assays, HIV-
infected inhibitory serum showed substantially less damaged and lysed cells than 
bactericidal serum. IgG, complement component C3 and C5b-9 were all observed on both 
the outer and inner membranes, as well as distal sites from the bacterial membrane of 
Salmonellae in both inhibitory and bactericidal sera. However, whereas damaged 
Salmonellae all had C3 and C5b-9 deposition on the OM, many healthy cells did not. 
Bactericidal serum deposited greater quantities of C3 and also C5b-9 on the Salmonellae 
than inhibitory serum. This suggests that the failure of inhibitory serum to kill Salmonellae is 
due to a reduced ability to deposit bactericidal complement. 
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1.  Introduction  
1.1  Theme and overview 
The main theme of this thesis is the potential role of bactericidal antibody and 
complement in immunity against nontyphoidal Salmonellae (NTS). Investigated within 
are: the kinetics of the antibody-dependent complement-mediated killing in vitro; 
influence of growth conditions of bacteria on their sensitivity to this killing; the relevance 
of this modality of immunity in mice models; the mechanism by which it achieves killing 
of NTS; and the antigen targets of such bactericidal antibodies. 
 
This chapter will discuss Salmonella, the diseases it causes and their epidemiology, its 
pathogenesis and the immune responses involved in control and protection from 
infection. In addition, the current situation regarding vaccines and potential future 
vaccines for Salmonellae is addressed. Finally, the specific aims and hypotheses of this 
study are detailed. 
 
1.2 Salmonella 
Salmonella is a genus of rod shaped, Gram-negative, non-spore forming and 
predominately pathogenic bacteria of the Enterobacteriaceae family. Salmonellae are 
approximately 0.5 to 1.5 µm wide and 1 to 5 µm in length and are facultative intracellular 
organisms (Fields et al., 1986) that are mostly motile, due to flagella which project in all 
directions. Salmonellae are chemoorganotrophs, obtaining energy from oxidation and 
reduction reactions using organic sources, and are facultative anaerobes.  
 
1.2.1 Taxonomy 
The nomenclature is complicated and has developed greatly over the last 40 years. 





by the World Health Organisation (WHO) (Grimont, 2007). There are two recognised 
species: S. enterica and S. bongori, which are thought to have diverged from a common 
ancestor with Escherichia coli around 100 million years ago (Doolittle et al., 1996). S. 
bongori is predominantly associated with cold-blooded animals, it shares a basic set of 
ancestral Salmonella virulence genes with S. enterica but lacks many genes important 
for infection in humans. However, infection in man is possible and has been recorded 
(Nastasi et al., 1999). In evolutionary terms, S. bongori likely lies between E.coli and S. 
enterica (Fookes et al., 2011). S. enterica has six subspecies: enterica (I), salamae (II), 
arizonae (IIIa), diarizonae (IIIb), hotenae (IV), and indica (VI). Within these six 
subspecies are over 50 serogroup classifications defined by the carbohydrate structures 
found in lipopolysaccharide (LPS), and over 2,500 serovars distinguished by flagella 
antigens (Popoff et al., 2004, Grimont, 2007). Serovar designation is commonly 
shortened in the literature (and herein). For example, the full designation of Salmonella 
enterica subspecies enterica serovar Typhimurium commonly becomes simply ‘S. 
Typhimurium’. S. enterica subspecies enterica contains the vast majority of medically 
important pathogens as well as those that affect farming industry, serovars such as S. 
Enteritidis, S. Paratyphi, S. Typhi and S. Typhimurium (Su and Chiu, 2007, Jones et al., 
2008). 
 
1.2.2 Salmonellae as pathogens 
S. enterica infections are generally acquired through the faecal-oral route and most 
commonly take on the form of one of three diseases: enteric fever, bacteraemia or 
enterocolitis. Chronic asymptomatic carriage is also possible (Coburn et al., 2007). The 
form of disease is dependent on the serovar, the host species and the host’s immune 
state. Salmonellae display a varying degree of host restriction at the serovar level. Some 





confined to one host species, whereas other serovars are ‘promiscuous’ and can infect a 
range of species. These generalist serovars, such as S. Typhimurium, cause a greatly 
differing ‘typical’ disease dependent on host. In genetically susceptible SLC11A1s 
(previously NRAMP-1) mice, S. Typhimurium infection causes a fatal enteric fever with 
symptoms similar to those observed after infection of humans with S. Typhi (Eisenstein, 
1999). Whereas in man it mostly results in a self-limiting diarrhoeal disease (Jones et al., 
2008, Zhang et al., 2003), typically an enterocolitis, with a lack of gastritis (Boyd, 1985). 
NTS are one of the most common causes of death from diarrhoeal diseases associated 
with microorgansims in the US (Olsen et al., 2000, Lynch et al., 2006). More rarely in 
man the infection can become systemic.  
 
Invasive NTS disease was first recognised in American children in the 1950s (Saphra 
and Winter, 1957). The problem became apparent in adults, with the onset of 
opportunistic NTS infections in AIDS patients in Africa during the 1980s (Feasey et al., 
2010, Clumeck et al., 1983). Since then, culture-based surveillance for invasive bacterial 
infections in sub-Saharan Africa identified that NTS infections rivalled Haemophilus 
influenzae type b (which is now increasingly controlled by widening implementation of an 
effective vaccine (Gessner, 2009)) and Streptococcus pneumonia infections in 
frequency and severity amongst children (Graham et al., 2000b, Morpeth et al., 2009). A 
recent meta-analysis of the whole of Africa found that over 15% of all child bloodstream 
infections were due to NTS (Reddy et al., 2010). Despite this, invasive NTS (particularly 
among the HIV-infected), is currently an under-recognised emerging infectious disease 








1.3 Epidemiology and outline of nontyphoidal Salmonella infections 
1.3.1 NTS in the developed world 
NTS are the leading cause of foodborne disease outbreaks in the USA (Mead et al., 
1999, Olsen et al., 2000). They cause an estimated 1.4 million illnesses in the United 
States each year, resulting in an estimated 15,000 hospitalisations and 400 deaths 
(Voetsch et al., 2004). This translates to an economical cost of $0.5–2.3 billion annually 
in medical care, lost productivity and mortality (Frenzen et al., 1999). Worldwide, the 
annual global burden of NTS diarrhoeal disease is estimated to be around 94 million 
cases with over 150,000 deaths (Majowicz et al., 2010).  
 
Salmonella infection of humans in industrialised countries is generally a foodborne 
zoonosis (Espie et al., 2005, Varma et al., 2005). The symptoms of NTS enterocolitis 
normally appear 12 to 72 hours after ingestion, and include fever, diarrhoea, abdominal 
cramps, nausea, and occasionally vomiting, though asymptomatic infections can occur. 
The illness lasts from between 4 and 7 days and the vast majority of cases typically 
resolve without treatment (Gill and Hamer, 2001). Systemic infections, such as 
bacteraemia, are infrequent (~5%) and generally confined to immunodeficient patients 
(Hohmann, 2001, Jones et al., 2008).  Infection in children is commonly more severe 
and carries an increased risk of invasive complications, though bacteraemia in young 
children typically has an excellent outcome (Zaidi et al., 1999). Antibiotic treatment is 
required in neonates as a prophylaxis to prevent invasive disease (Coburn et al., 2007).  
 
The prevalence of serovars varies dependent on location and some are even limited to 
certain regions of the world (Galanis et al., 2006). Worldwide, S. Enteritidis and S. 
Typhimurium cause the majority of human clinical cases, although globally the overall 
proportion for both serovars has decreased over time. Currently infections with S. 





(Hendriksen et al., 2011). The proportion of infections with serovars S. Choleraesuis and 
S. Dublin that result in invasive disease is around ten times higher than the average for 
NTS infections (Jones et al., 2008). However, because of the small number of total 
cases, these results might simply be due to particularly virulent strains rather than 
demonstrating serovar as a risk factor for invasive disease. In addition, in terms of 
overall cases S. Typhimurium and S. Enteritidis are also the most common causes of 
invasive disease in the US (Jones et al., 2008). 
 
1.3.2 NTS in Africa 
The World Health Organization (WHO) estimates that diarrheal diseases result in an 
estimated 2–3 million annual deaths among children in developing countries. However, 
in contrast with the spectrum of NTS disease in developed countries, NTS are also a 
leading cause of severe and invasive disease amongst children and 
immunocompromised individuals in sub-Saharan Africa (Reddy et al., 2010). They are 
estimated to be one of the most common causes of bacteraemia in Africa with case 
rates in excess of 500 000 per year (Morpeth et al., 2009). Presentation of NTS 
bacteraemia most commonly occurs in children below 2 years old (Brent et al., 2006, 
Graham et al., 2000b) and HIV-infected adults (Gordon, 2008).  
 
Serovars S. Typhimurium and S. Enteritidis are the most frequent cause of bacteraemia 
in Malawi and much of tropical Africa (Brent et al., 2006, Graham et al., 2000b).  Figure 
1.2 shows countries in which NTS has been reported as a major cause of childhood 
bacteraemia. It should be noted that the appropriate studies have not been carried out in 
many African countries and so occurrence is likely to be even more widespread. Clinical 
NTS isolates from African cases of salmonellosis are different to those found in animal 
contacts, suggesting human-to-human spread of infection (Kariuki et al., 2002, Kariuki et 





Genotype of Salmonella is not normally considered a risk factor. However, in Africa, 
multilocus sequence analysis of S. Typhimurium causing invasive infections in Malawi 
and Kenya has identified an overwhelming dominant type, termed ST313, which is rarely 
reported outside of Africa. Whole genome analysis of one of the most common African 
S. Typhimurium isolates, D23580, revealed a distinct prophage repertoire and a 
composite genetic element encoding multi drug resistance genes. In addition, there was 
genome degradation involving some genes previously implicated in S. Typhimurium 
virulence. A number of these chromosomal deletions and pseudo-gene formations 
involved genes which are either non-functional or absent in the systemic invasive 
pathogen, S. Typhi (Kingsley et al., 2009). These factors could point towards a more 
invasive genotype of S. Typhimurium as a risk factor for invasive disease. But, it may 
simply be a case that this genotype is the most common in the area and so therefore 
causes the greatest amount of invasive disease. Epidemiological studies of diarrhoeal 
Salmonella disease in Africa would help clarify the situation, though comprehensive data 
is not yet available. 
 
As well as bacteraemia, invasive NTS disease can present as meningitis, pneumonia or 
septic arthritis (Graham, 2002). Indeed, NTS are the second most common cause of 
neonatal meningitis in Malawi (Molyneux et al., 2000). Symptoms of NTS bacteraemia 
may include fever, vomiting, cough and diarrhoea, but there is frequently an absence of 
gastrointestinal symptoms (Graham et al., 2000b). The lack of specific clinical 
presentation of NTS bacteraemia makes diagnosis difficult (Graham et al., 2000b). Often 
only a fever is present and so NTS bacteraemia is commonly misdiagnosed as malaria. 
Almost half of all NTS disease cases seen fulfil the WHO criteria for pneumonia 
diagnosis, a diagnosis for which antibiotics ineffective against many strains of antibiotic-





ampicillin, chloramphenicol, streptomycin, and sulphonamides has been reported in NTS 
across the world. It developed countries where there is greater use of antibiotics, 
resistance is very common and widespread (Vandenberg et al., 2010, Morpeth et al., 
2009). In addition, development of resistance to quinolones and third-generation 
cephalosporins has been identified in numerous locations (Chimalizeni et al., 2010).  
 
Case fatality rates from NTS bacteraemia in Africa are as high as 24% in children and 
around 50% in HIV infected adults, even when culture facilities and appropriate 
antibiotics are available (Brent et al., 2006, Graham et al., 2000b). The majority of those 
who die do so during their acute hospital admission. These time-restraints mean the 
current ‘gold standard’, diagnosis of blood culture is far from ideal because it is a 
relatively slow process. There is no available vaccine against NTS for use in humans. 
Increasing development of multidrug resistance to NTS (Graham, 2002), a lack of new 
targets for drug development (Becker et al., 2006) and current treatment difficulties 
highlight the pressing need for a vaccine. For this an understanding of protective 
immune mechanisms against NTS bacteraemia is needed.  
 
1.4 Risk factors of invasive disease 
The incidence of invasive NTS disease in Africa is much higher than that in Europe or 
North America. The strongest data currently available suggest the primary reason is due 
to host factors. It is probable that pathogen and environmental aspects also contribute. 
A number of clinical associations have been reported, including: HIV (Gordon, 2008, 
Gordon et al., 2002), malaria (Graham et al., 2000a), severe anaemia (Brent et al., 
2006), malnutrition (Graham et al., 2000c), and sickle cell anaemia (Williams et al., 
2009). Young age is also a significant risk factor (Graham et al., 2000c). All of the 





they may help to explain the geographical disparity seen in systemic disease. Whether 
these clinical risk factors are co-existent or causative is not always known. 
 
1.4.1 Young age as a risk factor 
Children and infants <2 years old are particularly at risk for invasive NTS disease (Fig 
1.1) (Walsh et al., 2000, Gordon et al., 2008, Berkley et al., 2005, Sigauque et al., 2009, 
Brent et al., 2006). Young age is also associated with an increased risk of death 
(Graham et al., 2000b).  A study of around 350 cases of NTS bacteraemia between 
2003 and 2004 in Malawi showed NTS was commonest among young children under 24 
months (MacLennan et al., 2008). These data also showed a relative sparing  
of infants less than 4 months old. This sparing is notable as maternal IgG aids immunity 
during this period. Sera from children under 16 months old lacked Salmonella-specific 
antibody and failed to kill NTS, whereas sera from older children both contained this 
antibody and killed NTS. These results for age-incidence and serum-killing of NTS 
suggest that antibody is important in immunity against NTS. The absence of Salmonella-
specific antibodies in young children could be a key factor in the prevalence of invasive 
NTS disease in this age group. However, because invasive salmonellosis is much less 
common in developed countries, other risk factors are likely, for example increased 
exposure due to environmental factors. 
 
1.4.2  Malaria and Severe anaemia as a risk factors   
A link between invasive Salmonella infections and malaria was originally reported in the 
late 1920s in Africa (Giglioli, 1929). Since then further studies have strengthened the 
association of NTS bacteraemia and malarial parasitaemia (Mabey et al., 1987) 
(Graham et al., 2000). These concurrent infections with malaria and NTS lead to 





Severe anaemia, in which plasma haemoglobin levels are lower that 5g dl
-1
, is strongly 
linked with NTS in African children (Brent et al., 2006, Bronzan et al., 2007) (Mabey et 
al., 1987, Calis et al., 2008). Malaria is a common cause of severe anaemia in tropical 
African countries (Biemba et al., 2000). Severe anaemia that can develop due to malaria 
infection may be a key reason for the association between malaria and NTS (Bronzan et 
al., 2007, Graham et al., 2000). Malaria infection results in haemolysis, which prompts 
host cell production of heme oxygenase-1 (HO-1). HO-1 production could be important 
for protection against malaria (Seixas et al., 2009). However, HO-1 has recently been 
reported to increase susceptibility to NTS bacteraemia, probably through suppression of 
oxidative burst in granulocytes (Cunnington et al., 2012). 
 
As well as the effect of anaemia, Roux and colleagues recently reported that malaria 
parasite-specific factors contributed prominently to the increased systemic dissemination 
and/or replication of S. Typhimurium in mice with malaria (Roux et al., 2010). Malaria 
infection leads to an inhibition of Fc receptor-mediated phagocytosis, a system that is 
potentially important in immunity against NTS (Graham et al., 2000a). Moreover, patients 
with malaria are known to have lower levels of complement with lessened haemolytic 
activity (Nyakoe et al., 2009). These factors could increase the likelihood of invasive 
bacterial infection (Morgan and Walport, 1991). Studies in the mouse have shown that 
antibody-induced haemolysis prior to infection with S. Typhimurium results in a more 
rapid death of the mice (Kaye and Hook, 1964, Kaye et al., 1967). This is probably due 
to enhanced erythrophagocytosis of parasitised and non-parasitised red cells interfering 
with anti-microbial macrophage functions (Schwarzer et al., 1992, Gill et al., 1966, Kaye 



















Figure 1.1: Cases of NTS bacteraemia in Malawian children 352 cases of blood 
culture-confirmed NTS bacteraemia by age among children reported at QECH, Blantyre, 
Malawi between 2003 and 2004. (Figure taken from MacLennan et al., J Clin Inv. 2008) 
 
 
1.4.3 HIV-infection as a risk factor 
As stated in section 1.2.2, the link between Salmonella infections and HIV-infection and 
AIDS has been known since the early 1980s (Clumeck et al., 1983). Since then 
numerous studies have strengthened this association (Gilks et al., 1990, Gilks, 1998, 
Gordon et al., 2001, Kiratisin, 2008). The association is so strong that recurrent invasive 
NTS infection is a WHO determinant of HIV/AIDS stage IV and requires commencement 
of anti-retroviral therapy (Hung et al., 2007).  A HIV-infected adult with a CD4 count of 
less than 200/µl is around 50 times more likely to have invasive NTS disease than an 





invasive NTS in HIV-infected patients has been reported to be up to 100 times higher 
than in the general population (Gruenewald et al., 1994). 
 
HIV-infection causes the death of CD4+ T cells and macrophages which results in 
severe suppression of cell-mediated immunity. It is thought that this immunosuppression 
leads to increased susceptibility to NTS infections in HIV-infected patients (Celum et al., 
1987). Studies using rhesus macaques reported that T helper type 17 (TH17) responses 
were prominent in response to NTS infection. Prior infection of monkeys with simian 
immunodeficiency virus was detrimental to the TH17 response and resulted in an 
increased systemic dissemination of S. Typhimurium from the gut (Raffatellu et al., 
2008). 
 
In addition to suppression of cell-mediated immunity, dysregulation of humoral immunity 
may contribute to the susceptibility of HIV-infected patients to invasive NTS. High titres 
of antibodies that inhibit serum-killing of NTS in vitro have been identified in a proportion 
of HIV-infected patients and could play a role in increased NTS incidence among HIV-
infected patients (Maclennan, 2010). Interestingly, the co-incidence of invasive NTS 
disease and HIV infection in children is of a much lower proportion than in adults 
(Graham et al., 2000c), though comprehensive data is not yet published on this matter.  
 
1.4.4 Environmental factors 
Perhaps the most important environmental factor that may contribute to invasive NTS 
disease is water sanitation. The source and transmission of NTS in Africa is unknown. 
Though, as no animal food sources have been identified (Kariuki et al., 2006a, Kariuki et 
al., 2006b) contaminated water and human to human spread are likely to be important.  





particularly during wet seasons. The observation that NTS infection rises during the rainy 
season is consistent with this. Though, the incidence of diseases that are associated 
risks for NTS disease, such as malaria and malnutrition also peak in this period (Gordon, 
2008, Brent et al., 2006, MacLennan et al., 2008).  
 
1.4.5  Pathogen factors 
As discussed in sections 1.3.1 and 1.3.2, Salmonella genotype is not typically 
considered a risk factor in invasiveness of NTS, but there is limited data to suggest it 
may play a role. Some researchers believe the presence of spv genes are a possible 
contributor to the ability of Salmonella to cause invasive disease (Guiney and Fierer, 
2011, Fierer, 2001, Fierer et al., 1992). All isolates of serovars S. Dublin and S. 
Choleraesuis have the highly conserved spv operon that is encoded on virulence 
plasmids that are otherwise unique to each serovar (Gulig et al., 1993). The most 
important virulence gene in the operon is spvB, an ADP-ribosylating toxin that targets G-
actin and prevents polymerisation to F actin in macrophages, thereby disrupting the 
actin cytoskeleton (Lesnick et al., 2001). It has previously been reported that clinical 
isolates of S. Typhimurium from blood cultures are twice as likely to carry spv genes as 
are isolates from stool (Fierer et al., 1992), although other groups have not found this 
(Chiu et al., 2000a). In experimental mice, mutation of spvB decreases the LD50 of 
isogenic strains as much as 1000-fold (Gulig and Curtiss, 1987). Serovars S. 
Abortusovis and S. Gallinarum  also carry the virulence plasmid yet are not associated 
with invasive infection in humans (Rychlik et al., 2006) and it is likely that chromosomal 
genes are more important in determining both serovar specificity and type of infection 







1.5  Pathogenesis of infection 
1.5.1 Systemic infection 
In vivo studies of S. Typhimurium infection in genetically susceptible SLC11A1
s
 
(previously NRAMP-1) mice have given insights into the likely pathogenesis of 
Salmonella. Following ingestion, Salmonellae that survive the low pH of the stomach 
reach the small intestine. Here they adhere to and colonise the epithelium before 
crossing the intestinal barrier. There is controversy over the exact route S. Typhimurium 
takes after ingestion, but the ingested Salmonellae seem to either invade epithelial or M 
cells or alternatively are engulfed by resident macrophages in the submucosa (Clark et 
al., 1996, Jepson and Clark, 2001). The coordinated activity of Salmonella pathogenicity 
island 1 (SPI-1) type III secretion system (T3SS) (TTSS-1) effector proteins induces 
bacterial uptake by activating intracellular signalling cascades and cytoskeletal 
machinery (Coburn et al., 2005).  
  
Salmonellae moving into gut-associated lymphoid tissue spread into the lymph via the 
circulatory system which leads to a transient bacteraemia. This primary bacteraemia is 
rapidly cleared by CD18+ phagocytes to reach an intracellular location in the bone-
marrow, spleen or liver (Biozzi et al., 1960, Dunlap et al., 1991, Worley et al., 2006). 
These phagocytes are able to kill the Salmonella and there is an initial net reduction in 
Salmonellae number. However, Salmonellae are capable of intracellular survival within 
phagocytes and, by preventing normal formation of the phagosome, survive and 
replicate in the protected environment of the Salmonella-containing vacuole (Salcedo et 
al., 2001). The Salmonellae then instigate phagocyte death (Hueffer and Galan, 2004), 
which allows escape and infection of a new phagocyte. SPI-2 is crucial for systemic 
infection in the mouse (Hensel et al., 1995) because it directs the evasion of the anti-



















Figure 1.2: African countries in which NTS has been reported as a major cause 
of paediatric bacteraemia. Occurrence is likely to be more widespread than 





Within 24 hours there is development of the infection to a second phase, in which 
Salmonellae numbers in the aforementioned organs increase. Salmonella levels in 
individual infected phagocytes remain low as the infection progresses; instead the 
increase translates to an increase in the number of infected foci (Mastroeni et al., 2009, 
Mastroeni and Sheppard, 2004, Sheppard et al., 2003). Eventually, the growth leads to 
onset of a third infection phase, occurring within 72 hours and signalled by the 
development of a secondary bacteraemia and endotoxic shock which kills the mouse 
(Mittrucker and Kaufmann, 2000).  
 
Whether systemic S. Typhimurium infection in Africans follows the same progression as 
in mice is unknown. However, the fact that children with NTS bacteraemia typically have 
detectable anti-Salmonella IgG and IgM by the time of admission to hospital, in contrast 
to healthy children of the same age who tend to lack such antibody (MacLennan et al., 
2008) suggests that the infection has developed over a number of days, as opposed to a 
rapid onset of bacteraemia. 
 
1.5.2 Enterocolitis infection pathogenesis 
As NTS does not naturally cause enterocolitis in mice, most work on Salmonella 
intestinal disease has been performed on bovine ileal loop inoculations and cultured 
intestinal epithelial cells (Coburn et al., 2005). Recently, a mouse enterocolitis model 
that uses pre-treatment of mice with streptomycin has been developed and may allow a 
furthering of understanding of the disease in humans (Barthel et al., 2003). 
 
SPI T3SS effector proteins SipA, SopA, SopB, SopD, and SopE2 are required for 
eliciting inflammation and infiltration of neutrophils in the calf model of enterocolitis 





(McCormick et al., 1995). Just as in the development of systemic disease, invasion of 
epithelial cells is important in establishing an infection and entry into these cells is 
facilitated by T3SS-1 (Coburn et al., 2007). Full activation of T3SS-1 requires contact of 
the host-cell and bacterium. Critical saccharide residues of the outer core play different 
roles in the early interactions of serovars S. Typhi and S. Typhimurium with epithelial 
cells (Bravo et al., 2011). Inflammation occurs at the site of disease, namely the ileum, 
though often also the colon and occasionally in the stomach (Boyd, 1985, Coburn et al., 
2005).  Neutrophil recruitment begins within 1-3 hours of infection, and is associated with 
necrosis of the ileal mucosa (Zhang et al., 2003). Around 7 hours later, the injury to the 
intestinal epithelium leads to leakage of high protein exudates and massive 
transmigration of neutrophils into the intestinal lumen, a process normally prevented by 
the epithelial permeability barrier. Diarrhoea starts around 8-72 hours after bacterial 











Figure 1.3 Multiple infection routes of Salmonella in mouse.  
Following ingestion, Salmonellae adhere to the epithelium surface before crossing 
through, M cells, or through dendritic cells, or directly through enterocytes. From here they 
enter the mesenteric lymph nodes and then the efferent lymph, gaining access to the 
circulatory system. Phagocytes clear the bacteria from the blood and the bacteria 
colonises the spleen and liver. Some Salmonellae are carried directly from the intestinal 
lumen to the liver and spleen by CD18
+
 phagocytes via the bloodstream. After a period of 
control by phagocytes, the infection overwhelms the host defences and gives rise to a 
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1.6 Salmonella virulence and resistance to killing 
Salmonellae have approximately 4500 genes, and over 100 of these genes have been 
implicated in virulence (McClelland et al., 2001, Parkhill et al., 2001). A wide range of 
genes are required to establish an infection within a host, for example those involved in 
metabolism and biosynthesis (Hindle et al., 2002). During infection, Salmonellae deploy 
numerous mechanisms to evade the host immune system and they also can manipulate 
immune cell functions. They possess resistance against innate immune mechanisms 
and can avoid killing by macrophages and dendritic cells (DCs) (Jantsch et al., 2011). In 
addition, Salmonellae can prevent the formation of an efficient adaptive immune 
response by interfering with antigen presentation by DCs (Wick, 2004, Wick et al., 1995) 
and by directly inhibiting the proliferation of naive T cells by down-modulating T cell 
receptor expression on T cells (van der Velden et al., 2008). 
 
1.6.1  Salmonella pathogenicity islands 
The Salmonella pathogenicity islands (SPIs) encode a large number of important 
virulence genes, including virulence factors and the machinery for their secretion. 
Pathogenicity islands are products of horizontal transmission from other bacteria, 
indicated by their differing G+C content (Hensel, 2004). SPIs carry one or more 
virulence-associated genes and can occupy relatively large regions of the chromosome, 
ranging from 10 kb to more than 100 kb. They are common features of Gram-negative 
pathogens, but are notably lacking from related non-pathogenic species (Gal-Mor and 
Finlay, 2006). Salmonellae have numerous recognised SPIs, currently it is thought there 
are at least 17 (Vernikos and Parkhill, 2006). SPI-1 and 2 are the most comprehensively 
studied and have strong links to virulence, whereas little is known about the other SPIs.  
SPI-1 is present in both Salmonella species (Ochman and Groisman, 1995) and its main 





encodes a TTSS that transports bacterial effector proteins into the cytosol of host cells, 
resulting in cytoskeletal rearrangements that mediate uptake of the Salmonella into a 
membrane bound vesicle (Galan, 1999). In the mouse, SPI-1 mutants are attenuated for 
oral but not systemically administered infection (Galan and Curtiss, 1989). 
 
SPI-2 is present in S. enterica but not S. bongori, placing its likely acquisition date after 
that of SPI-1 (Hensel, 2004). SPI-2 mutants are profoundly attenuated in mice, failing to 
proliferate in the spleen or liver (Hensel, 2000). SPI-2 also encodes TTSS apparatus 
and is involved in modifying the intracellular environment of host cells by impairing 
trafficking of important mediators of oxidative (Vazquez-Torres et al., 2000) and 
nitrosative burst (Chakravortty et al., 2002) and as such enhances the survival of 
Salmonella within phagocytes. SPI-2 further aids survival within macrophages by 
directing the formation and maturation of the Salmonella containing vacuole (SCV). The 
SPI-2 encoded protein SpiC inhibits the fusion of SCV with lysosomes and endosomes 
(Uchiya et al., 1999) and another SPI-2 gene product, SifA, is required for the SCV 
membrane integrity (Waterman and Holden, 2003). As well as offering protection from 
innate immunity, SPI-2 helps Salmonellae to evade aspects of the adaptive immune 
system by inhibiting antigen presentation and T cell activation by dendritic cells (Bueno 
et al., 2008, Tobar et al., 2006).  
 
1.6.2  Lipopolysaccharide 
Despite the focus on cell-mediated immunity to Salmonella, resistance to complement-
mediated killing is a recognised virulence trait of Salmonella (Taylor, 1983) and LPS is 
an important determinant of this virulence. LPS can activate the classical and alternative 
pathways, and in some cases also the lectin pathway (Rautemaa and Meri, 1999). The 
length of LPS O-antigen (OAg) can influence interaction with complement and 





(Murray et al., 2003) and growth-phase dependent regulation of LPS OAg influences 
serum resistance (Bravo et al., 2008). Size and distribution of LPS OAg can determine 
serum resistance (Grossman et al., 1987). Rough O-Ag deficient mutants are attenuated 
in mice (Ilg et al., 2009) and such strains show more bound complement than wild type 
strains which possess OAg (Rautemaa and Meri, 1999). Deposition of MACs in a unique 
location that doesn’t lead to killing has been suggested as a mechanism by which 
Salmonellae confers resistance to serum-killing (Joiner et al., 1989). It has been also 
been hypothesised that lesions formed on the bacterial surface might not directly induce 
killing unless they are formed at precise targets, such as where the inner membrane is 
bound tightly with the outer membrane (Taylor, 1983). It is possible that LPS OAg 
prevents access of complement to these unique locations. Alternatively antibodies 
specific to LPS OAg might form an ‘umbrella’ which prevents binding of bactericidal 
antibody to the outer membrane (Maclennan, 2010). 
 
1.6.3  Plasmid encoded outer membrane proteins 
In addition to LPS, many Salmonellae have membrane proteins, mostly encoded by the 
virulence plasmid (pSLT), that serve as virulence factors by resisting complement killing 
and other antimicrobial defence systems. TraT increases resistance to complement-
mediated killing, likely by interfering with MAC assembly and insertion (Rhen and 
Sukupolvi, 1988); outer membrane protein Rck prevents formation of fully polymerised 
tubular MACs (Heffernan et al., 1992);  and the surface protease PgtE proteolytically 
cleaves C3b, C4b and C5, enhancing bacterial resistance to human serum (Ramu et al., 
2007).  
 
1.7  Regulation of virulence factors during infection 
Changes from an extracellular to intracellular environment, such as after phagocytosis, 





has reported that almost 1000 genes are altered in regulation in response to a 
phagosomal environment inside phagocytes. Driven by these changes is an extensive 
surface remodelling of the bacteria (Prost et al., 2008). Factors that are recognisable by 
the host immune system such as the SPI-1- T3SS and flagellin, are down-regulated by 
the bacteria (Trent et al., 2001). The LPS structure is also altered, OAg repeat length is 
reduced and the number of acyl chains in lipid-A structures is changed. Changes are 
made to the protein content of both the outer membrane and inner membranes. As well 
as an alteration of structure, there is also up-regulation of the synthesis of enzymes that 
allow the bacteria to cope with oxidative and nitrogen-intermediates, which prepare the 
bacterium for survival in an intracellular environment (Jantsch et al., 2011). 
 
Intracellular Salmonellae use a needle complex, the T3SS, consisting of more than 20 
proteins to secrete effector proteins from their own cytosolic compartment across three 
membranes and directly into the cytosol of the host cell (Galan and Wolf-Watz, 2006). 
To prevent production of this intracellular tool in inappropriate environments whih would 
waste the bacterium’s resources, the system is regulated by pH. By sensing sequential 
changes in pH the bacterium can coordinate its production to be most efficient. Upon 
entry into a host cell, the acid pH prompts the assembly of the T3SS needle complex, 
however, three regulatory proteins: SsaL, SsaM, and SpiC form a complex and prevent 
secretion of effector proteins. Pore-forming translocon proteins are released which allow 
the Salmonellae to create a holes in the vacuolar membrane of the cell and sense the 
neutral pH of the cytosol. This prompts disassembly of the regulatory protein complex 
and allows the secretion of bacterial effector cells into the cytosol (Yu et al., 2010). 
 
1.7.1 Transcriptional regulation 
In response to environmental factors, transcriptional regulation can change gene 





tuning gene expression in response to environmental factors, transcriptional regulation 
determines the molecular machinery to maintain homeostasis and aid adaptation 
(Reviewed in (Balleza et al., 2009)). There are numerous mechanisms by which this is 
achieved, including protein molecules that either stimulate or inhibit gene expression by 
binding to specific operator or enhancer sequences. The lac repressor is an example of 
this and ensures that the bacteria only invest energy into metabolism of lactose when 
lactose is available (Gilbert and Muller-Hill, 1966).  
 
1.7.2 Two-component systems 
Two-component systems are the most common form of signal transduction enabling 
bacteria to regulate cellular behaviour in response to their environment. In a two-
component system a sensor histidine kinase responds to specific signals by altering the 
phosphorylation of a response regulator protein. Binding of a specific ligand promotes 
conformational changes in the sensor protein that can potentially alter three enzymatic 
activities: autophosphorylation from ATP, transfer of the phosphoryl group to its cognate 
regulator, and dephosphorylation of the phosphorylated cognate regulator (Stock et al., 
2000, Casino et al., 2009). Most response regulators are DNA-binding transcription 
factors whose affinities for their target promoters are altered by phosphorylation. 
Through changing the phosphorylated state of a response regulator, a signal can gene 
expression profile of an organism (Kato and Groisman, 2004). The PmrA/PmrB and 
PhoP/PhoQ are two prominent examples of two-component systems in Salmonella. 
 
1.7.3  PhoP/Q regulation  
A major regulator of Salmonella gene expression, particularly genes that may be 
involved in virulence, is the PhoP/PhoQ two component regulatory system. It regulates 
expression of at least 40 genes, including 15 genes encoding outer membrane 





so is important for survival inside macrophages (Fields et al., 1986). Furthermore, it has 
a role in inducing macrophage apoptosis (Detweiler et al., 2001) and interferes with the 
presentation of antigens by phagocytes (Wick et al., 1995). As well as being involved in 
Salmonella:phagocyte interactions, PhoP/Q is implicated in active invasion of 
enterocytes (Behlau and Miller, 1993). Further to this, it has a role in LPS regulation; an 
NTS mutant constitutively expressing PhoP had reduced quantities of OAg (Guo et al., 
1997). The enzymes that make lipid substitutions on the core galactosamines of 
Salmonella are also regulated by PhoP/Q (Guo et al., 1997). Finally, its involvement has 
been reported in regulation of resistance to acidic pH (Foster and Hall, 1990) and 
antimicrobial peptides (Fields et al., 1989). 
 
1.7.4  Phase and antigen variation 
Phase variation was first described in Salmonella flagellar antigens (Andrewes, 1922) 
and involves the variation of protein expression in an on-off fashion by genetic or 
epigenetic alterations at specific loci (Henderson et al., 1999). Phase variation is 
generally a random event and switches in expression (of certain phenotypes) occur at 
higher frequencies (>10
−5





 per cell per generation) (Wisniewski-Dye and Vial, 2008). Antigen 
variation is the expression of one of a number of alternative surface phenotypes. Phase 
variation and antigen variation share certain features at the molecular level. Both result 
in phenotypically heterogeneous populations and are used by numerous bacterial 
species to increases bacterial fitness. In the context of infection, it can facilitate evasion 
of specific antibodies and immune responses and contribute to virulence (Ikeda et al., 
2001) (Reviewed in (van der Woude and Baumler, 2004)). Phase-variable expression 
mainly occurs in surface-exposed proteins or proteins that modify or regulate surface 





Salmonellae also show variation in expression of fimbriae (Nicholson and Low, 2000, 
Clegg et al., 1996) and pill (Morris et al., 2003). 
 
Noise in gene expression can result in differences in expression in genetically identical 
cells (Raser and O'Shea, 2005). The resultant population of different phenotypes can 
offer an overall advantage to bacteria. For Salmonella infection, this effect could 
promote the formation of cooperative sub-populations that die while preparing the 
ground for a successful infection; indeed such a model has been experimentally shown 
to capture key features of S. Typhimurium enterocolitis pathogenesis. Normally the 
presence of intestinal microflora hinders the colonisation by S. Typhimurium, however 
invasion into gut tissue by a subset of Salmonella expressing invasion mechanisms 
produces an inflammatory response which kills off competing microflora and so allows 
the Salmonellae, which are more resistant, to survive and colonise (Stecher et al., 2007). 
Invasiveness in the bacteria is controlled by flagella and T3SS, which are differently 
expressed throughout the population of Salmonella, allowing survival of a percentage 
and the development of an infection (Ackermann et al., 2008).  
 
1.8  Immunity against nontyphoidal Salmonella 
Control, clearance and protection of NTS infection involves the collaboration of many 
aspects of the innate and adaptive immune systems, with both cell mediated and 
humoral immunity involved (Uppington et al., 2006, Mittrucker and Kaufmann, 2000). 
It has long been appreciated from mouse studies (Blanden et al., 1966, Mackaness et 
al., 1966) and more recently from studies of patients with rare primary 
immunodeficiencies (MacLennan et al., 2004, Bustamante et al., 2008) that cell-
mediated immunity is important for protection against invasive Salmonella disease. 





Adoptive transfer studies have found that optimal protection against Salmonella in mice 
is conferred by antibody and T cells (Mastroeni et al., 1993). From studying NTS 
disease in Malawi, it has recently been shown that NTS bacteraemia particularly affects 
African children between four months and two years, the period in which antibody levels 
to NTS are low or absent (MacLennan et al., 2008). In vitro human work has further 
suggested at the importance of both bactericidal and opsonising antibody (Lindow et al., 
2011, Gondwe et al., 2010, MacLennan et al., 2008). Studies of Salmonella infections in 
mice have shown that blood antibody titres correlate with protection against Salmonella 
(Xu et al., 1993). Antibody has been shown to be important for protecting innately-
susceptible Nramp
s
 (SLC11A1) mouse strains (Hormaeche, 1979b, Hormaeche, 
1979a), such as C57BL/6 and BALB/c, both in adoptive transfer studies (Mastroeni et 
al., 1993, McSorley and Jenkins, 2000) and studies in T-cell deficient mice 
(Cunningham et al., 2007, Gil-Cruz et al., 2009). Despite rapid uptake of Salmonella by 
the spleen and liver during murine systemic salmonellosis, there is a chronic low-grade 
bacteraemia that can become uncontrolled and cause death (Collins, 1969). In C57BL/6 
mice, antibody against Salmonella has been shown to markedly reduce bacteraemia as 
well as to prevent primary infection and impede haematogenous spread of NTS 
(Cunningham et al., 2007).  
 
1.8.1 Innate recognition 
Pattern recognition receptors (PRRs) that recognise pathogen-associated molecular 
patterns (PAMPs) are innate mechanisms that are key to recognising and controlling 
Salmonella infection in its initial stages. The most important PAMPs that PRRs detect on 
Salmonellae are LPS and flagellin. LPS is recognised mainly by toll-like receptor 4 
(TLR4) (Royle et al., 2003) and flagellin is detected by TLR5, though detection without 
TLR involvement also occurs (Hayashi et al., 2001). These responses are key in the 





knockout mice show greatly increased susceptibility to infection, demonstrating that 
overall the response is advantageous to the host (Vazquez-Torres et al., 2004, O'Brien 
et al., 1980). 
 
1.8.2 Phagocytes 
Phagocytes are central to control of Salmonella infection in the initial stages of infection. 
Understanding the role of distinct phagocyte cell populations in vivo is complicated 
because they share many of the same surface molecules and their roles in directing 
immune responses overlap (Wick, 2007).  
 
Dendritic cells, macrophages and neutrophils are recruited early after Salmonella 
infection (Rydstrom and Wick, 2007). A rapid expansion occurs in the Payer’s patches 
and spleens of orally infected mice (Wick, 2004). Phagocytes are responsible for 
clearing the initial bacteraemia that results when Salmonellae cross the epithelial barrier. 
They also help to control early growth in the liver and spleen. This is evidenced by the 
fact that macrophages and neutrophils are critical for the survival of mice during NTS 
infection (Friedman and Moon, 1977, O'Brien et al., 1979, Vassiloyanakopoulos et al., 
1998).  
 
The outcome of a Salmonella-phagocyte interaction is dependent on a number of 
factors, most notably opsonisation and activation state. These elements determine 
whether killing, or alternatively survival and subsequent replication of the bacterium 
results. Prior opsonisation of the bacteria by antibodies and complement increases 
phagocytosis and respiratory burst activity of macrophages, monocytes and neutrophils 
in mice and man (Gondwe et al., 2010, Uppington et al., 2006). Experiments with C1q-
deficient mice demonstrate the role of C1q in successful phagocytosis and killing of 





infection and failed to control bacterial growth within macrophages (Warren et al., 2002). 
Knockout mice have also been used to provide evidence to the role of antibody in 
enhancing phagocytosis. Mice lacking FcγRI, II and III show impaired immunity to 
virulent S. enterica (Menager et al., 2007).  
 
1.8.3 Cytokines 
Activation state of phagocytes, such as macrophages, is largely mediated by cytokines. 
Cytokines are a diverse group of secreted signalling polypeptides. They function as key 
communication molecules between host cells in the defence against many 
microorganisms. Salmonella infection induces expression of numerous chemokines and 
proinflammatory cytokines in both cultured intestinal epithelial cells and macrophages. In 
animal models, protective roles have been shown for IL-1alpha, TNFalpha, IFNγ, IL-12, 
IL-18 and IL-15, whereas IL-4 and IL-10 inhibit host defences (Eckmann and Kagnoff, 
2001). IFNγ and TNFα are two particularly important cytokines that induce bactericidal 
mechanisms such as reactive oxygen and nitrogen-intermediates, as well as improving 
handling of bacteria-containing phagosomes (Gulig et al., 1997, Nauciel and Espinasse-
Maes, 1992). Macrophage activation by IFNγ enhances killing of intracellular Salmonella 
(Eckmann and Kagnoff, 2001).  Production of such inflammatory cytokines is a hallmark 
of Salmonella infection (Ramarathinam et al., 1991) and has an important role in 
protection (Nauciel and Espinasse-Maes, 1992), although the effect may only be present 
during the early stages on infection (Muotiala and Makela, 1990). Natural killer (NK) 
cells, an important component of the immune system, are thought to be a major source 
of IFNγ in this early infection stage of NTS infection. Cytokines’ importance is 
demonstrated in a clinical setting by the vulnerability of persons with defects in 






1.8.4 T cells 
Overall, the immunology of the initial stages of Salmonella infection is characterised by 
recruitment and activation of phagocytes and IFNγ-mediated inflammation. While these 
innate defences help to control infection, the involvement of adaptive immunity and a 
specific lymphocyte response is required to clear infection. This response is likely part 
initiated by the stimulation of Salmonella-specific T cells by antigen presenting dendritic 
cells (Valdez et al., 2009).   
 
The significance of T cells in both primary and secondary responses is well established 
(Mastroeni et al., 1992, Mastroeni et al., 1993, Nauciel and Espinasse-Maes, 1992, 
Hochadel and Keller, 1977), although the role of different T cell subsets and their effects 
during different phases of infection is less clear. CD4+ T cells seem to be the key αβ T 
cell subset, but CD8+ T cells may also be important, particularly in conferring resistance 
after vaccination (Mastroeni et al., 1992, Nauciel, 1990, Pie et al., 1997). Indeed, both 
are required for optimal resistance to infection (Mastroeni et al., 2009, Hess et al., 1996, 
Ugrinovic et al., 2003). The broad Salmonella-specific T-cell response is directed against 
Salmonella protein antigens such as the porins, flagellin, and pilli (Mastroeni, 2002, 
Bergman et al., 2005). CD8+ cells may help control Salmonella infection through 
antigen-specific target lysis. In addition to this mode of action, CD8+ T cells contain 
granulysin which has antimicrobial activity against S. Typhimurium (Stenger et al., 1998). 
T cells, specifically CD4 T-cells provide pathogen-specific help for activation and 
differentiation of B-cells (Cosgrove et al., 1991). This help is required for the production 
of antibody responses to Salmonella protein antigens and isotype switching of 
antibodies (Sinha et al., 1997). A study in T-cell deficient mice showed no production of 





1999). By modulating antibody production, T-cells are known to help establish a long 
lasting humoral response. 
γδ T cells may also contribute to defence against Salmonella. Despite being a minority 
subset of total T cells, they represent a large fraction of T cells in the gut mucosa (Mixter 
et al., 1994) and so may have increased importance against enteric pathogens, such as 
Salmonella. Mice depleted of γδ T cells were more susceptible to oral infection with 
Salmonella, although the importance of this subset seems less than that of αβ T cells 
(Weintraub et al., 1997). T cells seem to play only a minor role in combating early 
infection in mice, as αβ T cell knockouts are able to suppress early growth of Salmonella 
(Hess et al., 1996). Yet, upon re-infection prompt production of phagocyte-activating 
IFNγ by memory T cells is likely part responsible for the protective effect of T cell 
immunity (Mittrucker and Kaufmann, 2000).  
 
NK cells are important immune effectors for preventing bacterial invasion and 
dissemination (Vivier et al., 2008). They appear to have an important role in controlling 
Salmonella infection in both mice (Harrington et al., 2007, Griggs and Smith, 1991) and 
humans (Lapaque et al., 2009). NK cells can exert a protective effect through two 
means: cytotoxicity and the secretion of cytokines such as IFNγ.  
 
1.8.5  B cells 
B cells function as antibody-producing, cytokine-secreting cells and are also involved in 
antigen presentation. B cells are essential for full immunity to oral challenge and 
contribute to early protection in primary challenge (Mittrucker et al., 2000). B cell 
deficient mice show impaired resistance to primary Salmonella infections due to a defect 
in antibody production (Mastroeni, 2002). In addition, production of Th-1 type cytokines, 





control growth of virulent Salmonella in secondary infections (Mastroeni et al., 2000a). 
The principal modality of immunity is mediated through antibody production, which 
contributes to opsonising and complement-mediated killing of Salmonellae. But, B cells 
may also have another role in protective immunity, because passive transfer of immune 
serum into immunised B cell knockout mice did not provide full resistance as seen in wild 
type mice (Mastroeni et al., 2000).  
 
Marginal zone (MZ) and B1b B cells lack a requirement for T cell dependent germinal 
centre reaction which means that they can be rapidly recruited into the early adaptive 
immune responses (Weill et al., 2009, Berkowska et al., 2011). These B cell subsets are 
well positioned and adapted to mount a prompt T cell independent immunoglobulin 
responses as a first line of defence against systemic blood-borne antigens that enter the 
circulation and pass into the spleen (Balazs et al., 2002, Kearney, 2008). MZ B cells 
exist in a pre-activated state and respond rapidly certain antigens to secrete antibodies 
(Oliver et al., 1997) and B-1 B cells are a major source of natural IgM serum antibodies 
(Berland and Wortis, 2002). MZ and B1b B cells are particularly involved in type-2 T cell 
independent (TI) responses to LPS antigens, which further suggests their importance in 
Salmonella infection (Zouali and Richard, 2011).  
 
Murine MZ B cells are non-circulating and segregate anatomically into the marginal zone 
of the spleen (Martin and Kearney, 2002). This area of the spleen contains multiple 
subtypes of macrophages, dendritic cells, as well as MZ B cells. It is not fully formed 
until 2 to 3 weeks after birth in mice and 1 to 2 years in humans (MacLennan et al., 
1985). Human MZ B cells share many properties with their mouse equivalents. However, 
they also have key differences. In humans MZ B cells can recirculate and have somatic 





responses to blood-borne pathogens, it is unlikely that there are major differences 
between man and mouse in these populations. Very little is understood as to why, in 
mice, the spleen is the only site of MZ B cell localisation, or why exactly the spleen is 
required for MZ B cell generation in both mice and men (Pillai et al., 2005). 
 
1.8.6  Antigen responses 
Antigens are classified as T cell dependent (TD) or T cell independent (TI), depending 
on whether T cells are required to produce an antibody response. 
 
1.8.6.1  T-independent antigen responses 
There are two types of TI antigens, classified based on their interaction with B cells: TI 
types 1 and 2 (TI-1 / 2) (Mosier et al., 1977). TI-1 antigens, such as LPS, are polyclonal 
B cell activators and can activate both naïve and mature B cells non-specifically (Mond 
et al., 1995). For example, LPS interacts with TLR4 on the surface of B cells and 
activates it, producing a diverse array of antibodies (Lesinski and Westerink, 2001). In 
contrast, TI-2 antigens, such as bacterial capsular polysaccharides, are large molecules 
with repeating epitopes that are flexible and able to simultaneously engage multiple B 
cell receptors. They activate mature B cells by cross-linking surface exposed 
immunoglobulin and induce production of antigen-specific antibodies (Mond et al., 1995, 
Lesinski and Westerink, 2001). Responses to TI antigens develop significantly more 
rapidly than TD responses and thus can play a critical role against invasive Salmonella 
infection. However, B cells in young children and the elderly respond poorly to TI-2 
antigens (Adderson, 2001). Although, It now appears that TI-2 antigens, like TD 







1.8.6.2  T-dependent antigen responses 
Proteins and peptides are typically TD antigens. They are presented to T cells by the 
Major Histocompatibility Complex (MHC) molecules present on B cells, dendritic cells 
and macrophages. These T cells, specifically CD4 T-cells provide pathogen-specific help 
for activation and differentiation of B-cells (Cosgrove et al., 1991).  This help is required 
for the production of antibody responses to Salmonella protein antigens and isotype 
switching of antibodies (Sinha et al., 1997). A study in T-cell deficient mice showed no 
production of IgG1, IgG2a and IgG2b, and low production levels of IgG3 and IgM 
(Mittrucker et al., 1999). TD antigens result in long-lasting immunity by inducing memory 
B and T lymphocytes and long-lived plasma cells. The antibodies they induce are of high 
affinity and cover a wide range isotypes (Reviewed in (Parker, 1993)). 
 
1.8.7  Context in infection spread  
How Salmonellae spread from infected cell to a new cell during growth is not fully 
understand and is a topic of debate. Salmonella-infected mouse livers showed bacteria 
were only present in intracellular locations (Richter-Dahlfors et al., 1997). In addition 
there is evidence for Salmonella-induced apoptosis of host cells (Richter-Dahlfors et al., 
1997, Lundberg et al., 1999, Paesold et al., 2002). Apoptotic pathways could allow 
spread of infection to new cells without exposure to extracellular components of 
immunity, such as antibodies. The inability of gentamicin, an antibiotic with poor 
eukaryotic cell penetration, to completely clear NTS infection in mice supports this,  
suggesting a fraction of Salmonellae are not exposed to the extracellular environment 
(Bonina et al., 1998). Yet, mathematical models and microscopy observations have 
indicated that cells housing Salmonellae undergo predominantly necrotic death and 
release the bacteria into extracellular space (Brown et al., 2006, Mastroeni et al., 2009). 





was due to caspase-3-independent mechanisms (Grant et al., 2008). Such necrotic cell 
death has been reported in Salmonella lesions in humans (Mert et al., 2004). It seems 
that different types of cell-death play a role in spread of Salmonella in a host. It is likely 
that cell mediated immunity controls infection within phagocytes and the humoral arm of 
immunity is central for controlling spread after release from infected cells (Mastroeni et 









Figure 1.4: The key immunological factors that control the intracellular and 
extracellular phases of infection in humans. S. Typhimurium grows in phagocytic 
cells. Cell-mediated immunity enhances the antibacterial functions of phagocytes and 
may contribute to host-cell lysis. Mathematical modelling and microscopic observations 
indicate that S. enterica escapes from infected cells following density-independent, 
stochastic lysis of phagocytes (Mastroeni et al., 2009). This results in the formation of 
new clonal infection foci that start from a single founder bacterium (Mastroeni et al., 
2009, Mastroeni and Sheppard, 2004). During their cell-to-cell spread, the bacteria are 
transiently present in the extracellular space, where they are opsonised by Abs and 
complement, then targeted to Fc and complement receptors. This process enhances 
bacterial internalisation by macrophages through FcγRI and activates cellular 
antibacterial functions that are dependent on the production of reactive oxygen 
intermediates (ROIs) (Mastroeni et al., 2009, Uppington et al., 2006). In humans 
significant killing is seen through the direct action of bactericidal antibody and 
complement (MacLennan et al., 2008). FcγRI, high affinity immunoglobulin-γ Fc receptor 
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1.9  Complement  
1.9.1  Complement in host defence 
The complement system has an essential role in host defence against pathogens, 
playing a part in both non-specific and specific immunity (Brown et al., 1983, Carroll, 
2004, Fearon, 1998). It consists of more than 60 proteins that function as enzymes, 
binding proteins, activation products, regulators, inhibitors and cell-surface receptors.  
Cell-surface receptors exhibit specificity for sub components of complement proteins and 
are present on cells of the immune system (Zipfel and Skerka, 2009). There are several 
regulatory membrane and soluble proteins that function to prevent autologous 
complement activation and serve to limit host damage (Muller-Eberhard, 1988). Factor H 
is the key inhibitor of the alternative pathway and C1 inhibitor and C4bp are the classical 
pathway’s equivalent (Ziccardi, 1982, Liszewski et al., 1991).  
 
Complement can be activated by three different pathways: the classical pathway (Sakai 
et al., 1979), the lectin pathway (Fujita et al., 2004) and the alternative complement 
pathway (Pangburn and Muller-Eberhard, 1984). All the pathways serve the ultimate 
function of activating C3. However, the means of recognition by which they achieve this 
activation varies. The classical pathway is activated by the binding of antibody molecules 
(specifically IgM and IgG1, IgG2 and IgG3) to a foreign particle. The pathway is then 
initiated by binding of the antibody molecule to C1q (Schumaker et al., 1976). The 
capacity of the four human IgG subclasses to bind C1q decreases thus: 
IgG3>IgG1>IgG2. IgG4 does not activate complement (Flanagan and Rabbitts, 1982, 
van Loghem, 1986). The lectin pathway is activated after the recognition and binding of 
pathogen-associated molecular patterns (PAMPs) by lectin proteins, such as mannose-
binding lectin protein (Carroll, 2004). The alternative pathway is constantly ‘on’, rather 





protected by inhibitors (Carroll, 2004). The proteins C3, B, D, H, I, and P together 
perform the functions of initiation, recognition and activation (Schreiber et al., 1978). As 
well as possessing spontaneous initiation, the alternative pathway is unique in that it has 
a positive feedback amplification mechanism. C3 spontaneously forms C3b at a slow 
rate. If this C3b binds to an ‘unprotected’ surface it binds B to form C3 convertase which 
acts on more C3 to form C3b, which then binds to the surface too, and so on (Muller-
Eberhard and Gotze, 1972). This can quickly turn an initial small deposit of C3b, placed 
by any pathway, into a massive production of C3b.  
 
All activation pathways enzymatically catalyse the formation of the target cell bound C3 
convertase, which promotes the binding of large amounts of C3b to the cell, as 
described above. C3b binds covalently to the bacterial cell membrane and opsonises the 
bacteria, enabling phagocytes to internalise them and kill more effectively (Uppington et 
al., 2006). C3a, which is created from the same reaction, is an anaphylaxtoxin and 
mediates inflammation. The C3 convertase can be ‘activated’ by more C3b to generate 
C5 convertase (Medicus et al., 1976), this results in the cleavage of C5a. C5a is a strong 
mediator of inflammation and also chemotactic, hence it promotes leukocyte migration to 
its site of production. C5b triggers the assembly of the terminal components 
of complement into a membrane attack complex (MAC). The MAC is assembled from 
five hydrophilic precursor proteins: C5, C6, C7, C8, and C9 (Muller-Eberhard, 1986). 
Hydrophobic interactions with the lipid bi-layer of target membranes allow the developing 
MAC to from a strong bind to its target. The final step in formation of a MAC is 
polymerisation of C9, causing weakening of the membrane structure and the formation 
of trans-membrane channels and events that lead to cell death. MAC assembly is 
regulated by the fluid phase complement regulator S-protein of plasma, which binds to 





membranes also contribute to MAC regulation. Lysis can occur in many cells including 
Gram negative bacteria (Muller-Eberhard, 1986).  
 
1.9.2 Mouse complement  
Mouse serum, from both wild and inbred species, has long been known to lack 
bactericidal activity against a wide range of bacteria (Marcus et al., 1954). Furthermore, 
it lacks haemolytic activity against sensitised sheep cells (Brown, 1943). Mouse 
complement activity has since been demonstrated using modifications to standard 
haemolytic assay conditions, such as the use of rabbit erythrocytes and large quantities 
of sensitising antibody (Van Dijk et al., 1980, Rosenberg and Tachibana, 1962). The 
format of a haemolytic assay can greatly impact upon the results, for example Ish and 
co-workers showed a great variety in the specificity of alternative complement pathway-
mediated lysis of erythrocytes using both complement and erythrocytes from 25 different 
species (Ish et al., 1993). The current view is that mouse complement, in comparison to 
human complement, has weak alternative pathway activated activity and even weaker 
still classical pathway activated activity (Morgan, 2009). 
 
In addition to this generally weaker complement action, mouse complement is sexually 
dimorphic, with male mice having significantly higher titres than females (Baba et al., 
1984). There are also substantial differences in C4 levels between strains (Hansen et 
al., 1974). Some inbred species have been noted to lack certain complement 
components. For example A/J mice are deficient in C5 (Nakano et al., 1995). BuB/BnJ 
have been reported to possess elevated complement activity in haemolytic assays. 
However, a recent investigation using a bacteria based assay showed no increase in 
levels compared to other mouse strains (Osmers et al., 2006), highlighting the 






1.9.3 Complement-mediated Killing of Gram-negative bacteria 
Serum-susceptible Gram-negative bacteria are killed by deposition and insertion of the 
terminal complement components in their membrane and the subsequent formation of a 
membrane-attack complex (MAC / C5b-9) (Joiner et al., 1984, Joiner et al., 1985b). The 
disruption of the lipid bilayer leads to the loss of cellular homeostasis, disturbance of the 
proton gradient across the membrane, the penetration of enzymes such as lysozyme 
into the cell, and the rapid destruction of the pathogen (Taylor, 1983). Although many of 
the molecular details of this cell death are not currently understood, it is thought that 
dissipation of cellular energy is the fatal event for the cell (Dankert and Esser, 1986).  
 
1.9.4 Molecular details of complement-mediated bactericidal activity 
Killing requires formation of a stable MAC complex on the outer membrane (OM) (Inoue 
et al., 1968, Joiner et al., 1982b, Joiner et al., 1982a), though cell death is dependent on 
damage to the inner membrane (IM) (Wright and Levine, 1981, Feingold et al., 1968). 
While formation of poly-C9 (a tubular polymerisation product of C9, containing around 20 
subunits (Podack, 1984)) is not required for bacterial killing (Dankert and Esser, 1986, 
Dankert and Esser, 1985), multimeric C9 is required. Three or four C9 subunits are 
necessary per C5b-8 complex for the MAC to exert bactericidal activity, regardless of the 
amount of MAC inserted into the bacterium (Bhakdi et al., 1987, Bloch et al., 1987, 
Joiner et al., 1985b). Incorporation of additional C9 molecules does not increase killing 
(MacKay and Dankert, 1990). Addition of pre-formed C5b-8 or C5b-9 complexes to 
bacterial OMs, by liposome fusion (Tomlinson et al., 1990) or a bacterial cell donor 
system (Blanchard and Dankert, 1994), fails to kill bacteria. Illustratively, subsequent 
killing ensues upon incubation of purified C9 with cells baring the C5b-8 complex, but 






Bacteria naturally contain channels in their OM, known as porins, (Lugtenberg and Van 
Alphen, 1983).  Preformed C5b-9 MAC complement complexes transferred into the OM 
of Salmonella functioned as water-filled channels but did not affect viability (Tomlinson et 
al., 1990). In addition most of the OM can be removed, without greatly impairing cell 
viability (Neu and Heppel, 1964). As such, it is unlikely that pore formation by MAC alone 
would lead to cell death and it is probable that an additional process or factor is required 
to kill the cell. Nevertheless, insertion of MAC into the OM does significantly alter the 
membrane. Cell permeability is increased as a result of this pore formation (Born and 
Bhakdi, 1986) and/or a restructuring of lipids in the immediate vicinity of the MAC 
leading to a so called ‘leaky patch’ (McCloskey et al., 1989, Bhakdi and Tranum-Jensen, 
1991). Indeed, freeze-fracture electron microscopy (EM) studies have demonstrated that 
the lipids surrounding MACs in bilayers are severely distorted (McCloskey et al., 1989).  
 
Past studies using bactericidal lysozyme-free serum have shown MAC to only be 
deposited on the OM (Taylor and Kroll, 1984), which presents a puzzle as to how MAC 
can exert a bactericidal effect at a relatively distant position from the IM. The length of 
the MAC is estimated to be around 30nm (Podack, 1984). These dimensions pose 
physical problems for the generation of a transmural pore that could simultaneously 
damage the OM and IM, even in the absence of long chain OAg (and especially in the 
presence)/ Yet evidence shows anti-OAg antibody to be bactericidal and very long STm 
OAg can contain over 100 repeat units (Bravo et al., 2008) modelled at around 1 nm 
each (Kastowsky et al., 1992). It is possible that translocation of the entire complex or 
merely an aspect of it could effect killing which would allow causation of cell death with a 
more distant initial MAC binding (Blanchard and Dankert, 1994). There is support for an 
individual component of MAC being able to translocate. Dankert showed that when C9 





killing occurred. Other proteins, such as C8 or serum albumin, were not toxic. Insertion 
of C9 directly into the periplasm was ineffective against two serum-resistant strains. This 
indicates an additional non-LPS linked mechanism of resistance, especially considering 
that rough strains made serum-resistant by genetic addition of LPS remained 
susceptible to killing by C9 inserted into their periplasm (Dankert and Esser, 1987). 
Another group have established that C9 is converted from a protoxin to a toxin by 
periplasmic conditions in Escherichia coli and this toxic form was responsible for direct 
killing of the bacteria (Wang et al., 2000). An essential role for C9 is supported by the 
weak and slow or absent killing by C9-deficient sera (Pramoonjago et al., 1992), as well 
as increased Neisserial disease in those with absent or reduced C9 (Lassiter et al., 
1992, Botto et al., 2009, Morgan and Walport, 1991). 
 
One investigation by Goldman and Miller did show evidence of IM bound complement 
components (Goldman and Miller, 1989) though the presence of large amounts of OM 
proteins in the isolated IM fraction indicated by SDS PAGE analysis of membrane 
fractions was criticised by Tomlinson et al as a potential indication of contamination 
(Tomlinson et al., 1990). Studies showing a lack of complement on the IM have typically 
used lysozyme free serum. While this can still effect killing, it is unknown whether the 
mechanism of killing is the same as the mechanism naturally occurring in vivo. Analysis 
of MAC killing of erythrocytes revealed penetration of C9 in the C5b-9 complex across 
the membrane into the cytoplasmic space (Whitlow et al., 1985), though, the gram-
negative cell is a more complex target owing to its more complex envelope structure, 
and ability to respond rapidly to changes in the environment. 
 
Bacterial bio-adhesion zones, which connect the OM and IM (Bayer, 1991), have been 





simultaneous damage against the IM and so kill the bacterial cell (Wright and Levine, 
1981, Joiner et al., 1983, Born and Bhakdi, 1986, Bhakdi et al., 1987). As the relative 
amount of adhesion zone fractions decreases under conditions of limited or slow cell 
growth (Bayer, 1991, Blanchard and Dankert, 1994) this hypothesis could help explain 
the increased serum-resistance of bacteria in stationary phase or subjected to energy 
poisons (Dankert and Esser, 1987, Taylor, 1983, Davis and Wedgwood, 1965). 
Supporting this, Wright found that the kinetics of release of periplasmic enzymes and 
intracellular cations after exposure to lysozyme free serum are virtually identical, 
indicating that IM damage and OM damage are closely coupled events (Wright and 
Levine, 1981).  In addition, plasmolysis of bacteria in hypertonic media protected the 
cells from serum killing, potentially by limiting OM-IM adhesion sites due to the osmotic 
contraction of the IM (Feingold et al., 1968). Periseptal annuli have been suggested as 

















Figure 1.5: Overview of the main components and effector actions 
of complement. The early events of all three pathways of complement activation involve 
a series of cleavage reactions that culminate in the formation of C3 convertase, which 
cleaves complement component C3 into C3b and C3a. The production of the C3 
convertase is the point at which the three pathways converge and the main effector 
functions of complement are generated. C3b binds covalently to the bacterial cell 
membrane and opsonises the bacteria, enabling phagocytes to internalise them. C3a is 
a peptide mediator of local inflammation. C5a is also a powerful peptide mediator of 
inflammation. C5b triggers the late events in which the terminal components 
of complement assemble into a MAC that can damage the membrane of certain 
pathogens. MASP - mannan-binding lectin-associated serine protease; B- factor B; D – 





1.10  Antibodies in host defence 
Antibodies can effect anti-microbial action in several ways. They can neutralise 
pathogens to stop them entering or damaging host cells (Michetti et al., 1994). They can 
opsonise pathogens and bind to specific Fcγ receptors (FcγR) on phagocyte surfaces 
thereby increasing phagocytosis and killing rates. Finally, dependent on the pathogen, 
antibodies can be bactericidal either by activating complement through the classical 
pathway and inducing complement-mediated lysis (as mentioned in section 1.7), or 
without complement by inducing antibody-dependent cellular cytotoxicity (Casadevall, 
1998). 
 
Distribution of human IgG subclass in specific antibody responses varies based on the 
number and nature of the epitopes, and physicochemical properties of the antigen. 
Dosage and route of entry, as well as host factors are also significant. Polysaccharide 
antigens are typically T cell-independent and develop mainly in the form of IgG2 with 
some IgG1 production. In contrast, protein antigens are thymus-dependent, require 
interaction with T cells, and mainly produce IgG1 and IgG3.  Immunisation with several 
encapsulated bacteria leads to an almost exclusive IgG2 anti-polysaccharide response 
(Siber et al., 1980). Yet, typically the IgG subclass distribution in an anti-bacterial 
response is heterogeneous, due to the variety of antigenic epitopes that thy bacteria 
possess. Antibodies develop against a variety of antigens in mice immunised with NTS. 
A large proportion of the antibody response is directed against LPS, but antibodies 
against Omps, flagella and fimbriae are also present (Brown and Hormaeche, 1989, 
Mastroeni and Menager, 2003). Murine studies have revealed that while the initial 
antibody production is of the IgM class, as would be expected, switching to IgG 
subclasses can depend on the antigen and mouse strain (Cunningham et al., 2007, 





The effector functions of IgG subclasses and their ability to carry out different function 
varies due to structural differences, particularly the length and flexibility of the hinge 
region. IgG subclasses differ in their affinity to FcγR. Broadly speaking, IgG3 and IgG1 
are the most effective opsonising sub classes of IgG, though IgG2 has a strong affinity 
for FcγRIIa-H131 (Nimmerjahn and Ravetch, 2008). Binding of the Fc region of IgG to an 
FcγR is key in activation of a cell's effector functions (van de Winkel and Capel, 1993) 
and interaction between FcγRs and IgG antibodies can be pivotal in the immune 
response against some infectious agents (Bredius et al., 1994). Mice lacking FcγRI, II 
and III can control and clear primary infection with S. enterica of low virulence but have 
impaired immunity when challenged with virulent bacteria (Menager et al., 2007). 
 
1.11  Vaccines  
With increasing recognition of the problem of NTS in Africa, difficulty in diagnosis, and 
widespread antibiotic resistance, there is a need for a cheap and effective vaccine 
against this disease. Currently, there are no vaccines against NTS licensed for human 
use. 
 
In experimental models, live vaccines confer better protection than killed vaccines as 
they tend to induce mucosal, cellular and humoral immunity (Hormaeche et al., 1990). 
Whilst killed vaccines produce strong antibody responses and confer a moderate degree 
of protection (Levine et al., 1989), they are often reactogenic and typically induce poor 
cell-mediated immunity (Harrison et al., 1997).  Live attenuated vaccines also have other 
advantages over nonviable vaccines because of their ease of administration and ability 
to carry heterologous antigens (Mastroeni et al., 2001). Several live attenuated S. 
Typhimurium vaccine strains have been licensed for use against Salmonella infections in 





strains show success in vaccinating mice. While phase 1 clinical trials have been 
performed in humans using attenuated human diarrhoeal S. Typhimurium strains as live 
oral vaccines or as live vectors which express foreign antigens, none of these trials have 
advanced in development due to negative effects of reactogenicity or inadequate 
immunogenicity (Hindle et al., 2002, Angelakopoulos and Hohmann, 2000). Ideally, live 
attenuated Salmonella vaccine strain candidates should harbour multiple independent 
attenuating mutations to limit the chances of a reversion to virulence. Live attenuated 
Salmonellae have great potential as single-dose oral vaccines against salmonellosis and 
as delivery systems for the construction of multivalent vaccines (Mas 2001) 
 
Despite this promise, safety is a concerning factor for live attenuated vaccines. Some 
live attenuated Salmonella potential vaccines strains, such as aromatic dependent 
(aroA) mutants or SPI-2 mutants can cause fatal infections in animals with 
immunodeficiencies (Hess et al., 1996, Vazquez-Torres et al., 2000). This is problematic 
as immune-suppression is common in Africa, which is a major intended area for use of a 
NTS vaccine. As immunodeficiency may not be diagnosed in the individual at the time of 
vaccination, it is important that any live vaccine strains have no potential to cause 
disease. Promising new attenuated vaccine strains are being developed (Tennant et al., 
2011), although it will be difficult to generate a mutant that creates sufficient immunity in 
healthy individuals but cases no harm to those with immunodeficiency. 
 
Several vaccines have been developed and licensed for use against S. Typhi in 
humans: acetone or heat-phenol killed whole cell vaccines (Warren and Hornick, 1979), 
the Ty21a live attenuated vaccine (Levine et al., 1987) and purified Vi surface antigen 
(Acharya et al., 1987). Of these only the latter two remain in usage. While meta-analysis 





efficacious for preventing typhoid fever, their effectiveness is somewhat limited, with a 3-
year cumulative efficacy of around 50% (Fraser et al., 2007). To maintain this level of 
protection boosters are required every 5 or 2 years, respectively. In addition, only those 
older than six (Ty21a) or two (Vi) years of age can be vaccinated, as Typhoid can affect 
infants this leaves a demand for a suitable vaccine in young children. The heat killed 
vaccines have significantly greater efficacy (73% at 3 years), but because of frequent 
side effects (20% of vaccinees fell ill and 10% missed school or work) their use has been 
discontinued (Engels et al., 1998). The Vi vaccine is a rare example of an efficacious 
Salmonella subunit vaccine. However, Vi is only expressed by serovars S. Typhi, S. 
Paratyphi C and some strains of S. Dublin (Grimont, 2007) and so it is unsuitable for use 
against NTS. Other subunit based vaccines, such as those based on flagella, porins and 
polysaccharide fractions have proved ineffective (Mastroeni and Menager, 2003), though 
major NTS porin OmpD appears to be a strong vaccine candidate (Gil-Cruz et al., 2009).  
 
Efficacy of subunit vaccines is poor when administered without adjuvant or a delivery 
system. An alternative system, vaccine-conjugation has developed partly to avoid this 
problem. Conjugation of protective antigens to carrier proteins can be an effective way to 
generate a thymus-dependent response from what is a thymus-independent antigen 
when unconjugated. This gives immunogenic benefits in terms of a better response in 
infants and production of high levels of long-lasting antibody. There are conjugate 
vaccines in development such as Vi-rEPA - a conjugate of the capsular polysaccharide 
of S. Typhi and Vi bound to a recombinant Pseudomonas aeruginosa exotoxin A [rEPA]) 
which show good efficacy and mild side effects but as yet are not licensed for use in 
man (Fraser, 2007). Other potential vaccines using Vi in conjunction with carrier proteins 
such as, VI-CRM (CRM is a non-toxic mutant of diphtheria toxin) are also in early 





identified, these types of conjugated vaccines will also likely be a successful avenue of 
vaccine development for NTS strains. 
 
1.12 Aims  
The fundamental aim of the project is to further our understanding of complement and 
antibody-dependent immunity against NTS, with a focus on bactericidal antibody, in 
order to help in the creation of an effective vaccine. In this study we have achieved this 
in five ways: 
 Firstly, by determining whether antibody acts in the same way in mouse models 
of infection as in humans. 
 Secondly, analysing how growth phase and growth conditions can affect the 
resistance of NTS to serum-killing. 
 Thirdly, creating an in vitro model of the time course of infection following entry of 
NTS into the bloodstream. 
 Fourthly, by absorbing normal serum with different strains, serovars and 
genotypes of NTS  
 Finally, using electron microscopy analysis to image the location of antibody 
binding and complement deposition and to determine the potential roles of 











1.13 Hypotheses  
To accomplish these aims (1.12) we set key falsifiable hypotheses for each chapter of 
work: 
Chapter 3: Mice serum lacks antibody-dependent complement-mediated bactericidal 
activity against an invasive African S. Typhimurium isolate. 
 Mice serum also lacks complement-mediated bactericidal activity against an 
OAg-lacking mutant strain that is exquisitely sensitive to human serum. 
Chapter 4: Growth conditions and phase of S. Typhimurium affect its serum resistance. 
  In vitro phagocytosis of S. Typhimurium by neutrophils and monocytes in 
blood occurs before all Salmonellae are killed by cell-free serum-killing in a 
comparable in vitro system. 
Chapter 5: Antibodies specific against S. Typhimurium can be removed from serum in a 
manner that preserves complement activity. 
 Antibody-mediated cell-free complement-killing of NTS is serovar specific. 
Antibodies against Salmonella LPS and specifically OAg are not bactericidal.
  
Chapter 6: HIV-infected inhibitory serum does not damage S. Typhimurium  
HIV-infected inhibitory serum shows differences in location and quantity of 
deposition of antibodies and complement factors on S. Typhimurium 








2. Materials and Methods 
2.1 Bacteria and sera 
2.1.1 Bacteria 
This study principally used strains of Salmonella enterica enterica serovars Typhimurium 
and Enteritidis (S. Typhimurium and S. Enteritidis). These two serovars represent the 
most common causes of systemic nontyphoidal Salmonella (NTS) infection in Africa 
(Morpeth et al., 2009). A total of seven isolates taken from blood cultures from child 
patients in Malawi, Blantyre, were used, as well as a number of ‘laboratory’ strains 
(summarised in Table 2.1).  
 
The main clinical isolate strain used was S. Typhimurium D23580, a clinical invasive 
isolate from a 26-month-old female bacteraemic Malawian who was admitted to Queen 
Elizabeth Central Hospital in Blantyre, Malawi in 2004 (MacLennan et al., 2008, Kingsley 
et al., 2009). This strain is sensitive to killing by human adult serum, undergoing a one to 
three log10 kill over a three hour time course (SBA: section 2.2). It is representative of 
over 90% of NTS strains isolated from bacteraemic individuals in Malawi since 2002 and 
has been sequenced by the Sanger Core Sequencing Facility at the Wellcome Trust 
Sanger Institute (Kingsley et al., 2009). The rough galE knockout of this D23580 is 
exquisitely sensitive to killing of human serum in the absence of antibody (MacLennan et 
al., 2008). 
 
The main laboratory strain used was SL1344. Its aroA attenuated mutant, SL3261, 
kindly provided by B. A. D. Stocker was used for mouse immunisations. Various LPS 
knockouts (Table 2.2) and LPS chimera strains (Hormaeche et al., 1996) (Table 2.3) 
were also utilised. The LPS chimera strains expressed either their own LPS or that of 




another serovar (S. Typhimurium C5 O:4 or O:9, and S. Enteritidis Thirsk O:9 or 
O:4).The phenotypic effects on LPS expression are shown in Figure 2.2. 
 
2.1.2 Preparation of stationary phase cultures 
A few single colonies were picked from a growth of Salmonella on a lysogeny broth 
(commonly known as Luria Bertani) (LB) agar (Sigma) plate and inoculated into 10mls of 
LB broth. This was grown in a loose capped universal tube overnight at 37
o
C in an 
incubator (New Brunswick Scientific) to stationary phase. M9 minimal media (5 × M9 
salts 200 ml, D-glucose (20g/100ml) 20ml, 1M MgSO4 2ml, 1M CaCl2 0.1ml, L Histidine 
50µg/ml) (all Sigma) was used in place of LB for galE
- 
growths, as the phenotypic 
expression of the mutation depends on absence of galactose. 
 
2.1.3  Preparation of logarithmic phase cultures 
An overnight stationary phase culture was diluted 1 in 100 into pre-warmed (37
o
C) LB 
broth. Dependent on the volume required for the application, tight capped universal 
tubes or baffled flasks were used. For work carried out in Birmingham (Chapters 3, 4, 
parts of 5 and 6) this was incubated at 37
o
C for 2 hours in a tight capped universal tube 
on a rocker plate (Stewart Scientific) at 20rpm. Work undertaken in Siena (parts of 
chapter 5 indicated in text) used a shaking incubator (New Brunswick Scientific) at 
180rpm for the same time at the same temperature. To produce different phase growths, 
such as early, mid or late log phase, the inoculum was incubated for a different time 
period as determined by a growth curve. Viable Salmonellae were prepared by first 
pelleting the appropriate quantity (dependent on the desired concentration) of inoculum 
by spinning at 3,300 x g in an Eppendorff micro-centrifuge (Hamburg, Germany), then 
washing the bacteria by removal of the supernatant, addition of 1 ml of PBS and 
spinning as described above. The wash step was repeated and the bacteria 




resuspended in an appropriate amount of PBS to reach the desired concentration. The 
concentration of the final inoculum was checked by serial dilutions. As per section 2.1.2, 





C57BL/6, BALBc and C3H mice obtained from HO Harlan OLAC mice were age and sex 
matched, housed in pathogen-free conditions, and used between 6 and 12 weeks of 
age. For immunisations, Salmonellae were grown in LB media to log phase (as 
described in section 2.1.3) and heat-killed as required at 72°C for one hour. No 
exogenous adjuvants were used for immunisations. Mice immunised with heat killed 
Salmonellae were given 10
7
 Salmonellae/animal via the intraperitoneal (i.p.) route at day 
0, boosted with the same dose of heat-killed bacteria at day 14, and exsanguinated at 
day 28 by cardiac puncture. Those immunised with live Salmonellae were given 5x10
5 
 
bacteria i.p. at day 0 and exsanguinated at day 35. The schedule is summarised in 
Table 2.4. 
 
2.1.5 Ethical approval 
HIV-infected sera and clinical African Salmonella isolates were collected under ethical 
approval from The College of Medicine Research and Ethics Committee (COMREC), 
University of Malawi. Animal studies had ethical and home office approval. 
 
2.1.6 Serum preparation 
Human blood was obtained from volunteers and stood at room temperature until 
sufficient clotting had occurred. The blood was centrifuged at 3,300xg in a Megafuge 
1.0R (Hereus, Germany) or a microfuge (dependent on quantity) at 4
o
C for 20 minutes 
and then the serum supernatant aliquoted. Mouse blood was obtained by cardiac 




puncture. As it is more heat-labile, to maintain optimum complement activity it was 
clotted for one hour on ice and then separated and frozen. Serum samples were stored 
at -80
o
C and not subjected to freeze-thaw cycles. 
 
Table 2.1: Wild type Salmonella strains and isolates used in study 
Serovar Strain name Isolation 
Enteritidis ATCC4931 Human gastroenteritis, 
Copenhagen, Denmark 
Enteritidis D24359 Human child blood culture, 
Malawi 
Enteritidis D24953 Human child blood culture, 
Malawi 
Enteritidis D24954 Human child blood culture, 
Malawi 
Enteritidis P125109  Human gastroenteritis 
isolate  
Typhi D21685 Human gastroenteritis 
isolate  
Typhimurium D22477 Human child blood culture, 
Malawi 
Typhimurium D23005 Human child blood culture, 
Malawi 
Typhimurium D23580 Human child blood culture, 
Malawi 
Typhimurium LT2 (ATCC 700720) Unknown natural source 
(1948) 










Table 2.2: LPS knock-out Salmonella strains used in study 

























Table 2.3: Salmonella LPS chimera strains 
Serovar Parent Strain Strain number O-Antigen 
Enteritidis Thirsk SL7488 4 
Enteritidis Thirsk SL7490 9 
Typhimurium C5 SL5559 4 
Typhimurium C5 SL5560 9 
 
 
2.2       Serum bactericidal assay (SBA) 
5μl of, 2 hour log phase Salmonella culture (prepared as described in sections 2.1.3-4) 
diluted to a concentration of ~2x10
7
 cfu/ml was added to 45μl of serum. Samples were 
incubated at 37
o
C either in microfuge tubes with slight agitation on a rocker plate 
(20rpm), or without agitation in 96 well plates (Sarstedt). At desired time points, 5μl was 
removed from each sample and diluted as per the Miles and Misra method in order to 




allow calculation of cfu/ml. Viable bacteria concentrations were recorded after overnight 
incubation at 37
o
C on LB agar plates. Comparison of these values with the starting 
inoculum gave values for log10 change in bacteria. An increase in bacterial counts 
corresponded to a positive log10 change and therefore growth with the opposite applying 
for killing. The range of detection of the assay is a 3 log10 kill and a 2 log10 growth.  
 
For supplementation of mouse serum or adsorbed serum with either anti-Salmonella 
antibodies or complement, the serum was mixed at a 1:1 ratio with heat-inactivated 
immune serum or serum lacking anti-Salmonella antibodies. 
 
2.3 Flow cytometry assays 
2.3.1 Quantification of antibody binding on the surface of salmonella 
A 1-in-10 dilution of sample serum to PBS was prepared. 5μl of fixed and concentration 
adjusted (to 2x10
9
 cfu/ml) or live Salmonella inoculum was added to 45μl of diluted 
serum. PBS was used as a negative control. Samples were gently mixed and then 
incubated at room temperature for 20 minutes. 1ml PBS was added to each tube and 
samples were mixed by inversion and spun for 5 minutes at 3,300xg in an Eppendorf 
micro-centrifuge (Hamburg, Germany) to wash the bacteria. The supernatant was 
discarded and the samples washed again. An anti-antibody FITC conjugated antibody 
(Human: total IgG and total IgM; and mouse: total IgG and total IgM) (Table 2.5) was 
added to each sample and incubated at room temperature for 20 minutes, protected 
from light. Two more wash steps were performed before fixing the samples by adding 
200μl 1% Formaldehyde PBS. Samples were mixed and analysed by flow cytometry. A 
FACSCalibur (Becton Dickinson) or FACSCANTO (BD Biosciences) machine was used 
in combination with CellQuest (Becton Dickinson) or FACS DIVA (BD Biosciences) 
software respectively to acquire and analyse flow cytometric data. Further analysis and 




presentation of data was performed using FlowJo software (Tree Star Inc). The  
Salmonella population was gated by forward and side scatter light characteristics (Figure 
2.1) and the geometric mean fluorescence intensity (GMFI) of the fluorescence channel 
1 (FL1), FITC signal was used as the relative anti-Salmonella antibody titre. Internal 
quality control of the cytometer was determined using CaliBRITE beads (Becton 
Dickinson) on each day of use.  
  
2.3.2 Quantification of complement components on the surface of 
Salmonella by flow cytometry 
 
Assessment of the binding of complement was performed as described in section 2.3.1 
with two slight modifications. Namely, serum was used undiluted and the appropriate 
anti-complement antibodies were used in place of anti-immunoglobulin antibodies. Anti-
C3c FITC conjugated antibody was used for C3 measurement and MAC binding was 
analysed used an anti-C5b-9 neo-epitope antibody in combination with a rabbit-anti-
mouse FITC conjugated antibody (Table 2.5). 
 
2.4 Imaging of antibody and complement binding by confocal microscopy 
The protocols for complement and/or antibody assays (2.3.1 and 2.3.2) were followed up 
until the second wash after incubation with the relevant FITC labelled antibody. At this 
point fixative, either 1% Formaldehyde or various mixtures of paraformaldehyde (Sigma) 
and glutaraldehyde (Agar Scientific) were added. The sample was vortexed and then left 
overnight at 4°C. The following day the sample was again vortexed prior to spinning at 
3.300xg in an Eppendorf micro-centrifuge (Hamburg, Germany), for 5 minutes. The 
supernatant was aspirated off to a volume of 50µl and the pellet re-suspended. 5µl was 
pipetted onto a Superfrost Plus charged microscope side (Leica Microsystems) and the 
dried at 37°C for around 20 minutes. A drop of acetone (Sigma) was pipetted onto the 
sample and left to dry. Once dry, a drop of DAPI ProLong Gold mountant (Invitrogen) 




was added on top of the sample. A coverslip was applied and the slides stored protected 
from light at 4°C until viewing under an oil immersion 1003 objective lens with an 
Axiovert100M confocal microscope (Zeiss). Analysis and presentation of images was 
performed using LSM Image Browser (Zeiss). Where reference is made to a wet sample 
the drying and acetone steps were omitted. I.e. the sample was applied to the slide and 
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Table 2.4: Mice immunisation schedule 
 




Table 2.5: Antibodies used for antibody binding and complement deposition FACS and 
confocal format assays 
 





C3c Polyclonal Human/Mouse Rabbit FITC DakoCytomation 
C5b-9 Monoclonal Mouse Mouse N/A DakoCytomation 
Ig Polyclonal Mouse Rabbit FITC Sigma 
IgA Polyclonal Human Rabbit FITC Sigma 
IgG Polyclonal Human Rabbit FITC Sigma 
IgG Polyclonal Mouse Goat FITC Sigma 
IgM Polyclonal Human Rabbit FITC Sigma 


















Figure 2.1: Gating of Salmonella population by flow cytometry 
A pseudo-colour density dot plot of A forward scattered against side scattered light 
using FlowJo software shows the Salmonella population for antibody and complement 
FACS assays. B gating for single bacteria using information for the side scattered 
area and width of light.  
 







Figure 2.2: A cartoon representation of a generalised Salmonella LPS structure annotated with lines demonstrating the sites 
of truncations resulting from various LPS gene knockouts. Gene knockouts responsible for LPS truncation listed alongside 
line in corresponding colour to line. 




2.5 Imaging of antibody and complement binding by electron microscopy 
 
2.5.1 Assay 
The protocols for complement and/or antibody assays (2.3 and 2.4) were essentially 
followed up until the incubation of Salmonellae with serum. However, in order to produce 
a bacterial pellet large enough for sectioning, both serum and bacteria volumes were 
increased 20 fold. So that 100µl of Salmonellae (2x10
9
 cfu/ml) was added to 900µl 
serum. 
 
2.5.2 Pre resin-embedding staining technique 
2.5.2.1 Staining 
Following incubation with serum, the samples were washed in PBS for 5 minutes 3 
times. The bacteria were pelleted after each wash at 3,000xg and re-suspended in PBS 
containing 5% fetal calf serum (FCS) (Sigma). The samples were again pelleted and re-
suspended in antibody-gold (1:20) in PBS with 5% FCS and incubated for 30 minutes 
before pelleting (Table 2.6). Samples were re-suspended and rinsed in PBS 3 times for 
5 minutes a time, then pelleted.  
 
2.5.2.2 Fixation 
The samples were fixed for 30 minutes at 4°C in a solution of 2% glutaraldehyde (Agar 
Scientific), 5% paraformaldehyde (Sigma) and 0.1% ruthenium red (Sigma) in PBS. 
Samples were then washed in PBS before the addition of sonicated 1% osmium 
tetraoxide (Agar Scientific) in pH 7.4 0.1M sodum cacodylate (Sigma). After 30 minutes 
of fixation at 4°C, the samples were washed 3 times with sodium cacodylate and kept at 
4°C before transport to the electron microscopy facility.  
  
 




2.5.2.3 Dehydration processing  
Once at the facility, the samples were pelleted as described previously before addition of 
20% ethanol in dH2O in order to cover the whole surface of the pellet. At this stage of 
processing it is desirable to keep the pellet intact and so care was taken to avoid re-
suspension, additional centrifuging and thus re/pelleting was carried out only when 
needed. After 15 minutes incubation the solution was removed and 30% ethanol was 
added for 15 minutes. Following removal, a solution 1 part ethanol, 1 part uranyl acetate 
(Agar Scientific) and 1 part dH2O was added and incubated in the dark, again for 15 
minutes. The next few incubations were performed out of direct light to prevent any 
residue of uranyl acetate reacting. 15 minute incubations with 50%, then 70% and finally 
90% ethanol solutions followed, before a series of three 20 minute incubations with 
100% ethanol. When working with high concentrations of ethanol care was taken not to 
allow the pellet to remain uncovered by solution, as evaporation could lead to excessive 
drying. After the ethanol dehydration steps propylene oxide (Agar Scientific) was added, 
immediately changed with a new propylene oxide solution and incubated for 30 minutes. 
During this time 50ml of resin was made using an Agar 100 resin kit (Agar Scientific) and 
mixed by slow inversion in a 50ml falcon tube. After removal of the propylene oxide a 
solution of 50% propylene oxide and 50% resin was added to samples and allowed to 
incubate for one hour. Finally 1ml of 100% resin was added to each sample and allowed 
to set overnight at room temperature.  
 
2.5.2.4 Sectioning and analysis 
The following sections (2.5.2.4, and 2.5.3) were performed by Dr David Goulding.  
The next morning the resin embedded specimens were cured in an oven at 65°C on a 
flat moulded tray. Thin sections were cut on a Leica EM UCS and collected onto copper 
grids, contrasted with uranyl acetate and lead citrate (Agar Scientific) before viewing on 




an FEI 120kV Spirit Biotwin transmission electron microscope. Images were recording 
using an F4.15 Tietz camera. 
 
2.5.3 Post-embedding cryo-section technique 
2.5.3.1 Fixation and preparation 
Cells were fixed with 2% paraformaldehyde and 0.2% glutaraldehyde in PBS for 1 hour 
on ice. They were then washed with 0.1% glycine in PBS x2 at 37°C, pelleted at 
3000rpm. 1ml of 1% gelatin (Sigma) in PBS at 37°C was added and the samples were 
re-pelleted by centrifuging for 5 minutes at 37°C. The procedure was repeated but using 
10% gelatin before being stored at 4°C. The gelatin was chopped into pieces and 
infiltrated with 2.3M sucrose on a roller in the cold room overnight. Finally, the samples 
were mounted and frozen onto pins and cut into ultrathin sections using a Leica EM 
FC6. 
 
2.5.3.2 Immunocytochemistry for cryosections 
Sections were blocked, first with 0.02M glycine (Sigma) in PBS for 20 minutes and then 
with 10% FCS in PBS for 1 hour. Following blocking, the primary antibody was applied 
and incubated for 1 hour. The samples were washed in PBS for 30 minutes three times, 
centrifuging at 3,300xg after each wash. 10nm gold conjugated protein A was applied 
and incubated for 1 hour. Next, samples were washed 6 times, as described above, 
before fixation in 2.5% glutaraldehyde in PBS for 30 minutes. Thorough washing, 10 
times in ddH2O using capillary forceps followed. Uranyl acetate in methyl cellulose 
(Sigma) (1.8%/0.4%) was added to the samples and incubated for 10 minutes on ice. 
Afterwards, they were collected in loops, blot dried on Whatman paper and finally air 
dried. Samples were viewed on a FEI Spirit Biotwin 120kV TEM. 
 
 




Table 2.6: Antibodies used for electron microscopy 
Detection Specificity Clonal Target 
Species 
Host Conjugate Supplier 
C3 C3c Polyclonal Human Rabbit - Dako 
- IgG  Rabbit Goat 10nm Gold Agar 
Scientific 
C5b-9 C5b-9 Monoclonal Human Mouse - Dako 
- IgG  Mouse Goat 10nm Gold Agar 
Scientific 
IgG IgG  Human Goat 10nm Gold Agar 
Scientific 
IgM IgM  Human Goat 10nm Gold Agar 
Scientific 
 
2.6 Haemolytic assays 
2.6.1 Human serum 
Haemolytic kits, based on an a traditional radial immunodiffusion (RID) assay, were 
obtained from The Binding Site (Birmingham) and used to determine the alternative and 
total haemolytic activity of human serum. The alternative pathway haemolytic 
complement assay used is an adaptation of a classic method, using the principle that 
chicken erythrocytes will bind C3b, allowing the formation of C3 convertase. This 
activates the alternative complement pathway leading to the haemolysis of the 
erythrocyte. The total haemolytic complement assay uses the principle that sheep 
erythrocytes coated with anti-sheep-erythrocyte antibody (haemolysin) will, in the 
presence of normal human serum, activate the classical complement pathway leading to 
haemolysis of the erythrocytes. The kit features RID plates which house erythrocytes 
supported in agarose. To determine the degree of alternative and total haemolytic 
pathway activity, samples were added to the wells in the plate and incubated at 4
o
C 
overnight. This first incubation allows the complement components in the sample to 




diffuse through the gel. The temperature was then raised to 37
o
C for around 2 hours, 
which allows activation of the complement cascade that was previously being inhibited 
by the lower temperature. A clear zone of haemolysis is produced around wells with 
samples which have functional complement. The diameters of any zones were 
measured and, using a standard curve of known haemolytic activity, the activity of the 
sample was calculated. 
 
2.6.2 Mouse complement haemolytic assay  
2.6.2.1 Preparation of mouse anti-rabbit erythrocyte (sensitising) antibody 
Three female BALB/c mice (6-8 weeks of age) were subcutaneously immunised with 
100µl of packed rabbit erythrocytes (RE) washed in PBS, with an identical inoculation 
boost was given in the second week. A final inoculation was administered 
intraperitoneally (i.p.) in the third week. Two days post i.p. boost the mice were 
exsanguinated and serum was prepared and pooled before storage at -80°C. 
 
2.6.2.2  Complement assay 
Washed rabbit erythrocytes were re-suspended in complement fixation diluent (CFD) 
(Oxoid, UK) at 2% (vol/vol) and sensitised by incubation for 30 minutes at room 
temperature with a 1:500
 
final dilution in CFD of mouse anti-rabbit erythrocyte antiserum. 
Sensitised erythrocytes were washed, re-suspended
 
at 1% in CFD, aliquoted into the 
wells of a 96-well plate (50l/well), and
 
incubated at 37°C for 30 minutes with 50l 
dilutions of mouse serum in CFD. Zero, 50µl of CFD, and 100%, 50µl of distilled water, 
lysis controls were included in all assays. Plates
 
were centrifuged, and complement 
activity was assessed by hemoglobin release (absorbance at 415 nm). Percentage lysis 
for individual
 
wells was calculated from the following formula: % lysis = (A415(test) –




A415(min))/(A415(max)-A415(min)) x 100. Corresponding serum was heat inactivated at 
56
o
C for 30min and used to determine background, due to the colouring of the serum. 
 
2.7 Quantification of phagocytic activity of monocytes and neutrophils in   
whole blood 
2.7.1 FITC labelling of Salmonella 
1mg/ml FITC (Sigma) was made up in PBS and filtered. 1 part of this FITC solution was 
added to 40 parts (7.5μl to 300μl) of 3 hour grown 2x1010 cfu/ml heat killed nontyphoidal 
Salmonella (heat killed by incubation at 56
o
C for 30 minutes). The mixture was protected 
from light by foil and incubated for 20 minutes at 37
o
C on a rocker shaking at 20rpm. 
The labelled NTS was washed by adding 1ml PBS and spinning at 3,300xg for 5 
minutes. The supernatant was tipped off and the NTS washed again, this time the 
supernatant was aspirated off by pipette and re-suspended in 100µl (or the required 
volume) of PBS. Aspiration at this step is vital for consistent labelling. 
 
2.7.2 Phagocytosis assay 
50µl heparinised whole blood (1µl heparin per ml of blood) was transferred to a 5ml 
FACS tube. Negative control blood samples were placed in an ice bath. The other blood 
samples were pre-heated to 37
o
C in an incubator for 30 minutes. The FITC-labelled NTS 
was vortexed hard and 10µl was added to each blood sample and mixed. The labelled 
NTS was added at time intervals that allowed phagocytosis to be stopped at the same 
time in all samples. After the determined length of time incubation was stopped by 
placing the samples in an ice bath filled with ‘ice water’ and adding 50µl ice-cold trypan 
blue 0.16% (Sigma) which served as a fluorescence quenching solution. 1.5ml of ice 
cold PBS was then added per tube, before vortexing and spinning at 250xg for 5 
minutes at 4
o
C. Supernatant was tipped off and the pellet re-suspended. The cells were 
washed and the pellet re-suspended a second time prior to the addition of 1ml of pre 




warmed (at room temperature) 1x lysing solution (FACS Lysis (BD Biosciences) diluted 
1 in 10 in dH2O), samples were mixed and incubated for 20 minutes at room 
temperature, protected from light. After incubation, samples were spun at 250xg, 4
o
C for 
5 minutes. Supernatant was discarded and the pellet re-suspended by racking. A final 
wash step was performed before tipping away the supernatant, re-suspending the pellet 
and adding 100µl of 20µg/ml propidium Iodide. Propdium iodine binds to DNA and is 
detectable in the FL2 channel of a FACSCalibur flow cytometer, as it is excluded from 
viable cells it can be used to eliminate dead cells from analysis. Samples were mixed 
and incubated for 10 minutes on ice, protected from light. Samples were read within 60 
minutes on a FACSCalibur instrument. Analysis was performed using CellQuest 
software as shown in figure 2.3. 
 




















































Figure 2.3: Left Panel Typical dot plots FSC/SSC showing recommended gating and 
Right Panel FL1 histograms of the phagocytosis test (incubation time of 10 min with, kit 
provided, E.coli at 37°C). (A) Neutrophils, (B) Monocytes. (PhagoTest Operator’s 













2.8.1  Lipopolysaccharide capture 
50µl of 1mg/ml S. Typhimurium lipopolysaccharide (LPS) (Alexa) was mixed with 10ml 
carbonate coating buffer (Sodium carbonate(Na2CO3) and Sodium bicarbonate 
(NaHCO3) diluted in 1 litre of distilled water) giving a 5µg/ml final concentration of LPS. 
Flat bottom 96-well plates (Nunc) were coated with LPS by filling each well with 100µl of 
5µg/ml LPS and incubating overnight at 4
0
C. The coated plates were then washed 3 
times with PBS 0.05% Tween (500 µl Tween (Sigma) in 1 litre PBS). The blocking buffer 
(1% bovine serum albumin (BSA) in PBS) was made by mixing 160ml PBS with 1.6g 
BSA (Sigma). 100µl of 1% blocking buffer was added to each well, and incubated for 1 
hour at 37
0
C. Plates were washed three times with 0.05% PBS Tween. 150µl of a 1:10 
dilution of each serum in 1% BSA was added to the first row of the 96-well plate and 
100µl of 1% BSA was added to the rest of the wells. Three-fold dilutions of the each 
were made by transferring 50µl from the first well of each column in the 96-well plate to 
the second well, and serially diluting into each subsequent well (Fig 2.3). The plates 
were incubated at 37
0
C for one hour and washed four times with PBS 0.05% Tween. 
100µl of 1:2000 dilute AP-conjugated-secondary antibodies (IgG, IgM or IgA) were 
added to each well and incubated for 1 hour at 37
0
C. The plates were washed three 
times in PBS 0.05% Tween and 100µl Sigma-fast alkaline phosphate (AP) substrate was 
added as the AP chromogenic substrate. This was prepared by reconstituting 2 tablets 
of p-nitrophenyl phosphate (Sigma) with 20ml distilled water. The results were read 
using ELISA plate reader set at 405nm using SoftMax Pro software (Greiner). 
 
2.8.2  Outer membrane protein preparation for ELISA 





 were prepared by Dr Denisse Leyton from the School of Biosciences, 




Department of Immunity and Infection, University of Birmingham. Overnight culture of S. 
Typhimurium D23580 was grown by inoculating a few single colonies of the bacteria in 
5ml LB broth. 100ml LB broth was inoculated with a 1/100 dilution of the overnight 
bacterial culture and grown to a late log phase (OD600 1.0). For galE
- 
growths M9 
minimal media was used in place of LB. The cells were harvested by centrifugation at 
10,000 x g at 4°C for 10 minutes and re-suspended in 20ml 10mN Tris Buffer (pH 7.4). 
The bacteria were passed through a French pressure cell at 20,000 psi twice to disrupt 
the outer membrane of the bacteria. The cells were then centrifuged at 6,000 x g at 4°C 
for 10 minutes to remove unbroken cells. Separation of the cell envelope and 
cytoplasmic fractions was performed by centrifuging the cells at 50,000 x g at 4°C for 90 
minutes. The pelleted envelopes were re-suspended in 10ml 10mM Tris Buffer pH 7.4-
2% (v/v) TritonX-100 and incubated at 25°C for 15 minutes to allow solubilisation of the 
inner membrane. The TritonX-100-extracted envelopes were harvested by centrifugation 
at 50,000 x g at 4°C for 90 minutes. The pellet was washed three times in 1ml 10mM 
Tris Buffer pH 7.4 and re-suspended in 1ml 10mM Tris Buffer pH 7.4. The cell envelope 
suspension was aliquoted into 250 µl volumes and stored at -20°C. ELISA assay used 
for assessing levels of antibody against the outer membrane protein was performed as 
described in section 2.8. A concentration of 5 µg/ml of the outer membrane protein and 
1:2000 dilutions of AP-conjugated secondary antibodies (IgG, IgM and IgA) were used. 
Preparations were tested for contamination using a monoclonal anti-O:4 antibody as the 
primary antibody in the ELISA format described in section 2.7.1.                  
 
2.9 Mutagenesis: LPS gene knockouts 
LPS gene knockout was performed using the lambda red recombinase methodology 
outlined in Figure 2.4 (Datsenko and Wanner, 2000). This protocol replaces the target 
gene with an antibiotic resistance cassette. The study used mutants created by 




ourselves as well as some kindly gifted by Rob Kingsley, Sara Sa Silva and Francesca 
Necchi. All mutants were created using the protocol outlined here. 
 
2.9.1 Primer design  
Oligonucleotide primer pairs designed to amplify an antibiotic resistance cassette were 
designed using Artemis and the annotated genome of S. Enteritidis PT4 strain P125109 
(EMBL accession no. AM933172). Primers were constructed by Primm Biotech. The 5´ 
ends consisted of ~50bp homologous to the flanking sequence of the gene being 
targeted for deletion. The 3´ ends were specific to primer sites flanking the resistance 
cassette. Thus the PCR amplification product produced was a resistance gene flanked 
by sequence that defined the desired deletion site. 
 
2.9.2 PCR of antibiotic resistance cassette 
Ten 50µl PCR reactions were prepared in 0.2 ml thin walled PCR tubes using the 
designed primers. Each reaction mixture contained, 1µl template DNA, 1µl primer A 
(Forward), 1µl primer B (Reverse), 1µl 100mM dNTP`s (dNTP), 1.5ul MgCl (MgCl), 5µl 
10x PCR buffer (10x), 39.3µl PCR grade water (dH2O) and 0.2µl Taq polymerase (Taq) 
using a thermal cycler a PCR Cycle similar to shown in Figure 2.5. 
 
2.9.3 Concentration and de-salting of PCR product 
PCR reactions were pooled in a sterile 2ml microfuge tube. In order to concentrate and 
purify the PCR product, 2.5 x volume of 100% ethanol,  60l of 3M sodium acetate (pH 
5.2) and 1l of glycogen were added and mixed well then incubated on ice for 10 
minutes. Next, samples were centrifuged at 16,000x g for 15 minutes in a bench-top 
microfuge. The supernatant was aspirated off and 70% ethanol used to wash the pellet 
before another centrifuge spin at 16,000xg for 5 minutes. Once again supernatant was 




aspirated followed by air drying for around 10 minutes until no liquid was visible. 20l of 
sterile dH2O was added and mix by pipetting. The DNA samples were stored on ice. 
 
2.9.4  Analysis of PCR product size and concentration 
The size and concentration of purified PCR products was checked by running on a 1% 
agarose gel containing SYBR safe DNA dye (Invitrogen). 1l of PCR product was added 
to 39l of sterile dH2O and 10l of the mixture was loaded. Samples were run at 90v for 






Figure 2.4: Gene disruption strategy. H1 and H2 refer to the homology extensions or 
regions. P1 and P2 refer to priming sites. (Datsenko and Wanner, 2000) 
 





                            94
o
C – 30s   
Denaturing:        94
o
C – 30s 
Annealing:         55
o
C* – 30s                   30 cycles 
Extension:         72
o
C – 2mins**  
                           72
o
C – 2mins  
                       16
o
C*** – Forever 
Figure 2.5: PCR cycle for amplification of primers for replacing gene targets with 
antibiotic resistance casettes.* Dependent on melting temperatures of primers. ** 
Dependent on size of fragment. *** Storage at 4°C also used 
 
 
2.9.5 Preparation of electro-competent cells  
An overnight culture of Salmonella that had been previously transformed with the 
plasmid pSIM18 (Figure 2.6) was grown as section 2.1.2 and the next morning a 1-in-
100 dilution was made into 100ml of LB-hygromycin. The bacteria were incubated at 
30°C with shaking at 180rpm until an OD at 600nm of around 0.4. The pSIM18 plasmid 
encodes hygromycin resistance and a heat inducible (42°C) lambda red recombinase 
gene, as well as a temperature sensitive replicon to facilitate subsequent curing of the 
plasmid. The growth was split into two 50ml falcon tubes and incubated in a water bath 
at 42°C for 15 minutes. The tubes were then immediately transferred to ice water and 
left for 8 minutes. Cells were pelleted at 4°C by centrifuging at 3,300xg for 10 minutes. 
The supernantant was removed and the pellets pooled into one 50ml falcon in 45ml of 
ice-cold dH2O. The bacteria were again pelleted as above and re-suspended in 1.5ml of 
ice cold dH2O. The samples were washed through pelleting in a microfuge, at 4°C for 2 
minutes at 10,000rpm, and changing of the dH2O a further three times. After completion 
of the washing the cells were re-suspended in final volume of 100µl of ice-cold dH2O and 
placed on ice until required 












Figure 2.6: pSIM18 plasmid pSim plasmids provide an alternative convenient route for 
recombineering. Hygromycin (pSim18)-resistant gene-coding sequence is driven by 




2.9.6  Transformation of cells with PCR product 
Two 0.2cm electroporation cuvettes were chilled on ice for 5 minutes. 4µl of PCR 
product was added to one cuvette and the same volume of ultra-pure water to the other. 
40µl of electro-competent cells prepared in section 2.9.5 were added to each cuvette 
and mix gently by tapping the cuvette. The metal contacts of the electroporation cuvettes 
were dried and then electroporated using a Bio-Rad Gene Pulser set at 2.4kv, 25µF, 600 
ohms. An audible pop signals an unsuccessful electroporation and the cells should be 
discarded and the procedure repeated. Immediately after electroporation, 400µl of pre-
warmed SOC medium was added to each cuvette and mixed gently by tapping the 
cuvette. They were incubated at 37
o
C without shaking for 2 hours. After incubation the 
suspension was mixed by pipetting and spread on LB plates containing the homologous 
antibiotic transformed to the bacteria and incubated overnight at 37
o
C. The cuvettes 




were also incubated overnight, though at room temperature on bench at room 
temperature. The next morning plates were checked for growth. The negative control 
should not have any colonies. The remaining contents of the electroporation cuvettes 
were plated onto the appropriate selective media as above. 
 
2.9.7 Checking colonies for successful gene knockout 
Insertion of the antibiotic cassette and thus removal of the targeted gene was checked 
through PCR of genomic DNA from bacterial colonies and also, where needed, 
sequencing.  
 
2.9.7.1 Purification of bacterial genomic DNA 
DNA was purified using a GenElute Bacterial Genomic Kit (Sigma). Briefly, cells were 
harvested from an overnight growth, re-suspended in a lysis solution with RNase added. 
Following incubation at room temperature the cells were lysed by addition of proteinase 
K, incubation at 55°C and then addition of a second lysis solution and further incubation 
at 55°C. The lysed bacterial solution was spun through a column in order to bind DNA, 
before washing of the column and finally elution and collection of DNA. Concentration 
and purity of DNA was checked on a NanoDrop spectrophotometer (Thermo Sceintific). 
 
2.9.7.2 PCR of bacterial genomic DNA 
PCR and running of the products on an agarose gel were carried out as in section 2.9.2 
using the same primers, where appropriate primers with internal sites within the 
resistance cassette were also used. The fragment sizes obtained for knockout and wild 
type colonies were compared using a marker ladder. 
 
 




2.9.7.3  DNA Sequencing 
For cases in which the antibacterial cassette was similar in size to the gene that was 
being knocked out DNA sequencing was employed using the same primers as used for 
PCR. Prior to sequencing the DNA generated by PCR was purified using a Wizard® SV 
Gel and PCR Clean-Up System (Promega). DNA sequencing data was analysed using 
FinchTV software (Geospiza Inc) and the Nucleotide BLAST web-tool (NCBI). 
 
2.10 O:Antigen assays  
2.10.1 Agglutination assay 
A drop of monovalent anti-Salmonella O4, 9 or 12 antiserum (BioRad) was spotted onto 
a glass microscope slide (Menzel-glaser). A section of a single colony was picked from 
an agar plate using an inoculating needle (Nunc) and mixed with the antiserum on the 
slide. Agglutination was determined by eye. 
 
2.10.2 Flow cytometry O-antigen surface staining assay  
The flow cytometry assay as described in section 2.3 was used with modifications. 
Namely, instead of incubation with serum, an anti-O4/9/12 antigen mouse monoclonal 
antibody (AbCam) was used as a primary antibody source. A FITC conjugated rabbit 
anti-mouse Ig antibody (Dako) allowed relative quantification of O-antigen using analysis 
described in section 2.3. 
 
2.11  Antibody adsorption  
An inoculum of OD 0.1 at 600nm of the desired Salmonella was grown (as per section 
2.1.2-3) (around 4 hour growth dependent on the strain). It was washed in PBS before a 
100x concentration to a final inoculum concentration of ~1x10(11) cfu/ml. For every 1ml 
of sera, 100µl of the concentrated bacterial solution was required for each adsorption 
cycle. To limit the dilution of serum, the Salmonella suspension was spun at 3300x g in a 




micro centrifuge and the supernatant (around 50-70µl dependent on Salmonella strain) 
removed. The bacteria and serum were both pre-cooled to 4°C, before addition of serum 
direct to the Salmonella pellet, ensuring thorough re-suspension. This mixture was 
incubated for ~1 hour at 4°C per cycle. Salmonellae were removed between cycles by 
centrifuging at 4° at 3300 x g and the final cycle contained an additional filtration step 
through a 0.2µm syringe filter to ensure the sterility of the sera. Sera were stored at -
80°C until use. Sera for use in experiments requiring functional complement were 
always freshly defrosted. Adsorptions ranged from a single cycle to five cycles and the 
conditions used are listed in the relevant sections. A minimum of two cycles were 
required in most circumstances to remove bactericidal activity. 





Work in this chapter has been published in the Journal of Immunology. The full manuscript is 
included in the appendix. 
 
 




An improved knowledge of the relevant protective mechanisms of immunity against 
Salmonella is required for the development of an effective vaccine against NTS. Much of 
the assessment of vaccine candidates needs to be performed in vivo and so animal 
models of infection are required to complement in vitro studies with human tissues. 
Since S. Typhimurium causes invasive disease in the mouse, this animal provides a 
useful model for the study of NTS infections in vivo. As such, it is important to 
understand the similarities and differences between the immune response to Salmonella 
in mice and men. 
 
Antibodies are protective in the mouse model of salmonellosis (Cunningham et al., 2007, 
Gil-Cruz et al., 2009, McSorley and Jenkins, 2000, Xu et al., 1993), and in African 
children Salmonella-specific antibodies are associated with resistance to invasive NTS 
disease (MacLennan et al., 2008). It is likely that cell-mediated immunity controls 
infection within phagocytes and the humoral arm of immunity is important for controlling 
spread after release from infected cells (Mastroeni et al., 2009).  This potential role of 
antibodies in limiting NTS spread within the body may mean that a vaccine stimulating 
an antibody response could offer protection, especially in preventing more serious 
systemic NTS infections such as bacteraemia. Good cell-mediated responses have 
proved difficult to elicit through vaccination and so this vaccine strategy could prove a 
successful approach.  




Antibodies are thought to protect against Salmonella disease in two main ways: either in 
a cell-independent manner through complement-mediated bactericidal activity or through 
a cell-dependent mechanism involving the oxidative burst by opsonising bacteria for 
uptake and killing by phagocytic cells, increasing internalisation and killing (Menager et 
al., 2007). Antibodies have previously been shown to have an important role in 
opsonising Salmonella for phagocytosis and cellular killing in both C57BL/6 mice 
(Uppington et al., 2006) and humans (Gondwe et al., 2010). However, the ability of 
mouse serum to kill Salmonella using the cell-free complement-mediated mechanism 
described in humans is uncertain, particularly in view of the known poor function of 
mouse complement (Brown, 1943, Marcus et al., 1954). Clarification of this issue is 
important in harmonising in vitro and in vivo work and clinical evidence in order to assist 
with vaccine creation.  
 
To test the hypothesis that mouse serum lacks cell-free complement-mediated killing 
activity against African NTS, we studied the bactericidal capacity of serum, antibodies 
and complement from C57BL/6, BALB/c, and C3H/HeNHsd (C3H) mice immunised with 
heat killed S. Typhimurium strains D23580 and SL1344 and live-attenuated strain 
SL3261. 
 
3.2 Statistical Analysis 
For SBA data, which were normally distributed, comparison of two groups was 
performed using Student’s t test. One-way analysis of variance tests were used for 
comparisons of multiple groups. Haemolysis data displayed non-Gaussian distribution 
and thus statistical significance was tested using a Kruskal Wallis test. The D'Agostino-
Pearson omnibus K2 normality test was used to help make an informed decision about 
the distribution of data.  





3.3.1 Mouse serum has preserved complement function  
C57BL/6, BALB/c and C3H mice were found to have intact lytic activity against 
sensitised rabbit erythrocytes at a 1:20 dilution using the haemoglobin release assay to 
assess classical pathway complement activity (Fig. 3.1 A). There was no statistical 
difference in the degree of lysis between any groups including freshly-exsanguinated 
C57BL/6 serum (p=0.7799 Kruskal-Wallis) demonstrating that the processing and 
storage of the mouse sera had not adversely affected the quality of the complement. 
Heat inactivation absolved the activity of all sera, consistent with the assay being a 
determinant of haemolytic activity. 
 
3.3.2 Mice mount an antibody response to heat-killed African S. Typhimurium 
strain D23580 
Groups of six BALB/c, C3H or C57BL/6  mice were primed and boosted, after 14 days, 
with heat-killed African S. Typhimurium D23580 at a dose of 10
7
 bacteria/ml or PBS 
(negative control group) via the i.p. route. An additional two groups of C57BL/6 mice 
were either immunised with heat killed laboratory strain S. Typhimurium SL1344 (as 
described above) or with one immunisation of 5x10
5
 cfu/ml of live attenuated vaccine 
strain SL1344, also via i.p. After 28 days, for immunisations with heat-killed bacteria, or 
35 days for immunisations with live bacteria, mice were exsanguinated by cardiac 
puncture.  
 
Serum was assessed for antibody response to Salmonella. While no anti-Salmonella 
antibodies were detected in serum from the control group, all mice immunised except 
two had produced IgG and IgM antibodies to Salmonella (Fig. 3.1 B). The levels were 
approximately 10-100 times the level found in bactericidal control volunteer human 
serum. Sera from mice producing no response were discarded. 




The lack of anti-Salmonella antibodies in control mouse serum demonstrated both that 
the mice had an absence of natural and cross-reactive antibodies to Salmonella and 
indicted that the assay was specific to anti-Salmonella antibodies. Antibody titres were 
similar regardless of whether the assay was performed using S. Typhimurium D23580, 
SL1344 or SL3261 (Fig. 3.2). However, the low statistical power of using three samples 
might produce a false negative. A significant difference between capture stains may be 
illustrative of antigenic differences between the strains and so increasing the number of 



































































































































































































Figure 3.1: Antibody response and classical pathway complement activity in mouse sera 
following immunisation with African and laboratory strains of S. Typhimurium. 
A, Lytic activity of mouse sera against rabbit erythrocytes sensitised with mouse anti-rabbit 
erythrocyte antiserum, measured using the haemoglobin-release assay. Fresh C57BL/6 mice sera 
(diamonds), frozen freshly-thawed mice sera: BALB/c (inverted triangles); C3H (triangles); 
C57BL/6 (filled circles), heat-inactivated C57BL/6 sera (empty circles). Data are means of 
experiments with sera from six mice ± SD.B, IgG and IgM titres of anti-Salmonella antibody at 28 
days after i.p. immunisation with two doses of heat-killed Salmonella, immunisation with live-
attenuated Salmonella and unimmunised. Immunisations for heat-killed Salmonella were with 107 
heat-killed S. Typhimurium D23580 (African strain), SL1344 (laboratory strain). Immunisations for 
live-attenuated SL3261 were with 5x105 Salmonellae. Groups of BALB/c, C3H and C57BL/6 mice 
received D23580 immunisations with groups of C57BL/6 mice also receiving SL1344 and SL3261. 
Antibody measured by flow cytometric analysis of antibody-binding to fixed S. Typhimurium 






























































































































































































































































































Figure 3.2: Antibody characterisation of immune mouse sera by flow cytometry 
using heterologous and homologous strains of S. Typhimurium. 
Titres of anti-Salmonella antibody in diluted serum (1in10) from C57BL/6 mice immunised, 
as described in Fig 3.1, were measured using whole bacteria homologous and 
heterologous to the immunising strain. Sera from mice immunised with: A D23580 
(squares), B SL1344 (triangles), or C SL3261 (inverted triangles). IgG is shown in the left 
























































































































3.3.3 Sera from S. Typhimurium-immunised mice lack bactericidal activity 
against Wild Type D23580 
 
We next tested serum from immunised mice for ability to kill viable S. Typhimurium 
D23580 in log-growth phase. It has been reported that serum from African children, in 
the presence of specific IgG or IgM antibodies, is capable of antibody-dependent 
complement-mediated killing of D23580 (MacLennan et al., 2008).  
 
Despite the presence of anti-Salmonella antibodies, sera from immunised C57BL/6 (Fig. 
3.3A), BALB/c (Fig 3.3B) and C3H (Fig 3.3C) mice were unable to kill wild type D23580 
in vitro over a three hour time course, regardless of the immunisation strategy. 
Unimmunised sera were also unable to effect a kill. The concentration of viable 
Salmonella increased by over one log10 in this period and the same result was obtained 
using serum from unimmunised mice. In contrast, African adult serum effected a two 
log10 kill over three hours (Fig 3.3D). The lack of killing of Salmonella by sera from all 
groups of mice compared with the killing of Salmonella by human serum was highly 
significant (Student’s t test P<0.0001).  
 
These findings could result from the antibodies, induced following immunisation of mice 
with D23580, lacking inherent bactericidal activity. The antibodies may be unable to 
facilitate the deposition of complement membrane attack complex on the Salmonella 
outer-membrane. Alternatively, mouse complement per se may lack the necessary 
bactericidal activity to kill Salmonella, as suggested by early experiments on mouse 






























Figure 3.3: Absence of killing of African wild-type S. Typhimurium D23580 by neat 
mouse sera compared with human sera. 
In vitro serum bactericidal assay with 10
6
 Salmonellae/ml at 45, 90 and 180 minute time 
points using sera from A C57BL/6, B BALB/c, or C C3H mice immunised with D23580 
(squares) and unimmunised mice (circles). A also shows data from C57BL/6 mice 
immunised with SL1344 (triangles) and SL3261 (inverted triangles). Data are means of 
experiments with sera from three mice ± SD. D Killing of wild type D23580 by control 
serum from an African adult. Significant difference in log10 change of Salmonella at 180 
minutes between all mice and immunisations versus human control all 
P<0.0001(Student’s t tests). No significant difference between mice species and 
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3.3.4 Sera from C57BL/6 mice immunised with S. Typhimurium strain D23580 
also lack bactericidal activity against a galE
-
 knock-out rough mutant of 
D23580. 
To explore the two concluding possibilities of section 3.4.3, we repeated the serum 
killing assays using a galE
-
 knock-out mutant of D23580 that is unable to synthesise the 
O-antigen polysaccharide of LPS (MacLennan et al., 2008). It has previously been 
shown that this rough mutant is susceptible to killing by serum from African children 
lacking Salmonella-specific antibodies by alternative pathway complement activity 
(MacLennan et al., 2008).  
 
There was no difference between the results from these experiments with those using 
wild-type D23580. No Salmonella-killing occurred with sera from C57BL/6, BALB/c and 
C3H mice immunised with D23580, SL1344, and SL3261 or from unimmunised mice 
(Fig. 3.4 A-C). By contrast, African child serum lacking anti-Salmonella antibodies was 
able to effect a three log10 kill of S. Typhimurium D23580 (Fig. 3.4D). Again, the lack of 
killing of Salmonella by sera from all three groups of mice compared with the killing by 
human serum was highly significant (Student’s t test P<0.0001). These findings strongly 
suggest that the lack of bactericidal activity is the result of poor mouse complement 
function, regardless of mouse strains, the deficiency affecting both classical (antibody-


































Figure 3.4: Absence of killing of African rough galE- mutant of S. Typhimurium 
D23580 by neat mouse sera compared with human sera. 
In vitro serum bactericidal assay with 10
6
 Salmonellae/ml at 45, 90 and 180 minute time 
points using sera from A C57BL/6, B BALB/c, or C C3H mice immunised with D23580 
(squares) and unimmunised mice (circles). A also shows data from C57BL/6 mice 
immunised with SL1344 (triangles) and SL3261 (inverted triangles). Data are means of 
experiments with sera from three mice ± SD. D Killing of wild type D23580 by control 
serum from an African adult. Significant difference in log10 change of Salmonella at 180 
minutes between all mice and immunisations versus human control all 
P<0.0001(Student’s t tests). No significant difference between mice species and 
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3.3.5 Sera from S. Typhimurium immunised mice deposit reduced levels of C3 
complement on Salmonella compared with human sera. 
Since cleavage of C3 and deposition of C3b is the central event in all complement 
activating pathways, we next looked at deposition of C3 on the surface of wild type S. 
Typhimurium D23580 by sera from mice immunised with Salmonella using flow 
cytometry. While sera from unimmunised mice were unable to deposit C3 on 
Salmonella, sera from C57BL/6, BALB/c and C3H mice immunised with D23580, 
SL1344 and SL3261 were able to deposit C3 on the surface of D23580, though 
approximately one log10 less than the amount of C3 deposited by immune African serum 
(Student’s t test P<0.0001) (Fig. 3.5).  
 
Using confocal microscopy, qualitatively less C3 deposition was visualised on 
Salmonella incubated with mouse serum compared with human serum (Fig 3.6). These 
data therefore indicate deficiency in C3 deposition on Salmonella by mouse serum via 
the classical pathway relative to human immune serum. It has previously been shown 
that a minimum threshold level of C3 must be deposited on viable Salmonellae by serum 
from African children for antibody-dependent complement-mediated killing of Salmonella 
to proceed (MacLennan et al., 2008). Although the numerical value is likely to be 
dependent on assay conditions, it demonstrates the kinetics that might allow mice sera 
to deposit C3, but not kill the bacteria. The results also do not exclude the possibility of 
































Figure 3.5: Deposition of complement C3 on S. Typhimurium D23580 by mouse 
sera compared with human sera measured by flow cytometry. 
Titres of C3 deposited on S. Typhimurium D23580 following incubation in neat sera from 
BALB/c, C3H and C57BL/6 mice immunised with S. Typhimurium D23580, or 
unimmunised mice (control), C57BL/6 mice were also immunised with SL1344 and 
SL3261. Human panel shows serum ± heat inactivation (Immune/ HI Immune) from a 
healthy African adult as well as antibody deficient human serum (Ab-def). Each point 
corresponds to one experiment. Significant difference between C3 deposition by 
immunised mice sera and control human sera: all P<0.0001(Student’s t tests). No 
































































































































































Figure 3.6: Confocal microscopy images of deposition of C3 component of 
complement on S. Typhimurium D23580 by mouse sera compared with human 
sera. 
Confocal imaging of C3 deposited on Salmonellae using FITC conjugated anti-C3 
antibody following incubation in various neat mice and human sera. Human top panel 
shows normal immune serum (left) and heat-inactivated serum (right). Mouse middle 
panel shows C57BL/6 D23580 immunised (left) and unimmunised (right). Bottom panel 

























































































































3.3.6 Immune mouse sera supplemented with human bactericidal anti-
Salmonella antibodies do not kill S. Typhimurium D23580 
To check whether the absence of killing of Salmonella by mouse serum was due to a 
lack of bactericidal antibodies, we supplemented sera from unimmunised BALB/c, C3H 
and C57BL/6 mice with heat-inactivated serum from African adults containing antibodies 
to Salmonella. It has previously been shown that sera from African children that lack 
antibodies to Salmonella become bactericidal when exogenous anti-Salmonella 
antibodies are added (MacLennan et al., 2008). Addition of human anti-Salmonella 
antibodies did not correct the inability of mouse sera to kill D23580, the absence of 
killing of Salmonella being highly significant compared with the killing by fresh-frozen 
immune human serum (t test P<0.0001) (Fig. 3.7). This finding suggests that lack of 
killing of Salmonella by immune mouse serum is not due to a lack of antibody function, 
further implicating limited mouse complement function as the reason for absent 
bactericidal activity. 
 
3.3.7 Immune mouse sera supplemented with human complement can kill S. 
Typhimurium D23580 
To confirm that impaired mouse complement function was the reason for absent killing of 
Salmonellae, we supplemented C57BL/6, BALB/c and C3H mouse serum with human 
complement by mixing mouse serum with human serum lacking antibodies to 
Salmonella.  
 
Sera from all mouse immunisation groups could now kill and/or prevent the growth of 
Salmonella at 10- or 100-fold dilutions with PBS (Fig. 3.8). This killing was statistically 
significant compared with both the lack of killing by the anti-Salmonella antibody-
deficient human serum alone and immunised mouse serum alone (Student’s t test 
p<0.0001 for serum from mice immunised with heat-killed bacteria and p<0.05 for serum 
from mice immunised with live-attenuated bacteria). Killing was greater with serum from 




mice immunised with heat-killed Salmonellae compared with serum from mice 
immunised with live-attenuated bacteria.  This experiment confirms that absent killing of 
Salmonella by mouse sera is the result of limited mouse complement function and that 
the mouse antibodies against Salmonella have potential bactericidal activity leading to 
complement-mediated killing of Salmonella provided a suitable source of exogenous 
complement is available. 
 
Though the sera from live attenuated immunisation (Table 3.1) could not achieve killing 
comparable to that observed with heat killed bacteria when given a functional 
complement source, we were later able to demonstrate such a level of killing when live 
attenuated immunised sera from an earlier time point than day 35 was supplemented 
with exogenous complement. C57BL/6 mice were subjected to the same single dose of  
D23580, SL1344 or live attenuated SL3261 bacteria as before, but exsanguinated on 
day 14 (as opposed to day 28 or 35).  
 
The 14-day sera were also unable to kill Salmonella (Fig 3.9C). However, when given a 
source of functional complement, all sera (including the live-attenuated immunised) 
effected a ~2 log10 kill (Fig 3.9B). This killing was statistically significant compared with 
both the lack of killing by the anti-Salmonella antibody-deficient human serum alone and 
immunised mouse serum alone (Student’s t test P<0.001). Importantly, it demonstrated 
that immunisation with live-attenuated Salmonella could generate bactericidal antibodies 
of the same potency as heat-killed immunisation. Antibody levels were tested and 
revealed that the day 14 sera had much lower levels of anti-Salmonella IgG (Fig 3.9A) 
and IgM (Fig 3.9B) than day 28/35, (Fig 3.1B). This was reflected by the fact these sera 
killed without dilution in comparison to the day 28/35 sera which required a prior dilution 
of 1in10 or 1 in100. Whilst a prozone-like inhibitory effect resulting, at least in part, from 
an excess in antibody levels is well known in in vitro serum bactericidal systems 




(Muschel et al., 1969, MacLennan et al., 2010) the effect we encountered likely involves 
more factors than quantity alone and the reasoning is covered in the discussion (section 

















































Figure 3.7: Absence of killing of S. Typhimurium D23580 following 
supplementation of mouse sera with human anti-Salmonella antibody. 
In vitro serum bactericidal assay with 10
6
 Salmonellae/ml at 45, 90 and 180 minute time 
points using sera from A C57BL/6, B BALB/c, or C C3H unimmunised mice all 
supplemented with heat-inactivated immune human serum containing both anti-
Salmonella IgG and IgM. Data are mean of experiments with sera from three mice ± SD. 
D Lack of killing of wild type D23580 by heat-inactivated human control serum (hollow 
diamonds). Killing by control human serum (diamonds) and heat-inactivated human 
control serum with and without human complement added (diamonds with dashed line 
and open triangles). Significant difference in log10 change of Salmonella at 180 minutes 
between all mice and immunisations and heat-inactivated human serum versus normal 
human serum control all P<0.0005 (Student’s t tests). No significant difference between 
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Figure 3.8: Killing of S. Typhimurium D23580 following supplementation of mouse 
sera with human complement. 
In vitro serum bactericidal assay with 10
6
 Salmonellae/ml at 45, 90 and 180 minute time 
points using sera from A C57BL/6, B BALB/c, or C C3H mice immunised with D23580 
(squares) A also shows data from C57BL/6 mice immunised with SL1344 (triangles) and 
SL3261 (inverted triangles) all supplemented with human complement. Data are mean 
of experiments with sera from three mice ± SD. D Lack of killing of wild type D23580 by 
antibody-deficient human serum (hollow diamonds), killing by control human serum 
(diamonds) and antibody-deficient human serum supplemented with heat-inactivated 
immune human serum. Significant difference in log10 change of Salmonella at 180 
minutes between all mice and immunisations and equivalent mouse sera without 
supplemented human complement (shown in figure 3.3) C3H D23580 and C57BL/6 
D23590 and SL1344 P<0.0001, BALB/c D23580 P<0.005 and C57BL/6 P<0.05 
(Student’s t tests). 
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Figure 3.9: Antibody assay and wild type SBA experiments repeated with sera 
from mice immunised once and exsanguinated on day 14 
A, IgG and B, IgM titres of anti-Salmonella antibody at 14 days after i.p. immunisation 
with heat-killed or live-attenuated Salmonella and unimmunised. Immunisations for heat-
killed Salmonella were with 10
7
 heat-killed S. Typhimurium D23580 (African strain), 
SL1344 (laboratory strain). Immunisations for live-attenuated SL3261 were with 5x10
5
 
Salmonellae. Antibody measured by flow cytometric analysis of antibody-binding to fixed 
S. Typhimurium D23580. Each point represents serum from one mouse. C, In vitro 
serum bactericidal assay with 10
6
 Salmonellae/ml at 45, 90 and 180 minute time points 
using neat sera from C57BL/6 mice immunised with D23580 (squares), SL1344 
(triangles) or SL3261 (inverted triangles), D shows the same sera supplemented with 
human complement. Data are mean of experiments with sera from four mice ± SD. 
Significant difference in log10 change of Salmonella at 180 minutes between all mice and 
immunisations plus complement versus homologous sera without additional 
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The main finding from this study is that although BALB/c, C3H and C57BL/6 mice mount 
both an IgG and IgM antibody response to African invasive S. Typhimurium strain 
D23580, serum from immunised mice lacks bactericidal activity against Salmonella. This 
contrasts with the one to three log10 killing of D23580 which is effected by African adult 
and child serum containing anti-Salmonella antibodies. Serum from African children 
does not kill Salmonella when it lacks specific antibodies and this was the basis for 
previously describing bactericidal antibodies in Africans as an effector of humoral 
immunity against NTS (MacLennan et al., 2008). 
 
S. Typhimurium D23580 was chosen for this study because it is a typical invasive strain 
of NTS from Africa, representative of over 90% of NTS strains isolated from bacteraemic 
individuals in Malawi since 2002, is sensitive to killing by bactericidal antibodies and has 
been sequenced at the Wellcome Trust Sanger Institute (Kingsley et al., 2009, Institute, 
2009, MacLennan et al., 2008). Experiments using S. Typhimurium laboratory 
diarrhogenic strains SL1344 and, its aromatic amino acid auxotrophic mutant, SL3261 
were included to demonstrate that the lack of bactericidal activity was not restricted to 
African invasive NTS and was independent of whether the immunisation was with heat-
killed wild-type or live-attenuated Salmonellae. Our data also confirmed an absence of 
bactericidal activity in these immunised sera. 
 
C57BL/6 mice were chosen because mechanisms of immunity to Salmonella have been 
studied extensively in these mice (Cunningham et al., 2007, Gil-Cruz et al., 2009, 
Uppington et al., 2006) and the antibody response to vaccination with S. Typhimurium in 
C57BL/6 mice has been shown to protect against subsequent infection with S. 
Typhimurium (Cunningham et al., 2007, Gil-Cruz et al., 2009). The experiments were 
also performed with BALB/c and C3H mice to show that deficiency in serum bactericidal 




activity against Salmonellae is not restricted to one inbred strain of mice. Our findings 
suggest that the protective effect of mouse anti-Salmonella antibodies in mice is not 
mediated by cell-independent bactericidal activity in any of these strains.  
 
Of the mouse strains used, C57BL/6 and BALB/c are broadly classed as ‘extremely 
susceptible’ to Salmonella infection (Lam-Yuk-Tseung and Gros, 2003) and C3H/HeN is 
classed as ‘resistant’ (Roy and Malo, 2002). These classifications are somewhat 
arbitrary, being based on resistance to specific dosage and inoculation routes, but they 
represent relative resistance. This variation is likely to largely be due genetic factors 
such SLC11A1 alleles (formerly Nramp1), which controls replication of intracellular 
Salmonella by altering the intravacuolar environment of the phagosome (Cuellar-Mata et 
al., 2002). Natural resistance-associated macrophage proteins (Nramp) are multispecific 
symporters facilitating proton-dependent import of divalent metals. SLC11A1 restricts 
microbial access to essential micro-nutrients such as iron and manganese within 
professional phagosomes. SlC11A1 has many pleiotropic effects on macrophage 
activation, including regulation of the CXC chemokine KC, interleukin-1β (IL-1β), 
inducible nitric oxide synthase (iNOS), major histocompatibility complex (MHC) class II 
molecules, tumour necrosis factor α (TNFα), and nitric oxide (NO) release, L-arginine 
flux, oxidative burst and tumoricidal as well as antimicrobial activity (Blackwell et al., 
2001). The overall effect of these functions is that SLC11A1 is crucial to immunity 
against Salmonella. BALB/c and C57BL/6 are Nramp
s
 and C3H/HeN is Nramp
r
 (Malo et 
al., 1994). The C3H strain used, C3H/HeNHsd like C57BL/6 and BALB/c, has a normal 
LPS response (HarlanLabs, 2011) and is not to be confused with the LPS-
hyporesponsive C3H/HeJ strain (Sultzer, 1968, Roy and Malo, 2002). The mice also 
vary in major histocompatibility complex haplotypes, which have been shown to alter 
response to Salmonella infection (Hormaeche et al., 1985, Nauciel et al., 1988). We 
found that these differences did not affect either the IgG or IgM responses to 




immunisation with heat-killed D23580 as there was no statistically significant difference 
between either antibody titre for the three mouse groups (IgG and IgM both p= 0.3679 




 rough mutant of S. Typhimurium D23580 is sensitive to killing via the 
alternative pathway of complement by human serum lacking anti-Salmonella antibodies 
(MacLennan et al., 2008). Absent killing of the galE
-
 mutant by all mouse sera therefore 
implicates limited complement function rather than absence of bactericidal antibodies 
themselves as the reason for lack of killing with wild type D23580. Impaired complement 
function in mouse serum was first described over sixty years ago (Brown, 1943). Indeed, 
our finding that serum from immunised mice supplemented with human complement can 
effect cell-free killing indicates that the antibodies generated following immunisation with 
D23580, SL1344 or SL3261 is capable of directing complement deposition to the 
Salmonella surface at locations that enable membrane attack complex to kill the bacteria 
(MacLennan et al., 2008). 
 
Our data suggest that complement from BALB/c, C3H and C57BL/6 mice is defective in 
killing D23580 at multiple points in the complement pathway. Because it has been 
previously shown that deposition of complement and killing of wild type D23580 is 
antibody-dependent and does not proceed via alternative or mannose-binding lectin 
pathways (MacLennan et al., 2008), the low titres of C3 deposition on Salmonella seen 
with serum from immunised mice compared with human serum indicate that classical 
pathway activity is reduced compared to human serum. The lack of killing of the D23580 
galE
-
 mutant also indicates defective alternative pathway activity and indicates that the 
terminal pathway has limited activity. 
 




Nevertheless, functional classical pathway complement activity was detected against 
sensitised rabbit erythrocytes in the haemoglobin release assay. We employed this 
assay to ensure that lack of complement function against Salmonella was not merely an 
artefact of sub-optimal preparation and storage of sera. These finding suggest that 
differences exist between the susceptibility of red blood cells and Salmonella to the 
lytic/bactericidal effects of complement with Salmonella being more resistant than red 
cells. Complement that does not insert into the Salmonella outer membrane can be shed 
from the surface of S. Minnesota (Joiner et al., 1982a, Joiner et al., 1982b) and various 
molecules on the Salmonella surface including those encoded by the rck (Heffernan et 
al., 1992), traT (Rhen and Sukupolvi, 1988) and pgtE (Ramu et al., 2007) genes confer 
some degree of resistance to complement-mediated killing. Such mechanisms are likely 
to raise the threshold of complement-deposition required for bactericidal activity against 
Salmonella to proceed. It has been previously shown that the rck gene is encoded in the 
virulence plasmid of D23580 and that C9 is necessary for serum bactericidal activity 
against D23580 (MacLennan et al., 2008). In contrast, several studies on complement-
mediated haemolysis have demonstrated that this can proceed in the absence of C9 by 
limited perturbation of the membrane by C8 (Stolfi, 1968, Biesecker and Muller-
Eberhard, 1980, Dankert and Esser, 1985). 
 
With mouse complement lacking bactericidal activity against Salmonella, it is likely that 
the protective effect of anti-Salmonella antibodies in BALB/c, C3H and C57BL/6 mice is 
mediated by opsonisation facilitating phagocytosis, respiratory burst and intracellular 
killing of Salmonella by neutrophils, monocytes and macrophages. The importance of 
anti-Salmonella antibodies for these modalities of cell-mediated immunity has been 
previously demonstrated using serum and cells from C57BL/6 mice (Uppington et al., 
2006). Other work in men (in vitro) and mice has indicated that opsonisation of 
Salmonella with C3 is required for optimal intracellular killing (Gondwe et al., 2010, 




Liang-Takasaki et al., 1983, Saxen et al., 1987, Nakano et al., 1995) and work with C1q-
deficient mice has shown a role for the classical pathway of complement in protecting 
against S. Typhimurium (Warren et al., 2002). It has been found that a minimum 
threshold level of C3 must be deposited on viable Salmonellae by serum from African 
children for antibody-dependent complement-mediated killing of Salmonella to proceed 
(MacLennan et al., 2008). Although the numerical value is likely to be dependent on 
assay conditions it demonstrates the kinetics that might allow mice sera to deposit C3 
(Fig 3.5), but not kill the bacteria (Fig 3.3). 
 
Though Salmonellae are facultative intracellular bacteria, it has been hypothesised that 
the high case-fatality rate among young African children is due to extracellular bacterial 
growth unchecked by bactericidal antibodies (MacLennan et al., 2008). Since our 
findings indicate a lack of bactericidal activity in mouse serum against Salmonella, this 
could contribute to the sensitivity of BALB/c, C3H and C57BL/6 mice to infection with S. 
Typhimurium. Different mouse strains differ in their ability to handle infection with 
Salmonella and this may be due to a variety of reasons including differences in 
complement function, but also, importantly, the innate genetic susceptibility of each 
strain to Salmonella as discussed earlier. Variations in complement function between 
strains can be complex. For example, A/J mice are more effective at depositing C3b on 
Salmonella than C57BL/6 mice, but are deficient in the C5 component of complement, 
hence preventing complement-mediated bactericidal activity against Salmonella in such 
mice (Nakano et al., 1995). 
 
The serum bactericidal assays used in this study where the same as used in our prior 
published human studies (Maclennan, 2010, MacLennan et al., 2008) in order to serve 
as the best comparison of relative bactericidal activity. They were designed to fulfil the 
recommendations of Taylor in his comprehensive review of serum bactericidal activity 




(Taylor, 1983). The term ‘relative bactericidal activity’ is important to stress as the 
susceptibility of Salmonellae to serum, particularly in in vitro systems, is multifactorial. It 
is influenced by bacterial factors, such as the growth phase and growth medium; and 
also experimental factors, such as serum concentration, bacterial concentration, time of 
incubation, and washing of bacteria. Salmonella are exposed to a large range of 
environments and undergo multiple changes of environment during an infection, for 
example: from external environment to human gastro-intestinal tract; from intracellular in 
M cells or macrophages to extracellular in blood. Hence variance of serum resistance 
with growth conditions and environment means that replication of the serum resistance 
of the bacteria in vivo is complex. The ratio of components in a SBA is also important: 
excess bacteria can inhibit net killing, probably through exhaustion of complement, but 
also, too little bacteria with an excess of antibodies can inhibit killing. This effect, named 
the Neisser-Wechsberg (antibody prozone) phenomenon (Muschel et al., 1969) is most 
prominent in immunised sera which have high titres of antibody. It has been extensively 
studied through the early and middle 20
th
 century but as yet no definitive explanation has 
been described.  
 
In this study we observed the Neisser-Wechsberg effect in primed and boosted heat-
killed Salmonella immunised mice and the day 35 live-attenuated immunised mice sera. 
Both had to be diluted between 10 and 100 times in PBS in order to exert a bactericidal 
effect. It has been reported that the artefact can be removed with addition of extra 
complement (Muschel et al., 1969) so it is thought unlikely to lead to inhibition of killing in 
vivo. Interestingly, we found difficulty in determining a dilution of day 35 live-attenuated 
immunised antibody that was bactericidal, despite it having similar antibody titres to the 
other immunised sera. This could indicate that the antibody response, in relation to 
antibody class, subclass, avidity or antigen target holds the explanation of the 
mechanism of the inhibitory prozone effect. Alternatively, it may be unlinked to any 




prozone effect, but demonstrative of an antibody response that is basically just less 
bactericidal.  
 
Considering the effect of conditions on bacterial serum resistance it may appear difficult 
to conclude definitively from in vitro work that mouse serum is unlikely to have 
bactericidal activity in vivo, particularly considering the concentration of bacteria we used 
was around 10 times higher than is usually reported in Salmonella bacteraemia in mice. 
However, crucially, there are considerations that help to give confidence in such a 
conclusion. Firstly, the bacteria we used for SBAs were grown rapidly in LB media and in 
log phase and washed, conditions which produce the most serum susceptible 
inoculums. Bacteria growing at sub-maximal rates in vivo are likely to be more resistant 
(Taylor 1978). Secondly, the format of the assay maximised potential bactericidal activity 
by using undiluted serum. Finally and perhaps most convincingly, the failure to kill 
exquisitely sensitive galE
-
 shows a huge discrepancy in bactericidal activity with human 
sera, which can kill an inoculum 100 fold greater inside 15 minutes. These observations 
as well as sparse published data using different SBA systems (Rosenberg and 
Tachibana, 1962, Brown, 1943, Collins, 1967) allow us to conclude with a high degree of 
confidence that mouse serum (specifically complement) has much weaker bactericidal 
activity against S. Typhimurium than human serum which implies an absent or minimal 
role for cell-free complement-dependent killing in mice. Whilst this result is not 
unexpected considering the dogma concerning the inefficiency of the mouse 
complement system, there are a lack of published data about this and so we chose to 
investigate the phenomenon more fully. This is especially true as the striking bactericidal 
effects of human serum against Salmonella in vitro suggest this it is a modality of 
immunity that is likely to at least contribute to immunity against Salmonella in vivo in 
humans. According to Taylor in his review of the bactericidal effect: ‘The weight of 
published evidence indicates that resistance to the bactericidal action of antibody- 




complement systems is likely to play a role in the pathogenesis of at least some 
infections due to gram-negative bacteria’ (Taylor, 1983).  
 
3.5 Conclusion 
C57BL/6, BALB/c and C3H mice immunised with heat-killed S. Typhimurium strains 
D23580 (African invasive isolate), SL1344, and live-attenuated strain SL3261, produced 
a Salmonella-specific antibody response. Sera from these mice deposited reduced 
levels of C3 on Salmonella compared with human sera and were unable to kill both wild 
type and galE
-
 rough mutant of D23580 indicating absent cell-free killing via classical 
and alternative complement pathways. Supplementing immune mouse sera with human 
complement enabled killing of Salmonella, while addition of human anti-Salmonella 
antibodies to immune mouse sera had no effect. These findings indicate that mouse 
serum cannot effect cell-free complement-dependent killing of Salmonella, because of 
reduced mouse complement ability to kill these bacteria compared with human 
complement. This difference in antibody-dependent immunity to Salmonella in mice and 
human clinical disease must be considered when applying findings from the mouse 

















The influence of antibody-dependent complement-mediated killing and 
growth-phase of bacteria on the in vitro kinetics of immunity against invasive 
African Salmonella. 
 
4.1  Introduction 
In healthy adults in developed countries salmonellosis is usually a self-limiting GI 
infection. However, deficiencies or immaturity in certain aspects of immunity can lead to 
severe Salmonella disease. A lack of specific-antibodies in African infants is associated 
with fatal invasive Salmonella disease (MacLennan et al., 2008). In contrast, individuals 
with defects IFNγ production pathways, which affect killing of Salmonella within 
phagocytes, typically develop non-fatal, though severe, recurrent focal infection in lymph 
nodes despite presence of specific antibodies (Lammas et al., 2002, MacLennan et al., 
2004) and unpublished observations). 
 
Proliferation, spread and distribution of Salmonella within a host is heterogeneous and 
not fully understood. Current models of NTS infection from experiments in mice suggest 
that upon infection, a proportion of Salmonellae gain access to the blood where 
complement-mediated clearance can proceed (Warren et al., 2002). In addition, spread 
from infected to uninfected cells during bacterial growth is likely to occur mainly by 
necrotic cell death and release of individual bacteria into the extracellular space 
(Mastroeni et al., 2009). Hence, a proportion of Salmonellae are likely to be, at least 
transiently, present in the extracellular space or blood. Here they are exposed to 
humoral components of immunity. Antibody-dependent complement-mediated killing of 
Salmonella is likely to be minimal in mice (Siggins et al., 2011). Though, in humans there 
is a powerful bactericidal complement activity in the presence of specific antibodies in 




vitro (Taylor, 1983, MacLennan et al., 2008). As the majority of work on the spread of 
Salmonella within a host has been performed in mouse models, the potential 
contribution of cell-free complement killing to the dynamics of infection may have been 
under-estimated. Another complication in determining the impact of antibody-dependent 
complement-mediated killing of Salmonella is that the growth conditions and phase of 
bacteria have can alter potential virulence factors. In Salmonellae growth phase and pre-
exposure to serum has been reported to modify LPS structure and alter resistance to 
serum-killing (Bravo et al., 2008, Murray et al., 2005).   
 
Here we have performed serum bactericidal, phagocytosis, and antibody and 
complement bacterial-binding assays with human blood and sera to test the hypothesis 
that in vitro phagocytosis of S. Typhimurium by neutrophils and monocytes in blood 
occurs before all Salmonellae are killed by cell-free serum-killing in a comparable in vitro 
system. By comparing the relative timing of the deposition of humoral factors, serum-
killing and phagocytosis uptake, we propose a model for the influence of antibody-
dependent complement-mediated killing upon the spread of invasive African S. 
Typhimurium in humans. Because in vivo conditions and growth phase of Salmonella 
during infection probably vary and are difficult to predict we have tested the serum-
susceptibility of an African invasive isolates of S. Typhimurium over a range of growth 
conditions to confirm the hypothesis that it can also vary in resistance to killing by human 
serum.  
 
4.2 Statistical Analysis 
One-way analysis of variance tests were used for comparisons of multiple groups. 
Pearson correlation coefficient was used to determine correlation. The D'Agostino 




Pearson omnibus K2 normality test was used to help make an informed decision about 
the distribution of data. 
 
4.3  Results 
4.3.1  Kinetics of deposition of complement and binding of IgG to S. 
Typhimurium 
All sera used were from healthy adult donors and had specific antibodies and 
bactericidal activity against S. Typhimurium. Maximal IgG deposition varied between 
donors (One way ANOVA p > 0.05). IgG deposition on S. Typhimurium was rapid for all 
sera and reached peak levels within 15 seconds (Fig. 4.1 A). Opsonisation of 
Salmonellae by antibodies alone is insufficient to effect optimal phagocytosis in humans 
and complement is also required for maximum uptake and killing efficiency (Gondwe et 
al., 2010). Deposition of the most abundant complement opsonin, C3, was slower to 
initiate than IgG binding (Fig. 4.1 B). The deposition rates varied between donors and 
the rank order for the four donors corresponded to the rank level of IgG deposition levels 
after 10 minutes. This is consistent with the observation that specific antibodies are 
needed for deposition of complement on smooth Salmonellae (MacLennan et al., 2010). 
Antibody-directed complement-mediated killing of Salmonella also requires the binding 
of additional complement factors to form a bactericidal C5b-9 membrane attack complex 
(MAC). C5b-9 deposition on S. Typhimurium was slower than both IgG binding and C3 
deposition (Fig. 4.1 C). Again, the rank order of the rate of C5b-9 deposition by serum 
corresponded to the rank level of IgG binding. C3 and C5b-9 showed significant 
correlation (Pearson, p < 0.0001, R
2 
= 0.48). Confocal microscopy images were 
recorded for IgG and C3 binding to Salmonellae and were consistent with flow cytometry 
measurement of the GMFI (Fig. 4.2). 
 


























Figure 4.1: Time course of binding of IgG and deposition of complement 
components on S. Typhimurium. (A) IgG, (B) C3, and (C) C5b-9 deposited on African 
S. Typhimurium D23580 measured by flow cytometry (GMFI) following a time-course 
incubation in neat human serum. Each line represents one donor. Data are a mean of 
three experiments ± SD.   
 


























Figure 4.2: Confocal microscopy images of a time-course of binding of IgG and 
C3 to Salmonellae. 2x10
8
 live S. Typhimurium D23580 were incubated in neat (C3) or 
dilute (IgG) serum from a healthy adult donor for 15 seconds or 10 minutes.  Negatives 
were incubated in PBS. Samples fixed post incubation with 1% formaldehyde PBS 
solution. Salmonellae appear blue (DAPI) (A) or are imaged by transmitted light (B) and 










4.3.2 Kinetics of serum killing and phagocytosis of S. Typhimurium 
Serum-killing was minimal for all donors over the first 5 minutes and even longer for 
some donors. Following this latency there is a rapid increase in killing rate. Such a latent 
period after exposure to serum has been observed in other bacterial species and it has 
been suggested that it corresponds to assembly of the MAC  (Taylor, 1983). Our data 
supports this theory as maximal serum-killing only occurs once C5b-9 deposition has 
occurred. Serum-killing continued throughout the entire time course of 45 minutes, 
although the rate slowed near the end of the incubation period (Fig. 4.3 A).  
 
Overall, there was a lack of clear correlation with ranked killing rate and binding and 
deposition of IgG, C3 and C5b-9. Though the serum with the highest deposition effected 
both the quickest kill and phagocytosis of Salmonellae. This suggests that not all 
antibody binding and complement deposition on Salmonella, detected by flow cytometry, 
may contribute to the bactericidal complex. Phagocytosis by neutrophils (Fig. 4.3 B) and 
monocytes (Fig. 4.3 C), determined by internalisation of FITC-labeled S. Typhimurium, 
began quickly and this early period coincided with the period of Salmonella survival as 
determined by SBA.  
 
4.3.3 Production of a growth curve for S. Typhimurium D23580 
To explore the effect of different growth phases on serum-susceptibility of our invasive 
African S. Typhimurium isolate, we first produced a 12-hour growth curve. The 
Salmonellae were grown as described in sections 2.1.2-3 according to ‘Birmingham 
conditions’. Figure 4.4 A shows that logarithmic (log) phase growth starts at around 80 
minutes. The log phase lasts around 5 hours. After approximately 390 minutes, the 
growth curve begins to flatten indicating late log and the approach of stationary phase.  




























Figure 4.3: In vitro time-course of serum-killing and phagocytosis of S. Typhimurium. 
(A) Serum-bactericidal assay and (B) phagocytosis by neutrophils or (C) by monocytes of 
African S. Typhimurium D23580. Phagocytosis measured by flow cytometry. Each line 
represents a different donor. Data are mean of three experiments ± SD.  




Our experiments mainly use Salmonellae grown for 120 or 180 minutes which 
corresponds to mid-log and late-log phases respectively. This difference could be 
important as LPS synthesis has been reported to vary between these growth-phases in 
Salmonella (Rojas et al., 2001) and growth-phase regulation of LPS OAg chain length 
can influence serum resistance in Salmonellae (Bravo et al., 2008). Optical density (OD) 
(Fig. 4.4 B) and viable colony counts were taken at half an hour intervals. OD values 
gave a strong positive correlation with cfu/ml counts (R
2
=0.89), indicating that OD values 
can potentially be used to indicate both colony number and growth phase.  
 
4.3.4  Growth medium affects Salmonella resistance to serum-killing 
Serum-killing of Salmonellae grown in either heat-inactivated human serum (56°C for 30 
minutes) or LB broth, to both log and stationary phase was examined. Log phase S. 
Typhimurium grown in heat inactivated serum and stationary phase S. Typhimurium, 
grown in both heat inactivated serum and LB broth had marked serum-resistance (log10 
kill of ~ 0 – 0.5 after 180 minutes). (Fig. 4.5A) The results highlight the possibility that 
Salmonella-host interactions may be influenced by the conditions of growth in vivo. 
Bacteria can be capable of rapid growth in a nutrient-rich in vitro environment, such as 
LB media. In contrast, in vivo the same bacteria may achieve only very low rates of cell 
division when present in tissue or body fluids (Maw and Meynell, 1968, Meynell and 
Subbaiah, 1963). Our data is consistent with prior suggestions that bacteria dividing at 





































Figure 4.4: Growth curve of S. Typhimurium D23580 at 37
o
C in LB broth with 
shaking, cfu/ml determined by viable colony counts. (A) Growth curve from early log 
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4.3.5  Growth-phase affects Salmonella resistance to serum-killing 
An SBA was performed using Salmonella growths representative of lag, early log, mid 
log, late log phases and stationary phases (1, 2, 3, 4 and ~16 hour growths). The one 
and two hour growths exhibited comparable killing (log10 kill of ~2.00 after 90 minutes), 
but marked resistance to serum killing was seen for three hour (log
10
 kill of ~0.20 after 
90 minutes), four hour (log10 growth of ~ 0.02) and overnight inoculums (log
10
 kill of 
~0.50 after 90 minutes) (Fig. 4.5B). This represented a statistically significant difference 
between groups (p = 0.0233 1-way ANOVA). This variable serum-susceptibility is a 
consideration in understanding the in vivo protective role of bactericidal antibodies and 
complement in salmonellosis. The resistance to serum-killing of the 4 hour late-log 
Salmonella growth could negate the contribution of bactericidal antibodies to immunity. 
However, it should be noted that the serum still has a potentially important bacteriostatic 



















These results are consistent with Salmonellae entering the bloodstream being rapidly 
opsonised by specific antibodies and complement. Opsonisation facilitates faster uptake 
by phagocytes, particularly neutrophils (Gondwe et al., 2010), allowing the bacteria to 
escape from potential complement-damage mediated by C5b-9 formation. Around 90% 
of invasive NTS isolates in Malawi are sensitive to serum killing in vitro, so the ability of a 
proportion of Salmonellae to evade this cell-free bactericidal mechanism may be 
clinically important. Our data suggest that serum-susceptible Salmonellae, such as S. 
Typhimurium D23580, have a window of opportunity to escape the bactericidal 
environment of blood and move into phagocytes where they are adapted to survive by 
utilising virulence genes encoded by their pathogenicity islands (Vazquez-Torres et al., 
2000).   
 
Nevertheless, the effective C5b-9 deposition and antibody-dependent complement-
mediated killing of Salmonellae suggests that sustained high grade bacteraemia in the 
presence of specific antibodies and functional complement is unlikely. Salmonellosis in 
IL-12/23-IFNγ (IFNγ) axis deficient patients presents extra-intestinally as focal disease, 
particularly in cervical lymph nodes.  
 
Moreover, work in IFNγ–/– animals has demonstrated that intracellular densities of 
Salmonellae reach higher levels than in  healthy controls (Mastroeni et al., 2009). Yet, 
despite the impact on cell-mediated immunity and associated increased Salmonella 
growth, IFNγ-axis-deficient patients do not develop fatal Salmonella bacteraemia. In 
contrast, salmonellosis in African infants that lack specific antibodies often presents as a 
fatal bacteraemia. 
 




































Figure 4.5: Growth phase and media affects killing of S. Typhimurium by serum. In 
vitro serum-killing assay of S. Typhimurium isolate D23580 10
6
 /ml. (A) Logarithmic 
phase (red) and stationary phase (blue) S. Typhimurium grown in heat inactivated 
human serum (dashed lines) or LB broth (solid lines). (B) Serum-killing of S. 
Typhimurium grown for one hour (blue diamonds), two (red triangles), three (green 
squares) or four hours (purple crosses). Data are a mean of four (A) or two (B) 








































Minutes exposure  
LB stationary  
HI serum log 










It is likely that the inability of these children’s sera to deposit complement on 
Salmonellae prevents antibody-dependent complement-mediated-killing and effective 
phagocytosis. As such, these patients are predisposed to fail to clear Salmonella from 
their blood and are therefore susceptible to fatal bacteraemia. 
 
The role of antibody-dependent complement-mediated killing of Salmonellae is further 
complicated by the variation in serum-susceptibility exhibited by Salmonellae grown in 
different conditions and to different growth-phases.  Our data using an African invasive 
S. Typhimurium isolate are consistent with previous findings using laboratory 
Salmonellae strains demonstrating that that growth-phase can alter serum-susceptibility 
(Murray et al., 2005, Bravo et al., 2008). 
 
We have reported that growth in heat-inactivated serum also lead to development of 
serum resistance. Crucially, our bactericidal experiments used 100% human serum and 
a representative African invasive strain of S. Typhimurium, which gives a closer 
representation of what occurs in vivo in NTS bacteraemia in Africans. Considering these 
points, and also how readily D23580 can lose its susceptibility to serum, resistance to 
complement-mediated serum killing could be a true phenotype of NTS during an 
infection. While the range of potential growth conditions of Salmonella in vivo makes 
testing of every possible condition unfeasible, the existence of variation should be 
considered upon drawing conclusions from models. Ideally, a more directed analysis of 
variance in expression, such as a gene expression-profiling microarray of ex vivo 
bacteria could be used to give an informed estimate of the metabolic and virulence 
states of Salmonella during infection.  
 




Nevertheless, even serum-resistant Salmonella did not undergo a net growth in human 
serum that contains anti-Salmonella antibodies and functional complement during 
incubation at 37°C. This contrasts with the ~1 log10 growth seen when, even serum-
susceptible, Salmonellae are incubated in serum that lacks anti-Salmonella antibodies 
(Fig 3.7). This implies a bacteriostatic role for antibody-dependent complement-mediated 
immunity, which could be important in limiting Salmonella concentration, and could 
assist preventing development of disease.  
 
Our data display kinetics of complement and antibody binding, serum-killing and 
phagocytosis which are consistent with these clinical observations. The relative 
slowness of serum-killing compared to opsonisation and phagocytosis could allow the 
escape and survival of a sufficient percentage of Salmonella to continue infection. This 
perhaps explains how of complement-fixing specific antibodies are unable to prevent 
severe salmonellosis despite their mediation of bactericidal processes. However, near-
instantaneous binding of antibodies to Salmonella, in combination an opsonic and 
bactericidal contribution from complement factors could prevent persistence of 
Salmonellae in the blood. In an in vivo setting this contribution of antibodies could be 
life-saving and thus a vaccine inducing an antibody response, even in the absence of a 
strong cellular response, may dramatically reduce mortality caused by invasive NTS 












4.5  Conclusion 
Nontyphoidal strains of Salmonella are a major cause of morbidity and mortality 
worldwide. Infection in African children that lack specific antibodies frequently results in 
fatal bacteraemia, whereas IFNγ-deficient patients can suffer from serious extra-
intestinal, yet non-fatal disease. Mouse models of salmonellosis may not consider the 
impact of antibody-dependent complement-mediated immunity on bacterial spread. We 
have used serum bactericidal, phagocytosis, and antibody and complement deposition 
assays with human blood and sera to assess the contribution of cell-fee antibody-
dependent complement-mediated-killing of invasive African Salmonella. Phagocytosis 
overlapped Salmonellae survival in serum, potentially creating a window in the kinetics in 
which a proportion of Salmonellae can escape from extracellular complement-fixing 
bactericidal antibodies and re-establish intracellular infection. However, C5b-9 is 
deposited on Salmonellae remaining in serum and leads to fast and efficient killing. This 
antibody-dependent complement-mediated bactericidal activity likely stops sustained 
and fatal bacteraemia. Such a model helps to explain how specific antibodies alone 
might, in the absence of a strong cellular immune response, not prevent salmonellosis, 
but could halt fatal development of the disease. Growth condition-dependent variation in 
serum-susceptibility of Salmonellae complicates interpretation of antibody-dependent 
complement-mediated immunity in vivo. Nonetheless, specific antibodies and 
complement had a bacteriostatic effect on even the most serum-resistant Salmonella 
growths we tested.  The current findings support the protective effect of an antibody 










Adsorption studies demonstrate that the O-antigen of invasive African 




Anti-lipopolysaccharide (LPS) and particularly anti-O-antigen (OAg) antibodies have 
been reported to be protective in mouse models of salmonellosis (Watson et al., 1992, 
Carlin et al., 1987, Colwell et al., 1984). Such antibodies have also been shown to be 
bactericidal against NTS in a complement-fixing capacity (Schulkind et al., 1972). 
However, there are mixed reports on the ability of exogenous LPS remove bactericidal 
activity against Salmonella (Skarnes, 1978, Michael et al., 1962, Cundiff, 1941). The 
most recent data of this kind demonstrated that exogenous Omp was capable of 
removing bactericidal activity against S. Typhimurium, while LPS was not (MacLennan et 
al., 2010). As well as this, a lack of bactericidal activity against invasive African NTS 
isolates in the sera of a sub-set of HIV-infected patients was due to the inhibitory effect 
of large titres of anti-OAg antibodies was reported. In contrast anti-Omp antibodies, 
generated by immunisations in mice, had bactericidal complement-fixing activity against 
S. Typhimurium. These anti-Omp antibodies have shown to be protective in challenge 
studies in C57BL/6 mice (Cunningham et al., 2007).  
 
A major challenge in developing a vaccine against NTS for Africa is to identify the key 
molecular targets of the protective immune response against Salmonella. An OAg 
conjugate based approach to a NTS vaccine is seen as a relatively quick and cost-
effective solution. However, the above findings have brought some doubt concerning the 
role of anti-OAg antibodies in at least one modality of immunity against invasive NTS 
disease in Africa.  




Specific-antibody free serum is a useful research tool to help determine specificity of 
bactericidal antibodies. However, anti-Salmonella antibody-free human sera are not 
common. The only natural sources are young children or those with antibody deficiency 
disorders. It is difficult and unethical to take large volumes of blood from children for 
study and patients that lack antibody are only a transient source, if a source at all, as 
they typically start treatment soon after diagnosis of the condition. In healthy humans 
development of acquired and/or natural antibodies, reactive against Salmonella, to a 
level required to effect serum-killing occurs by 2 years of life (MacLennan et al., 2008).  
 
Adsorbing out specific antibodies from serum using bacteria is a simple process that has 
been frequently used since around the turn of the 20
th
 century by researchers such as 
Lipstein in 1902 (Pandit, 1923, Mackie and Finkelstein, 1930, Collins, 1967). However, 
despite the age of the system, or perhaps because of it, the effects on the serum have 
never been fully characterised, with researchers mainly only relying on SBAs as 
demonstration of antibody removal. 
 
Here, we have characterised the effect of adsorption of serum using whole Salmonella 
on specific Salmonella antibodies and complement activity of serum. To help identify the 
antigenic targets of bactericidal antibodies in human serum we have performed serum 
adsorptions, serum bactericidal assays (SBA) and flow cytometry antibody and 
complement-deposition assays, using a range of NTS isolates, including African clinical 









5.2 Statistical Analysis 
Comparisons of two groups were performed using two tailed student’s t tests. All 
statistical tests were performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego California USA). 
 
5.3  Results 
5.3.1 Effect of adsorption on specific antibodies in serum 
Sera from four healthy adults were assessed for their ability to deposit IgG, IgM, C3 and 
C5b-9 on the live African invasive S. Typhimurium D23580 isolate using flow cytometry. 
Cell-free bactericidal activity was determined by SBA. These sera were then adsorbed 
as described using a live suspension of 1x10
11
 cfu/ml of the homologous bacterial 
isolate. One adsorption cycle produced a marked and significant reduction of specific 
anti-Salmonella IgG (Fig. 5.1A) and IgM (Fig. 5.1B) in all four sera (Student’s t test, all p 
< 0.001), though IgG was still detectable in the sera from three of the donors.  Specific 
antibodies are required to deposit complement on smooth forms of NTS (MacLennan et 
al., 2008) and the removal of specific antibodies by adsorption produced an associated 
decrease in both C3 (Student’s t test, all p < 0.005) and C5b-9 deposition (Student’s t 
test, all p < 0.001) (Fig. 5.1C + 5.1D).  Following adsorption, C3 deposition was only 
detectable in two of the sera and C5b-9 deposition was absent in all sera. A serum 
killing assay using 1x10
7 
cfu/ml S. Typhimurium showed a net growth of up to ~0.5 log10 
for adsorbed serum, contrasting with a ~1.5 log10 for un-adsorbed serum (Student’s t 
test, all p < 0.0005)  (Fig. 5.1E). However, with the usual 10-fold lower concentrations of 
S. Typhimurium used in previous SBAs (MacLennan et al., 2008) the reduction in 
bactericidal activity produced by pre-adsorption was reduced such that only three of the 
adsorbed sera were still bactericidal, producing ~1 log10 kill (Fig. 5.1F). The difference in 
kill between unadsorbed and absorbed sera was still significant for all donors (Student’s 
t test, all p < 0.01).  























Figure 5.1: Effect of adsorption of serum with Salmonella on antibody and 
complement binding and bactericidal activity. (A) IgG, (B) IgM, (C) C3 and (D) C5b-9 
GMFI measured by flow cytometric analysis of binding to S. Typhimurium by four human 
sera. Serum was adsorbed with S. Typhimurium (blue circles) or unadsorbed (red 
squares). Each point represents one experiment. Horizontal bars indicate mean values. 




 Salmonellae/ml at 45, 90, and 
180 minute time points using unadsorbed (red lines) or adsorbed (blue lines, adsorption 
as above) human serum from four healthy donors. Data are means of three experiments 
± SD.  
 










5.3.2 Effect of multiple adsorption on specific antibodies in serum 
To increase the efficiency of the adsorption protocol, the serum with the highest antibody 
levels and bactericidal activity after one adsorption cycle was chosen and subjected to 
additional adsorption cycles. As Figure 5.2 A-D shows, the first adsorption cycle 
removed the majority of specific antibody and complement binding. Specific IgG titre was 
slightly lowered further by a second and third adsorption cycle (Student’s t test, both p < 
0.005). In addition to flow cytometry analysis of antibody and complement binding, an 
ELISA was performed using highly pure exogenous LPS and a preparation of S. 
Typhimurium outer membrane as capture antigens (Fig. 5.2E). The LPS capture format 
gave similar results to the flow cytometry assay, with adsorption producing a ~100 fold 
reduction in specific IgG and a ~10 fold reduction in specific IgM. Outer membrane 
capture showed a more modest decrease of ~3 fold. The decrease in specific antibodies 
after one cycle of adsorption was highly significant (Student’s t test, all p < 0.0001) and 
subsequent cycles produced small but significant reductions in antibody titers (Student’s 
t test, p < 0.05). These small reductions in specific antibodies achieved by additional 
adsorptions translated to a large difference in serum killing (Fig 5.2F). Two adsorption 
cycles removed net bactericidal activity and resulted in a net growth of ~0.5 log10 after 
180 minutes (Student’s t test, p < 0.005 compared to one adsorption), three cycles 

























Figure 5.2: Effect of multiple adsorption cycles on antibody and complement 
binding to Salmonella and bactericidal activity. (A) IgG, (B) IgM, (C) C3 and (D) C5b-
9 GMFI measured by flow cytometric analysis of binding to S. Typhimurium by human 
serum. Serum was either unadsorbed or adsorbed with S. Typhimurium one, two or 
three times. Each point represents one experiment. Horizontal bars indicate mean 
values. (E) IgG and IgM titres against either exogenous LPS or outer membrane 
antigens measured by ELISA. (F) In vitro serum bactericidal assay with 10
6
 wild type 
Salmonellae/ml at 45, 90, and 180 minute time points using unadsorbed or adsorbed 
human serum (adsorbed as above). Numbers in legend correspond to number of 
adsorption cycles performed on serum. Killing activity restored when heat inactivated 
(HI) serum was added as a complement source. Data are means of three experiments ± 
SD. (G) Serum bactericidal assay as above but using galE
- 
S. Typhimurium, which is 
susceptible to killing by specific-antibody free serum, and a single 180 minute time point. 
Dilutions of adsorbed (blue lines, prepared as above) and unadsorbed (red lines) serum 
made in PBS. Data are means of three experiments ± SD. (H) Haemolytic alternative 
and total complement function determined by radial immunodiffusion assays. Serum was 
adsorbed with Salmonella (blue circles) or unadsorbed (red squares). Each point 
represents one experiment and horizontal bars indicate mean values. 














5.3.3 Adsorption has minimal detrimental effect on complement activity. 
Adsorption was performed at 4
o
C to minimize the binding and consumption of 
complement components. Adsorptions were carried out for three cycles. Reconstituting 
the adsorbed non-bactericidal serum with heat-inactivated serum, as an antibody 
source, restored normal killing (Fig. 5.2F) (Student’s t test, heat-inactivated or adsorbed 
alone compared with heat-inactivated plus adsorbed p < 0.0001). Additionally, the killing 
of galE
-
 S. Typhimurium (which, unlike wild type, is susceptible to killing in the absence 
of specific antibodies) was identical in adsorbed and unadsorbed serum even at dilutions 
in excess of 1/8 serum in PBS (Fig. 5.2G). Finally, hemolytic assays showed no 
significant difference in either alternative or total activity between unadsorbed and 
adsorbed serum (Fig. 5.2H). These results demonstrate the complement in adsorbed 
serum is still functional. 
 
5.3.4 Adsorption of specific antibodies and removal of bactericidal activity is 
serovar-specific. 
To test whether bactericidal antibodies were serovar or strain-specific, serum was 
adsorbed for three cycles with a range of laboratory and invasive clinical isolate strains 
of S. Typhimurium and S. Enteritidis (Table 5.1). All sera adsorbed with S. Typhimurium 
strains produced a significant decrease in bactericidal activity against S. Typhimurium 
D23580 (Fig. 5.3A) (Student’s t test, all p < 0.0001), whereas all sera adsorbed with S. 
Enteritidis failed to remove killing against S. Typhimurium (Fig. 5.3B). This result was 
reflected in antibody binding assays, which demonstrated that all serum pre-adsorptions 
with S. Typhimurium strains produced a significant, complete or near-complete removal 
of both specific IgG and IgM (Student’s t test, all p < 0.0001), while in contrast, S. 
Enteritidis strains produced a much smaller reduction (Fig. 5.3C + D). The effect was not 
limited to binding to S. Typhimurium, and when whole S. Enteritidis was used as the 




capture bacteria, the opposite result was seen (Fig. S1 A-C). This suggests that 
bactericidal antibodies mediating cell-free complement-killing are serovar-specific. 
 
 
Table 5.1 Salmonella strains and isolates used for adsorption study 
Serovar Strain name Isolation 
Enteritidis ATCC4931 Human gastroenteritis, 
Copenhagen, Denmark 
Enteritidis D21685 Human systemic, Malawi  
Enteritidis D24359 Human systemic, Malawi 
Enteritidis D24953 Human systemic, Malawi 
Enteritidis D24954 Human systemic, Malawi 
Enteritidis P125109  Human gastroenteritis 
isolate 
Typhimurium D22477 Human systemic, Malawi 
Typhimurium D23005 Human systemic, Malawi 
Typhimurium D23580 Human systemic, Malawi 




Figure 5.3: Effect of adsorption with different Salmonella strains and isolates on 
antibody and complement and bactericidal activity. (A) In vitro serum bactericidal 
assay with 10
6
 wild type Salmonellae/ml at 45, 90, and 180 minute time points using 
serum adsorbed with S. Typhimurium strains or (B) S. Enteritidis and S. Typhi strains. 
Strain names indicated in legend. Data are means of three experiments ± SD. (C) IgG or 
(D) IgM GMFI measured by flow cytometric analysis of binding to S. Typhimurium by 
human serum adsorbed with either a strain of S. Enteritidis, S. Typhi or S. Typhimurium 
(indicated on X axis) or unadsorbed (NHS). Each point represents one experiment. 
Horizontal bars indicate mean values. 
 
































Table 5.2: LPS knock-out Salmonella strains used in study. 
Serovar Strain Name Knockout Gene 



























Figure 5.4:  Schematic representation of S. Typhimurium lipopolysaccharide 
molecule and sites of truncation of mutants. (A) Lines indicate the level of LPS 
truncation resulting from each mutation. (Gal: Galactose; Glc: glucose; GlcNAc: N-
acetylglucosamine; Hep: Heptose; Kdo: 3-deoxy-D-mannooctulosonic acid; P: 
phosphate; PPEtN: pyrophosphorylethanolamine; 




5.3.5 Rough mutants lacking OAg are unable to remove bactericidal activity 
against the wild type parent strain. 
One of the main immunogenic differences between serovars of Salmonella is the OAg 
expressed. We used a range of knockout mutants that had truncations of their LPS and 
all lacked OAg (Table 5.2 + Fig. 5.4) to investigate the contribution of OAg to the serovar 
specificity reported. Mutants cannot bind antibody against the LPS components they 
lack and so comparison of binding across a range of Salmonella with varying 
completeness of LPS gives insight into antigen targets (Fig. 5.5). Adsorptions were 
carried out for three cycles. All sera pre-adsorbed with the OAg knockouts of S. 
Typhimurium and S. Enteritidis failed to remove killing against a wild type strain of S. 
Typhimurium (Fig. 5.6A) (Student’s t test, all p < 0.0001 compared to wild type S. 
Typhimurium adsorbed). Flow cytometric analysis of antibody binding to wild type S. 
Typhimurium demonstrated no significant difference between unadsorbed serum and 
serum adsorbed with OAg-knockout strains for either IgG (Fig. 5.6B) or IgM (Fig. 5.6C) 
(Student’s t test). This is in clear contrast to the large and significant reduction achieved 
by adsorption with a wild type S. Typhimurium strain (Student’s t test, p < 0.0001).  In 
addition, non-bactericidal wild type-adsorbed serum had high levels of IgG and IgM 
specific against the OAg knockout strains remaining (Fig. 5.7 D-I). This suggests that 
either antibodies against the exposed surface of OAg knockout strains of NTS are not 
bactericidal, or that bactericidal antibodies specific to those targets are not present in the 
normal sera we tested. Addition of highly pure exogenous S. Typhimurium LPS was able 
to reduce IgG binding to S. Typhimurium (Student’s t test, all p < 0.0001), and S. 
Enteritidis LPS did not produce a significant reduction (Fig. 5.6D). However, the 
decrease in specific IgG was much less than achieved with whole, live S. Typhimurium 
(Student’s t test, all p < 0.0001). As well as this, adsorption with Salmonella LPS failed to 
produce a reduction in serum bactericidal activity against S. Typhimurium (Fig. 5.6E). 
 





















Figure 5.5: Rationale of LPS mutant serum adsorption / antibody capture systems

























Figure 5.6: Effect of adsorption with LPS mutant Salmonellae or 
lipopolysaccharide on antibody and complement and bactericidal activity. (A) In 
vitro serum bactericidal assay with 10
6
 wild type Salmonellae/ml at 45, 90, and 180 
minute time points using serum adsorbed with mutant OAg knockout Salmonellae. 
Knockout names indicated in legend. Data are means of three experiments ± SD. (B) 
IgG or (C) IgM GMFI measured by flow cytometric analysis of binding to smooth wild 
type S. Typhimurium by human serum adsorbed with rough strains of Salmonella, all 
lacking OAg and possessing truncated LPS (knockout indicated on X axis). Each point 
represents one experiment. Horizontal bars indicate mean values. (D) Percentage of 
specific anti-S. Typhimurium IgG remaining in serum after adsorption with exogenous S. 
Typhimurium or S. Enteritidis LPS. IgG GMFI measured by flow cytometric analysis of 
binding to smooth wild type S. Typhimurium. Data are means of three experiments ± SD. 
(E) Serum bactericidal assay as A, but using serum adsorbed with exogenous S. 
Typhimurium or S. Enteritidis LPS. Data are means of three experiments ± SD. 


































5.3.6 Adsorption with an OmpR
- 
mutant removes bactericidal activity and 
specific antibody as wild type. 
In addition to LPS mutants, Fig. 5.6 shows that adsorption (for 3 cycles) with an OmpR
- 
S. Typhimurium strain, deficient in both OmpC and OmpF was able to remove specific 
IgG and IgM antibodies as well as serum bactericidal activity (Student’s t test, all p < 
0.0001). This suggests that antibodies against OmpC and OmpF are not present or not 















Figure 5.7: Antibody binding to Salmonellae and LPS mutant Salmonellae after 
adsorption with rough and smooth Salmonellae. (A) IgG GMFI measured by flow 
cytometric analysis of binding to S. Typhi D21685, S. Enteritidis (B) D24954 and (C) 




, or (F) waaC
-
 by either unadsorbed serum 
(NHS) or serum adsorbed with Salmonellae (listed on X axis). (G) IgM measured as 




, or (I) waaC
-
   Each point 
represents one experiment. Horizontal bars indicate mean values. 









5.3.7 Adsorption with mosaic OAg S. Enteritidis and S. Typhimurium 
demonstrate that OAg, rather than serovar, is the key determinant of 
bactericidal activity. 
To help clarify the contribution of antibodies against OAg in serum killing, we obtained 
mutant strains of S. Enteritidis and S. Typhimurium that expressed either O:4 or O:9 
(Table 5.3) and used them to adsorb serum (for 3 cycles). We used these adsorbed sera 
for serum bactericidal (Fig. 5.8 A-D) and specific antibody binding assays (Fig. 5.8 E-H) 
against each of the four strains. Adsorption of bactericidal activity was achieved by 
Salmonella with a homologous serovar and OAg for all strains (Student’s t test, all p < 
0.0001). However, when the alternative OAg was expressed, no reduction in killing was 
recorded, irrespective of serovar. Conversely, expression of the homologous OAg on the 
heterologous serovar produced a significant adsorption of bactericidal activity (Student’s 
t test, both p < 0.0001). For O:9 expressing strains, adsorption with heterologous 
serovar-homologous OAg NTS removed killing as effectively as the completely 
homologous strain (Student’s t test, both p < 0.0001). For O:4 expressing strains 
homologous NTS adsorbed killing most effectively, but the homologous OAg-
heterologous serovar strains adsorbed killing more effectively than homologous serovar-
heterologous OAg strains (Student’s t test, both p < 0.0001). This pattern of removal of 
bactericidal activity corresponded to the results for adsorption of specific IgG binding.  
 
Table 5.3: Salmonella LPS chimera strains 
Serovar Parent Strain Strain number O-Antigen Name 
Enteritidis Thirsk SL7488 4 SEn T O4 
Enteritidis Thirsk SL7490 9 SEn T O9 
Typhimurium C5 SL5559 4 STm C5 O4 
Typhimurium C5 SL5560 9 STm C5 O9 
 























Figure 5.8: Effect of adsorption with chimera OAg Salmonellae on antibody and 
complement and bactericidal activity. (A) In vitro serum bactericidal assay with 10
6
 S. 
Typhimurium O4, (B) S. Typhimurium O9, (C) S. Enteritidis O4 or (D) S. Enteritidis O9 
/ml at 45, 90, and 180 minute time points using serum adsorbed with each of the above 
Salmonellae (indicated in legend). Data are means of three experiments ± SD. (E) IgG 
GMFI measured by flow cytometric analysis of binding to S. Typhimurium O4, (B) S. 
Typhimurium O9, (C) S. Enteritidis O4 or (D) S. Enteritidis O9 by either unadsorbed 
serum (NHS) or serum adsorbed with Salmonella listed on X axis. Each point represents 
one experiment. Horizontal bars indicate mean values. 
 



































We have described and characterised a simple method for adsorption of anti-Salmonella 
antibodies for the generation of specific-antibody free serum that retains complement 
activity. This is beneficial for research into complement and antibody-mediated 
mechanisms of immunity against NTS because anti-Salmonella antibody-free human 
serum is rare. While the adsorption method is essentially similar to those first described 
in the early 1900s (Mackie and Finkelstein, 1930, Pandit, 1923), the consequence of 
adsorption has been tested more rigorously than was possible for earlier researchers. 
We employed a range of assays, both bacterial and erythrocyte based, to test 
complement activity. The specificities and levels of antibodies were investigated using a 
combination of flow cytometry, ELISA and LPS mutant Salmonella. These were used to 
measure important factors in the context of cell-free complement-killing: specific IgG or 
IgM is required for killing; cleavage of C3 and deposition of C3b is the central event in all 
complement activating pathways; and C5b-9 formation indicates the formation of a 
membrane attack complex required to kill bacteria 
 
The data demonstrates that removal of specific bactericidal antibodies from serum could 
be achieved by the incubation with live Salmonella at 4°C without detriment to the 
complement activity of the serum. For our SBA system, which conforms to Taylor’s 
recommendations on SBAs (Taylor, 1983) and has been utilised in a number of recent 
publications on serum bactericidal activity against NTS (MacLennan et al., 2010, Siggins 
et al., 2011, MacLennan et al., 2008, Gondwe et al., 2010), removal of bactericidal 
activity required two adsorption cycles. However, as many as five adsorption cycles 
were performed without a reduction in complement activity. 
 




The specific-antibody depleted serum generated by the described adsorption process 
was used to investigate the antigen specificities of complement-fixing bactericidal 
antibodies in human serum. Although adsorption with bacteria is a low-tech approach, 
use of live bacteria allows the interaction of antibodies with bacterial antigens in their 
native conformation in situ on the bacterial surface. As such, the steric hindrance of 
antigenic sites (Pollack et al., 1989) in LPS and on the bacteria is potentially closer to 
that present in physiological conditions during bacteremia. Use of live bacteria avoids 
processing which can alter immunogenicity. For example, boiling of smooth 
enterobacteria exposes rough epitopes and permits binding of antibodies to core 
glycolipids that would otherwise not occur (Aydintug et al., 1989) (Reviewed in 
(Greisman, 1997)). These advantages mean that adsorption is a productive method of 
investigation in combination with animal immunisations and more specific column 
adsorptions using isolated antigens. 
 
We have demonstrated that adsorption of serum bactericidal activity with smooth wild 
type NTS is serovar specific. Our work supports previous literature on the contribution of 
Salmonella serovar to protection in mice (summarised in Table 5.4) and in adsorption of 
bactericidal activity from serum (Collins, 1967, Michael et al., 1962). It also adds a novel 
aspect to prior adsorption reports through the incorporation of a range of clinically 
relevant African invasive isolate strains as well as laboratory stains. S. Typhimurium 
D23580 was chosen for this study because it is a typical invasive strain of NTS from 
Africa. It is representative of >90% of NTS strains isolated from bacteraemic individuals 
in Malawi and has a distinct genotype (Kingsley et al., 2009). Such genotypic differences 
might also correspond to immunogenic differences and so the use of clinical strains from 
endemic areas of disease is a valuable strategy for vaccine research. 
 




    Immunisation provides   
Host species 
Immunisation with serovar 
(immuno-dominant O-
antigen) 
protection against serovar 
(immuno-dominant O-
antigen) 
no protection against serovar 
(immuno-dominant O-antigen) 
Reference 
Mouse S. Dublin (O9) S. Dublin (O9) S. Typhimurium (O4) Lindberg et al. (1993)  
Mouse S. Enteritidis (O9) S. Enteritidis (O9) S. Typhimurium (O4) Hormaeche et al. (1996)  
Mouse S. Gallinarum (O9) S. Enteritidis (O9) S. Typhimurium (O4) Collins et al. (1966) 
Mouse S. Typhimurium (O4) S. Typhimurium (O4) S. Enteritidis (O9) 
Hormaeche et al. (1996) Norris and 
Bäumler (1999) Hormaecheet al. 
(1991) 
Mouse S. Typhimurium (O4) S. Typhimurium (O4) S. Dublin (O9) 
Lindberg et al. (1993) Coynault and 
Norel (1999) 
Chicken S. Enteritidis (O9) S. Enteritidis (O9) S. Typhimurium (O4) Cooper et al. (1994)  
Chicken S. Gallinarum (O9) S. Enteritidis (O9)   Nassar et al. (1994)  
Chicken S. Gallinarum (O9) S. Gallinarum (O9)                 
S. Infantis (O7) 
 S. Typhimurium (O4) 
Silva et al. (1981) 
Human S. Typhi (O9) S. Typhi (O9) S. Paratyphi A (O2) Simanjuntak et al. (1991) 
Table 5.4: Lack of cross serovar protection after immunisation with Salmonella. 
(Kingsley and Baumler, 2000)  




The serovars S. Enteritidis and S. Typhimurium, used in this investigation, are highly 
conserved in terms of surface features: both express important Omps; C, D and F (Gil-
Cruz et al., 2009) and the primary structure of LpfA fimbrial proteins varies by only one 
amino acid (Nicholson and Baumler, 2001). The LPS and OAg backbone are also well 
conserved, though their dideoxyhexose branch sugars have an important distinction, 
with abequose in group O:4 (B) and tyvelose in O:9 (D) (Curd et al., 1998). Other key 
antigen differences are present in ‘H’ flagella antigens, however antibodies against 
flagella are as they are not thought to be relevant to cell-free complement killing (Taylor, 
1983), leaving OAg as the key distinction for this aspect of immunity. 
 
Immunisation of mice with rough Salmonella mutants, that lack OAg, does not provide 
protection against wild type parent strains (reviewed in (Greisman, 1997)). Our results 
agreed with this finding, showing that adsorption of serum with a range of LPS mutant 
strains that lack OAg failed to remove killing against smooth parent strains. Mosaic OAg 
Salmonella strains have previously been used to look at protection in challenge studies 
of mice (Hormaeche et al., 1996). The authors found a contribution of OAg to immunity, 
but ultimately concluded that ‘LPS alone cannot fully account for the specificity of 
protection.’ Our work isolates cell-free complement-mediated killing, and for this 
mechanism of immunity it seems that OAg makes a more significant contribution. 
 
Genetic, immunological and serological evidence also supports an important role for 
OAg and anti-OAg antibodies in Salmonella immunity. OAgs are assembled by a set of 
sugar synthases and transferases encoded by genes clustered in the chromosomal wba 
locus. The wba locus is a hypervariable DNA region across serovars (Reeves, 1993). 
The high level of variability in the wba locus suggests that OAg polymorphism is driven 
by large selective pressure, from a source such as the immune system (Kingsley and 




Baumler, 2000). In addition, analysis of the serologic response against serovars S. 
Typhimurium and S. Enteritidis shows that the immune-dominant determinants of their 
LPS are O:4 and O:9 antigen respectively (Smith et al., 1995, Barrow et al., 1992, 
Nicholson and Baumler, 2001).  
 
However, adsorption with exogenous LPS failed to remove bactericidal killing. Use of S. 
Typhimurium LPS did lower antibody titres against S. Typhimurium, but not to the same 
extent as after adsorption with wild type S. Typhimurium. It is probable that an artefact of 
the LPS adsorption experiment is preventing full removal of specific antibodies. For 
adsorptions with bacteria, the bacteria itself and therefore all bound antibodies are 
removed from the serum after incubation. However, for adsorptions with LPS, the LPS 
and its bound antibodies remain in the serum for the subsequent assay. Therefore, 
dissociation of the antibodies from the LPS and binding to the bacteria can occur. 
Alternatively, it could be that the processing of the isolated LPS means it does not 
resemble the native form on the bacterial surface and as such does not adsorb the 
relevant antibodies. The amphiphilic nature of LPS may lead to self-aggregation when is 
not anchored, which could mask some OAg epitopes. There also could be differences in 
the quantity of OAg per weight of LPS between the exogenous preparation and on 
bacteria. NTS OAg consists of a repeating unit with typically bimodal distribution 
between ‘long’ and ‘very long’ lengths (Bravo et al., 2008), the lengths of these OAg 
repeats and also the microheterogeneity of LPS, due to factors such as acetylation, can 
vary and may impact antibody binding. 
 
The majority of data reported here strongly suggests that antibodies against OAg are the 
key effectors of bactericidal activity in normal human serum. This may be positive news 
for vaccine design. It appears that the anti-OAg inhibitory antibodies discovered in a 




sub-set of HIV-infected individuals, which brought doubt to the use of an OAg based 
vaccine, might be inhibitory because of another factor other than antigen specificity. The 
lack of bactericidal activity of these antibodies and sera could be a result of HIV-infection 
interfering with antibody development. Although, there are a number of reports in the 
literature from the pre-HIV era detailing patients with chronic infections with Gram-
negative bacteria, including NTS, whose sera lacked bactericidal activity against the 
homologous bacteria (Waisbren and Brown, 1966, Adler, 1953). The inhibitory factor in 
these cases was a large titre of antibodies against the bacteria and so perhaps it is the 
excess of antibodies that results in inhibition of bactericidal activity. Such an effect has 
long been acknowledged, though not explained, in in vitro SBA systems (Muschel et al., 
1969).  
 
Experiments with LPS mutants did not provide evidence that antibodies to antigens 
other than OAg were key contributors to bactericidal component of the sera we tested. A 
mutant lacking OmpC and OmpF (but not OmpD) did not influence the effect on 
adsorption of bactericidal activity. However, antibodies against Omps have been shown 
to be both bactericidal (MacLennan et al., 2010) and partially protective against 
Salmonella in the mouse (Gil-Cruz et al., 2009). As such, it is possible that, like with 
bactericidal anti-factor H-binding protein antibodies against meningococci, the levels of 
antibodies present in normal serum (without vaccination) are insufficient to produce a 
bactericidal effect (Pizza et al., 2008). If this is the case, then it may in fact be a positive 
for hopes of an Omp-based vaccine generating pan-serovar-specific protection. The 
absence of a prominent bactericidal anti-Omp antibody population may indicate that 
these antigens they are under less selective pressure by the host immune system. If this 
was so it would increase the chance of a higher degree of conservation in Omp 
antigenic sites. The sera we used was from healthy adult donors and all contained 




bactericidal activity and antibodies specific against S. Typhimurium D23580, though 
none had a confirmed history of Salmonella disease. It may be that the lack is due to 
how B cell populations respond to different antigens. Perhaps proliferation of long-lived 
plasma cells is greater in response to OAg than Omps and convalescent serum might 
show a different antibody profile with a natural role for bactericidal anti-Omp antibodies. 
 
An overview of antibody-targeting against protein antigens in systemic salmonellosis 
using sera from Malawian children with Salmonella bacteraemia and immune mouse 
serum has recently been generated (Lee et al., 2012). To support this, adsorption 
analysis of such sera could help to determine specifically which epitopes complement-
fixing bactericidal antibodies are generated against. This would build upon the work 
presented here and towards a vaccine that fully harnesses the potential contribution of 
cell-free complement-mediated immunity to immunity. 
 
Large titers of anti-OAg antibodies that inhibited bactericidal activity against NTS in a 
sub-set of HIV-infected Africans have recently been described (MacLennan et al., 2010). 
Because a glycoconjugate OAg-based vaccine is an obvious candidate for a NTS 
vaccine in Africa, clarification of the effector functions of antibodies against OAg is 
needed. This study clearly demonstrates the bactericidal capacity of complement-fixing 
antibodies against the OAg of invasive African Salmonella LPS. Moreover, we report that 
such antibodies can be major effectors of antibody-dependent complement-mediated 
bactericidal activity against invasive African isolates of Salmonella. These findings 








5.5  Conclusion 
Nontyphoidal strains of Salmonella are a major cause of fatal bacteremia in Africa. 
Antibodies are important for protection against Salmonella and an important role has 
been found for antibodies in cell-free complement-mediated bactericidal activity against 
Salmonella in Africans. Determining the antigen targets of these bactericidal antibodies 
is a key consideration in developing a vaccine against nontyphoidal Salmonellae and the 
OAg of lipopolysaccharide is an obvious candidate for a glycoconjugate vaccine. 
However, the discovery of inhibitory anti-OAg antibodies in a subset of HIV-infected 
patients has cast doubt on the suitability of OAg as a vaccine agent. We used a range of 
invasive African Salmonella isolates, laboratory Salmonella strains and Salmonella LPS 
mutants to adsorb human serum in order to investigate the targets of bactericidal 
complement-fixing antibodies. The effect of adsorption on specific-antibodies and 
complement binding were assessed by flow cytometry and ELISA, and hemolytic and 
bactericidal activity of sera was determined. Adsorption of serum with whole Salmonella 
produced an effective serovar-specific removal of both antibodies against surface 
elements of Salmonella and bactericidal activity. Adsorption did not adversely affect the 










  mutants, which all lack 
OAg, failed to remove Salmonella serovar-specific antibodies and killing against their 
parent strains. S. Typhimurium and S. Enteritidis OAg chimera strains, expressing either 
native or heterologous OAg (O:4 or O:9) demonstrated that removal of antibodies and 
bactericidal activity against O:9-expressing strains was entirely dependent on the OAg of 
the adsorbing strain rather than other serovar-specific antigens. O:4-expressing strains 
showed a similar, but less pronounced effect. These data indicate that anti-OAg 
antibodies are major effectors of complement-mediated killing of invasive African 
nontyphoidal Salmonella by normal human serum. These findings support the 
development of an OAg based vaccine. 
 




Chapter 6  
Analysis of antibody and complement binding to Salmonella by confocal and 
electron microscopy 
 
Electron microscopy work represents collaboration with Dr. David Goulding in Professor 
Gordon Dougan’s laboratories at the Wellcome Trust Sanger Institute in Cambridge. 
 
6.1 Introduction 
Killing of Gram negative bacteria by complement requires formation of a stable C5b-9 
membrane attack complex on the outer membrane (OM) (Joiner et al., 1982a, Joiner et 
al., 1982b, Inoue et al., 1968) and death is dependent on damage to the inner 
membrane (IM) (Wright and Levine, 1981, Feingold et al., 1968). Therefore, deposition 
of terminal complement components at locations too far from the bacterial membrane 
surface to exert killing has been theorised as a reason for the resistance of some 
bacterial strains to serum-killing (Taylor, 1983). As such, the ‘long’ and ‘very long’ chain 
O-antigens (OAg) of Salmonellae (Murray et al., 2005, Bravo et al., 2008) have been 
suggested to contribute to inhibition of serum-killing by binding anti-OAg antibodies at 
their distal end and blocking access to internal sites. Furthermore, the recent description 
of a sub-set of HIV-infected patients who had large titres of anti-OAg antibodies which 
inhibited serum-killing (MacLennan et al., 2010) was consistent with this hypothesis. Yet, 
we reported in chapter 5 that anti-OAg antibodies were a major source of bactericidal 
antibodies in the healthy adult sera we examined. Although anti-OAg antibodies are not 
inhibitory per se, the binding of antibodies and associated complement deposition may 
sterically hinder access to bactericidal sites on the Salmonellae in serum with a high titre 
of anti-OAg antibodies. Alternatively, (or additionally) complement may be exhausted by 
this deposition in non-bactericidal sites (MacLennan et al., 2010). 




Here, we have developed a confocal microscopy assay to image antibody binding and 
complement deposition on Salmonellae. We have then used transmission electron 
microscopy (TEM) to determine complement and antibody binding requirements for 
effective serum-killing of an African S. Typhimurium clinical isolate. In addition, we have 
imaged this serum-mediated damage against NTS in high resolution. Finally, we have 
compared the activity of both bactericidal and inhibitory HIV-infected sera to identify 
mechanisms responsible for inhibition of serum-killing. We hypothesise that HIV-infected 
inhibitory serum shows differences in the location and quantity of deposition of 
antibodies and complement on S. Typhimurium compared to bactericidal sera. 
 
6.2 Statistical Analysis 
Comparisons of two groups were performed using two tailed student’s t tests. All 
statistical tests were performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego California USA). 
 
6.3  Results 
6.3.1 Antibody and complement deposition confocal microscopy assay 
To develop a confocal assay for imaging of antibody and complement binding to 
Salmonellae, we adapted our flow cytometry assays (section 2.3.1-2). Only minor 
changes were made, most notably the bacterial solution was slightly concentrated post 
serum incubation. The sample was applied to charged glass slides and stained with 
DAPI. Dry and wet samples were prepared as described in the methods. Figure 6.1 
shows that bacteria were detectable either by transmitted light (A) or fluorescence 
(DAPI) (B, C, and D). The confocal system was somewhat less sensitive than flow 
cytometry. While the abundant C3 binding was easily detectable, the less plentiful IgG, 
IgM and C5b-9 binding and deposition were only clearly distinguishable from 




background levels in donor serum that contained the highest levels of these components 
(IgG shown in Fig. 6.2, other data not shown). There was no discernible increase in the 
magnitude of binding associated with using wet samples and so dry samples were 
chosen for further usage due to their relative ease for capturing images with a suitable 
quantity and distribution of bacteria in the same focal plane.  
 
6.3.1.2 Influence of fixative solution 
EM generally uses harsher fixatives that flow cytometry. In order to identify any potential 
problems with the interaction of the fixatives and bacteria, antibody and 
antibody/complement binding, we tested a typical EM fixative solution, common for pre-
embedding transmission EM (TEM) 2% paraformaldehyde + 0.1 – 0.5% glutaraldehyde, 
with FITC conjugated anti-C3 and anti-IgG antibody using our confocal and flow 
cytometry data protocols. The flow cytometry showed little difference in binding between 
fixatives. The confocal images revealed more intense fluorescence with the 
formaldehyde solution than the glutaraldehyde solutions, which was due to high 
background values. It is well known that glutaraldehyde generates free aldehyde groups 
that can result in non-specific binding with antibodies (Kiernan, 2000). However, 
samples that were fixed only after labelling showed similar effects suggesting there was 
influence with the fluorochrome and that the effect was a confocal-specific problem   
 
The timing of fixation had a large effect of fluorescence intensity. Prefixing the 
Salmonellae before incubation with serum reduced the signal recorded on confocal 
images and by flow cytometry for both C3 (Fig. 6.3) and IgG (data not shown). The effect 
was particularly prominent for C3 binding. It is likely that the fixation limits binding of 
antibody and complement by altering epitope conformations and samples should be 
fixed after incubation with serum. 



























Figure 6.1: Antibody and complement binding on Salmonellae imaged by confocal 
microscopy. Binding of IgG, IgM and deposition of C3 and C5b-9 on S. Typhimurium 
D23580 by confocal microscopy. 2x10
8
 Salmonellae were incubated in healthy adult 
donor serum for 10 minutes. Negatives were incubated in PBS and used to determine 
settings for positive images. Salmonellae appear blue (DAPI) (B,C,D) or are imaged by 
transmitted light (A). C3 (A), IgG (B), IgM (C), and C5b-9 (D) are green (FITC-
































Figure 6.2: Variation in binding of IgG on STm D23580 between donor sera. 2x10
8
 
S. Typhimurium D23580 were incubated in serum from four healthy adult donors (A-D) 
for 10 minutes. Negative (E) was incubated in PBS. Analysis by confocal microscopy.  
Salmonellae imaged by transmitted light. IgG is green (FITC-conjugated anti-human IgG 
antibody). (F) Overlayed histograms of IgG binding of same four donor sera compared to 
baseline (grey line and shading) determined by flow cytometry. 
 









































Figure 6.3: Effect of ‘prefixing’ bacteria on imaging C3 deposition on salmonellae 
by confocal microscopy. 2x10
8
 live (left panel) or prefixed (middle panel) S. 
Typhimurium D23580 incubated in serum. Samples were fixed in 2% paraformaldehyde 
PBS with (A) 0.1% (B) 0.2% or (C) 0.5% glutaraldehyde. Negative incubated in PBS and 
used to determine settings for positives. Salmonellae imaged by transmitted light. C3 is 
green (FITC-conjugated anti-human antibody). Right panel: histograms of C3 deposition 
of serum compared to negative baseline (grey line and shading) determined by flow 
cytometric analysis. Flow cytometry samples identical to confocal sample. Coloured lines 
correspond to coloured bar indicating fixative treatment. 
Postfixed C3 deposition 
Postfixed C3 deposition 
B 
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6.3.2 Electron microscopy imaging of serum-mediated damage of Salmonellae 
A resin pre-embedding TEM technique (section 2.5.2) was used to visualise the effects 
of incubating healthy Malawian pooled sera with clinical African isolate S. Typhimurium 
D23580. Figure 6.4 shows that observed damage was not uniform and presented in a 
number of stages. Healthy Salmonellae were also observed even in bactericidal serum 
(Fig. 6.4 A), though they were in the minority. Of the damaged cells, severe plasmolysis 
(Fig. 6.4 C), contraction and disruption of cytoplasm integrity (Fig. 6.4 D), breaks in both 
outer and inner membranes (Fig. 6.4 E-H), formation of ghost cells and spheroplasts 
(Fig. 6.4 I-K), and finally, complete destruction of the bacterial cell, leaving only curled 
membrane debris (Fig. 6.4 L) were all prominent. Plasmolysis did not always occur in a 
regular distribution around the cell, contrary to as is commonly observed with hypertonic 
solutions. Many Salmonellae had spheres of material in the widened periplasmic space 
(Fig. 6.4 C) and in some Salmonellae, the cytoplasm within the IM contracted away from 
the membrane edge. In other Salmonellae the entire cytoplasm contents, including the 
associated IM, escaped through a hole in the OM (Fig. 6.4 G, H). The exit holes in the 
OM in these cases are large, up to around 500nm in size, and are likely forced open by 
the passage of the cytoplasm. Bacteria lacking an OM can survive in balanced solutions, 
but in serum damage to the OM of Salmonellae appears to lead to lysis. In other 
Salmonellae, diminishment or disappearance of the cytoplasm precedes extensive OM 
damage and leads to the formation of membrane-only structures termed ghosts. It is 
likely that both ghosts and Salmonellae with extensively damaged OMs are not stable in 
serum and that they disintegrate into the tangles of membrane also visualised (Fig. 6.4 









Figure 6.4: Serum-mediated damage to Salmonellae 
TEM of pre-embedded S. Typhimurium D23580 after incubation in neat pooled 
Malawian sera. Images are representative of commonly observed damage in samples. 




6.3.3 Comparison of damage to Salmonellae inflicted by bactericidal and HIV-
infected inhibitory sera 
Incubation of S. Typhimurium D23580 with HIV-infected inhibitory serum did not to lead 
to the same degree of damage described with bactericidal serum. The majority of 
Salmonellae lacked any physical signs of damage, which is consistent with the lack of 
killing reported from SBAs with the inhibitory serum (MacLennan et al., 2010). A minority 
of Salmonellae displayed damage, but there was a clear difference between bactericidal 
and inhibitory sera (Fig 6.5). No damage was observed in PBS controls. 
 
6.3.4 Presence of ‘blocking layer’ on Salmonellae after serum-incubation 
When a pre-embedding method (section 2.5.2) was used for TEM, Salmonellae 
incubated with neat serum showed a distinctive layer around the OM. This layer seemed 
to impede labelling of antibody and complement binding with secondary antibodies. C3 
(Fig 6.6 D) and C5b-9 (data not shown) labels were seen on the outer edge of the layer, 
while IgG labelling was absent (Fig. 6.6 B). Dilution of the serum to 1 in 10 with PBS 
(10% serum is non-bactericidal in the SBA used, described in section 2.2) led to the 
disappearance of the layer on the majority of Salmonellae observed. In addition to this, 
C3 and C5b-9 deposition was no longer present (data not shown). In contrast, IgG 
labelling was present on 10% serum-incubated Salmonellae, in, or close to the OM (Fig 
6.6 C). It is likely that the layer is made up from a build-up of deposition of complement 
components on the surface of the Salmonellae. To avoid this problem, we used a post-
labelling method using cryosections (section 2.5.3). In which Salmonellae are sectioned 
after incubation with serum, but crucially, before the addition of secondary gold-
conjugated antibodies. Although the layer should still remain, the secondary antibodies 
have access to internal areas of the bacterium and layer above and below the section 
and so detection of antibodies and complement bound to the Salmonellae is not 
impeded 
























Figure 6.5: Serum-mediated damage to Salmonellae 
TEM of S. Typhimurium D23580 after incubation in either PBS, neat pooled Malawian 
sera (Bactericidal serum) or HIV-infected inhibitory serum (Inhibitory serum). Images are 
representative of numerous observations. 




























Figure 6.6: Effect of serum-deposit layer on labelling of Salmonellae with C3 and 
IgG. S. Typhimurium D23580 labelled with anti-IgG, incubated with PBS (A) or neat (B) 
or 10% serum (C). (D) Incubated with neat serum, labelled with C3. Immunogold labels 
have 10nm diameter. Red arrows highlight layer deposited by serum and associated 
anti-C3 antibody binding. Blue arrows show deposited layer and general absence of 









6.3.5 Comparison of location of antibody binding and complement deposition 
on Salmonellae after incubation with bactericidal or inhibitory sera 
The ultrastructure of cryosections was well preserved and the antibody labelling worked 
well, being very clean with high affinity. The controls were clear both of label and the 
complement layer.  
 
Complement component C3 (Fig 6.7 A), membrane attack complex (C5b-9) (Fig 6.7 B) 
and IgG (Fig 6.8) were all observed on both the OM and the IM and even in the 
cytoplasm, as well as distal sites from the bacterial membrane of Salmonellae in both 
inhibitory and bactericidal sera. Overall, there were no striking differences in the location 
of complement deposition and antibody binding on Salmonellae between bactericidal 
and inhibitory sera.  
 
However, whereas damaged Salmonellae all had C3 and C5b-9 deposition on the OM 
and IM, many healthy Salmonellae did not. Some healthy cells did show IM C3 
deposition, though this was generally of a low level and probably represented the start of 
damage progression. The heaviest labelling of both complement components and IgG 
seemed to occur on damaged, particularly lysed, Salmonellae (scoring counts are being 
performed to statistically confirm these observations at the time of writing, as well 
labelling of both IgA and IgM antibodies). Furthermore, contraction of the IM seemed to 
be associated with C3 deposition on the IM. Where plasmolysis proceeded 
predominantly from one side, or area, the C3 deposition was focussed in that area on 
the leading edge of the withdrawing IM. This suggests the origin of damage allows an 
influx of complement components from serum from outside into the interior of the 
Salmonella cell.  
 
 




Figure 6.7: Deposition of complement on Salmonellae 
TEM cryosections of S. Typhimurium D23580 after incubation in neat pooled Malawian 
sera (bactericidal serum) or HIV-infected inhibitory serum (inhibitory serum) labelled with 
anti-C3 or C5b-9 antibody. Immunogold labels have a 10nm diameter. Images are 
representative of numerous observations. 






Figure 6.8: Binding of IgG to Salmonellae 
TEM cryosections of S. Typhimurium D23580 after incubation in neat pooled Malawian 
sera (bactericidal serum) or HIV-infected inhibitory serum (inhibitory serum) labelled with 
anti-IgG antibody. Immunogold labels have a ~5nm diameter and some are indicated by 
blue arrows. Images are representative of numerous observations. 




6.3.6 Comparison of quantity of antibody binding and complement deposition 
on Salmonellae after incubation with bactericidal or inhibitory sera 
We scored the levels of deposition of C3, C5b-9 and IgG binding on randomly selected 
Salmonella in order to compare levels between inhibitory and bactericidal sera (Fig 5.9 
A).  As expected, binding of IgG was higher in HIV-infected inhibitory serum (Student’s t 
test p < 0.001). However, contrary to results gained with flow cytometry (Fig 5.9 B), 
deposition of both C3 and C5b-9 on Salmonellae was reduced in HIV-inhibitory serum in 
comparison to bactericidal serum (Student’s t test both p < 0.001). These results 
suggest that the lack of ability for inhibitory serum to kill Salmonellae is due to a reduced 
ability to deposit complement on Salmonellae. Scoring for IgA and IgM binding to 
Salmonellae and a detailed analysis of the complement deposition and antibody binding 
differences between damaged and undamaged Salmonellae is ongoing at the time of 
writing. 
 
6.3.7 Evidence for dissociation of complement membrane attack complexes 
from Salmonellae incubated in inhibitory serum 
Clumps of material, heavily labelled with C5b-9, distant from the surface of the bacterial 
OM were observed on some Salmonellae. These appeared more often in samples 
incubated in HIV-infected serum and may be evidence of dissociating C5b-9. However, 























































Figure 6.9: Quantification of complement and antibody binding to S. Typhimurium 
(A) C3, C5b-9 and IgG deposition on S. Typhimurium D23580 by bactericidal (NHS) and 
inhibitory (HIV) sera, measured by counting of gold-conjugated antibodies on randomly 
selected Salmonellae using TEM. (B) C3, C5b-9, IgG, IgM and IgA deposition (GMFI) 
measured by flow cytometry analysis of binding to S. Typhimurium D23580 by 
bactericidal (NHS) and inhibitory (HIV) sera. Data are means of three experiments ± SD. 
*** represents statistical significance of p < 0.001 determined by Student’s t test. 


































Figure 6.10: Potential dissociation of C5b-9 deposition from Salmonellae in 
inhibitory serum. S. Typhimurium D23580 incubated in HIV-infected ‘inhibitory’ serum. 
Cryosections labelled with anti-C5b-9, Imaged by TEM. Immunogold labels have a 10nm 










The primary purpose of the EM study was to look at the differences in antibody and 
complement binding on Salmonellae between normal bactericidal and HIV-infected 
inhibitory sera, in order to verify a role for anti-Salmonella ‘blocking’ antibodies, which 
was suggested by prior research (MacLennan et al., 2010). Despite the large difference 
in the number of damaged and lysing cells between the sera, in terms of the location of 
binding of antibodies and complement on Salmonellae, overall there was no obvious 
difference. Both bactericidal and inhibitory sera exhibited bound C3, C5b-9 and IgG in 
OM, IM, cytoplasmic sites, as well as distal from the Salmonella membrane. Separation 
of bacteria in terms of ‘damaged’ and ‘undamaged’ cells suggested some associations 
with complement-deposition location and damage, as discussed in section 6.3.2. 
Preliminary observations suggested that Salmonellae incubated in bactericidal serum 
had higher levels of C5b-9 deposition in OM, IM and inner cell locations than inhibitory 
serum. While scoring of complement and antibody deposition associated with 
Salmonellae was performed, more images would be needed to give suitable power to 
confidently discern site specific comparisons. If possible, scoring of complement and 
antibody deposition at sites potentially key in complement-mediated killing, such as the 
OM and IM, would represent a worthwhile addition to this study. 
 
The main difference we saw between the sera was the quantity of IgG and complement-
components deposited on Salmonellae (Fig. 6.10A). HIV-infected serum had higher 
levels of IgG binding, as expected from prior flow cytometry analysis (MacLennan et al., 
2010) and the associations of HIV-infection with hypergammaglobulinemia. But, HIV-
infected inhibitory serum also had reduced deposition of both C3 and C5b-9. This 
suggests that lack of killing of Salmonellae by this serum is due to its reduced ability of 
to deposit stable C5b-9. This is consistent with previous reports that binding of C9 to 




serum-resistant Salmonella spp. and E. coli isolates is minimal (Joiner et al., 1982a, 
Joiner, 1988).  
 
Previous reports on similar types of inhibitory ‘blocking’ antibodies against Neisseria 
reported the presence of inhibitory antibodies lead to increased complement 
consumption (Frank et al., 1987). Some EM images of Salmonellae incubated in 
inhibitory serum showed large clumps of material, heavily labelled with C5b-9, distant 
from the bacterial surface (Fig 6.10). These may be evidence of C5b-9 dissociation from 
a site closer to the Salmonella membrane. If so, this would provide an explanation for 
how increased consumption of complement without increased deposition on 
Salmonellae is possible. Shedding of bound C5b-9 has been reported to be associated 
with serum-resistance in Salmonella spp. and E. coli isolates (Joiner et al., 1982a, Joiner 
et al., 1982b, Joiner, 1988). Furthermore, complement-mediated LPS release has been 
reported in strains of E.coli (O'Hara et al., 2001). The relative and overall levels of 
bactericidal and blocking antibodies in serum determine the ultimate location and 
configuration of bound C5b-9 on the Neisseria bacterial surface (Joiner, 1988). This 
could apply in Salmonella too, demonstrating a mechanism by which dissociation of 
C5b-9 complexes was elevated in Salmonellae incubated in inhibitory serum. 
 
Interestingly, flow cytometry analysis gave the opposite result to EM analysis, showing 
that HIV-infected serum deposited higher levels of complement on Salmonellae. 
However, our discovery, using EM, of a layer around neat serum-incubated Salmonellae 
(Fig 6.6) that binds high levels of anti-complement antibodies suggests that the flow 
cytometry results may be influenced by an artefact. The layer prevented the passage of 
secondary labelling antibodies. As the flow cytometry method uses whole Salmonellae, it 
would only record complement deposition on the outside of this layer rather than 




complement associated with the Salmonellae themselves. Although the flow cytometry 
assay correlates well to serum bactericidal (SBA) data and predicts killing with 
bactericidal serum, this is probably a coincidence. Both anti-Salmonella antibodies and 
complement are required both for serum killing and deposition of the complement layer 
and so with bactericidal serum, the assay effectively measures an indirect surrogate of 
serum-killing. However, with serum-resistant Salmonellae or HIV-infected inhibitory 
serum antibodies and complement can bind to the bacterium but cannot effect killing and 
as such the indirect measurement of complement components at the edge of the 
complement layer is irrelevant in the prediction of bactericidal activity.  
 
Our observation of complement-components deposited on the IM and in the cytoplasm is 
important. As recently as 1994 (recent in terms of the investigation in the mode of action 
of complement-mediated killing) it was stated that no direct evidence of any complement 
elements becoming associated with the inner membrane after cell killing has been found 
(Blanchard and Dankert, 1994). One study that did report the presence of complement 
components on the IM (Goldman and Miller, 1989) using sucrose density centrifugation 
was criticised as being potentially contaminated (Tomlinson et al., 1990). Our results, 
using TEM, which not at risk of such contamination, agree with the findings of Goldman. 
The key difference between studies supporting IM and inner cell deposition and those 
refuting it, is the use of lysozyme-free serum in the latter.  
 
Lysozyme and complement components are a prerequisite for bacteriolysis (Inoue et al., 
1968) and lysis of bacteria cannot occur in the absence of lysozyme (Taylor and Kroll, 
1983, Wright and Levine, 1981), but there are mixed reports on the role of lysozyme in 
complement-killing. The key question in determining the mechanism of complement-
mediated killing is whether the removal of lysozyme helps to determine the mechanism 




or merely demonstrates a different process of serum-killing that does not take place in 
vivo. Some studies report killing without lysozyme can occur with no or minimal 
reduction in rate (Schreiber et al., 1979, Pramoonjago et al., 1992), while others report a 
small reduction (Taylor and Kroll, 1983) and others still reported a large reduction in 
bactericidal activity (Glynn and Milne, 1967). Much like the situation with SBAs 
(discussed in section 3.4) these differences are probably a result of varying assay 
conditions. Differences in bacteria used, rough or smooth and serum incubation 
conditions can account for large differences in bactericidal activity. Even factors such as 
insufficient sampling over a time course of killing can mask differences in killing rate 
(Taylor, 1983).  
 
A criticism of removing lysozyme based on studies showing no difference in killing with 
and without would be that removing a component from a system does not necessarily 
validate a functional redundancy or irrelevancy, especially as it is difficult to determine 
what the true rate of serum-killing of an microorganism is and so the effect could be 
hidden. C9-deficient serum, which can effect killing of some bacteria (Pramoonjago et 
al., 1992, Harriman et al., 1981) and can haemolyse erythrocytes demonstrates how 
complement can effect non-optimal killing in the absence of certain components.  Both 
processes occur to a lesser extent when compared to normal serum and it has been 
reported, at least for haemolysis, that the mechanisms may differ to that of C5b-9 
haemolysis (Takeda et al., 1986). Complement may be able to exert a deadly effect on 
bacteria using distinct mechanisms either in the presence or absence of IM and 
cytoplasmic deposition. It could be that the primary killing mechanism doesn’t require 
inner cell deposition of complement components but its presence can contribute to killing 
effectiveness or rate, as may be the case with haemolysis by C9-deficient serum 
(Takeda et al., 1986) Complement has multiple roles in homeostasis and disease 




(Ricklin et al., 2010) and considering this diversity it has been suggested that 
complement may not possess a singular clear mode of action by which it exerts it 
bactericidal effect (Bhakdi and Tranum-Jensen, 1991).  
 
Further to these considerations, the lysozyme removal process itself may create 
problems as processing of the serum can have unwanted side-effects, removal using 
bentonite (montmorillonite, MMT) can also remove any serum component that is basic 
(positively charged) such as C1q  and ‘beta-lysins’ (Myrvik and Weiser, 1955, Bugla-
Ploskonska et al., 2009). Removal of C1q can affect the classical complement pathway 
and beta-lysins have been reported to be required for optimal killing of some Gram-
negative bacteria (Donaldson et al., 1974). Lysozyme-removal using the other widely-
used method of anti-lysozyme antibody has been suggested as a cause of complement 

















Evidence for important complement-fixing bactericidal and opsonising antibody roles has 
been identified in Africans. However, high titers of anti-O-antigen antibodies, capable of 
inhibiting the bactericidal action of serum, have been discovered in a subset of HIV-
infected patients. This has cast doubt on the suitability of inducing large antibody 
responses against some antigens. We incubated invasive African Salmonella in both 
healthy bactericidal and HIV-infected inhibitory sera. Next, using transmission electron 
microscopy (TEM) we imaged the resulting bacterial damage. In addition, we recorded 
the location and quantity of antibody binding and complement deposition on the 
Salmonellae. Consistent with viable counts from serum bactericidal assays, HIV-infected 
inhibitory serum showed substantially less damaged and lysed cells than bactericidal 
serum. Damage was not uniform and presented as severe plasmolysis, contraction and 
disruption of cytoplasm integrity, breaks in both outer and inner membranes and 
formation of ghost cells and spheroplasts. Finally, complete destruction of the bacterial 
cell, leaving only curled membrane debris occurred. IgG, complement component C3 
and membrane attack complex C5b-9 were all observed on both the outer and inner 
membranes, as well as distal sites from the bacterial membrane of Salmonellae in both 
inhibitory and bactericidal sera. However, whereas damaged Salmonellae all had C3 
and C5b-9 deposition on the OM, many healthy cells did not. Furthermore, bactericidal 
serum deposited greater quantities of C3 and also C5b-9 on the Salmonellae. This 
suggests that the failure of inhibitory serum to kill Salmonellae is due to a reduced ability 
to deposit bactericidal complement complexes mediated by the high titre of antibodies. 
 
 




7.  General discussion  
A vaccine is urgently needed for invasive nontyphoidal Salmonella (NTS) disease in 
Africa. Antibodies have a protective effect against NTS and prior In vitro work has 
demonstrated important roles for both complement-fixing bactericidal antibodies 
(MacLennan et al., 2008) and opsonising antibodies (Gondwe et al., 2010) in African 
children. In this thesis we have investigated the mechanisms by which these antibodies 
direct complement-mediated bactericidal activity and how this modality of immunity 
contributes to protection against Salmonella. Understanding antibody-dependent 
immunity against Salmonella has significant implications in developing an efficacious 
vaccine for NTS in Africa.  
 
In Chapter 3 we demonstrated undetectable bactericidal activity of mouse sera against 
NTS. As well as the lack of antibody-dependent complement-mediated bactericidal 
action in the mouse, we showed reduced complement component C3 deposition on the 
surface of Salmonellae. Complement deposition is vital for effective opsonisation and 
respiratory burst of Salmonellae in human blood (Gondwe et al., 2010, Shaio and 
Rowland, 1985, Vreede et al., 1986). Therefore, mouse models may underestimate the 
potential protective effect of antibodies against Salmonella in humans, although 
antibodies alone are enough to enhance phagocytosis, oxidative burst, and killing of 
Salmonellae in mouse macrophages (Uppington et al., 2006). Future work using an 
animal model with complement activity more similar to levels in humans could give a 
better prediction of the protection mediated by antibodies in humans. But, selecting an 
alternative model is difficult. Few commonly used research animals have complement 
activity equivalent to humans. Ish and co-workers surveyed complement activity of sera 
from 25 species using haemolysis against all the erythrocytes from each species and 
also antibody-coated human tumour cells (Ish et al., 1993). They found that popular 




laboratory animals such as mice, guinea pigs and rabbits had relatively weak 
complement systems. Although complement-mediated killing of some 
Enterobacteriaceae by calf, chicken, guinea pig, pig and rabbit sera has been recorded 
(Kenny and Herzberg, 1967, Collins, 1967, Ogata and Levine, 1980, Taylor, 1983), 
comparisons show human serum to possess much more effective bactericidal activity 
(Ogata and Levine, 1980, Collins, 1967, Schwab and Reeves, 1966).  
 
Another problem with selecting an alternative animal model is Salmonella serovar 
species specificity. The two most common serovars causing invasive disease in Malawi 
and much of tropical Africa are the generalist serovars S. Typhimurium and S. Enteritidis 
(Brent et al., 2006, Graham et al., 2000). Generalist Salmonellae can infect a wide range 
of mammals, but the manifestation of the disease they cause can greatly vary between 
host species. This in turn can alter the immune response, for example, vaccination of 
cattle, chickens, pigs, and humans with live attenuated strains of the corresponding 
host-specific serovars leads to strong immune responses that guard against reinfection 
(Zhang-Barber et al., 1999, Van Immerseel et al., 2005). In contrast, vaccination against 
non-host-specific Salmonella serotypes, such as S. Typhimurium in chickens, has shown 
mixed rates of success (Zhang-Barber et al., 1999, Van Immerseel et al., 2005).  
 
The dominance of the mouse in modelling systemic NTS disease somewhat limits the 
value in expanding our study to other species. The use of the bovine enterocolitis 
models may warrant a repeat in the investigation conducted in Chapter 3 using immune 
serum from cows, though this would present logistical problems as facilities capable of 
researching NTS infection in cows are rarer. Our investigation included three of the most 
commonly used mouse strains (PubMed, 2006). These strains cover those that have be 
used in some of the most important antibody related discoveries in the context of NTS 




infection (Cunningham et al., 2007, Xu et al., 1993, Hormaeche, 1979, McSorley and 
Jenkins, 2000, Mastroeni et al., 1993, Gil-Cruz et al., 2009) and so give a good 
coverage for investigation. All the strains we tested showed similar performance despite 
variance in a number of factors relevant to Salmonella infection (Section 3.4). 
 
Confirming the contribution of opsonising activity in the mouse is important. Antibodies 
have a well-established protective effect against NTS in the mouse (reviewed in Dougan 
et al., 2011) and our work suggests that this protection is not mediated through 
bactericidal antibodies. Using immune mouse blood and serum for phagocytosis 
(Section 2.7), respiratory burst and whole blood cell killing assays (Gondwe et al., 2010) 
would demonstrate if opsonising antibodies are responsible for protection. Such a study 
would also allow comparison of the relative efficiency of mouse and human phagocytes 
in killing NTS. This could both help to explain host-specific differences in presentation of 
the disease, as well as highlight key mechanisms of immunity in humans. The latter is 
significant in helping determine the key immunological responses a successful vaccine 
would need to evoke. 
 
Unlike mice, humans have a complement system that has a powerful bactericidal action 
against range of Gram negative bacteria in vitro (Reviewed in (Taylor, 1983)). However, 
the extent of the contribution of bactericidal antibodies against Salmonellae in humans in 
vivo is unknown (discussed in depth in Section 3.4). It is difficult to determine the degree 
of cell-free complement-mediated bactericidal activity in vivo. Separating the 
contributions of other aspects of immunity is troublesome, particularly because (as 
discussed above) antibodies can activate both cell-free and cell-mediated bactericidal 
activity. Furthermore, as previously reported in the literature, and confirmed for our 
representative invasive African S. Typhimurium isolate D23580 (Chapter 4), serum-




susceptibility of bacteria can vary dependent on the conditions and the growth phase of 
the bacteria. Yet, even for the most serum-resistant growths of S. Typhimurium D23580, 
the presence of specific antibodies and complement had a bacteriostatic effect. 
Salmonella infections are occasionally described in complement-deficient patients, but 
the association is much weaker than with other major causes of bacteraemia, such as 
meningococcal and pneumococcal diseases (Morgan and Walport, 1991, Ross and 
Densen, 1984, Botto et al., 2009, Taylor, 1983). The lack of correlation may be due to 
the complex immunity to Salmonella and the redundant nature of the immune system, 
meaning that other immune responses can prevent the development of disease. 
 
In Chapter 4 we also modelled the in vitro kinetics of the deposition of antibodies and 
complement on Salmonellae, as well as phagocytosis by neutrophils and monocytes and 
complement-mediated cell-free killing. This model suggested that the speed that a 
proportion of the Salmonellae exited the extracellular bactericidal environment of the 
blood meant that an infection could continue even in the presence of bactericidal anti-
Salmonella antibodies. Individuals with defects in IFNγ production pathways typically 
develop severe recurrent Salmonella infections, but strikingly, the disease is focal and 
non-fatal (MacLennan et al., 2004, Lammas et al., 2002). We suggest that specific 
antibodies protect against the development and spread of a fatal bacteraemia in those 
with certain cell-mediated deficiencies. This is consistent with the suggestion that 
antibodies contain the spread of Salmonella infection in mice (Mastroeni et al., 2009).  
 
In Chapter 5 we demonstrated that the O-antigen (OAg) of Salmonella is a major target 
of bactericidal antibodies in human sera examined. As discussed, this is positive news 
for OAg-based vaccine design. Anti-OAg inhibitory antibodies described in a sub-set of 
HIV-infected individuals had cast doubt on the suitability of an OAg-based vaccine 




(MacLennan et al., 2010). However, our data suggests that anti-OAg antibodies are not 
inhibitory per se. As expanded upon in Section 3.4, it is possibly an example of an in 
vitro artefact due to a gross excess of antibodies, termed the Neisser-Wechsberg 
phenomenon (Neisser, 1901). The effect appears to have a correlation with complement 
levels (Muschel et al., 1969) and it is not thought to be a problem for humans in vivo.  
The poor complement-fixing effector ability of some antibody subsets potentially 
contributes to the inhibition of serum-killing observed. For instance, IgA, IgG2 and IgG4 
are poor binders of C1q (Flanagan and Rabbitts, 1982). Typically, HIV-infection (stages 
III and IV) is associated with decreased IgG2 and IgG4 levels. Titres of the more 
effective complement-fixing IgG subclasses IgG1 and IgG3 are increased (Parkin et al., 
1989, Bartmann et al., 1991). Though, it could be that in HIV-infected patients with 
recrudescent Salmonella infections, the repeated exposure to the polysaccharide 
antigens of the Salmonellae OAg increases production of IgG2 (Siber et al., 1980). 
Chapter 6 further strengthens the link of inhibitory antibodies to complement. We show 
using electron microscopy that the major difference between bactericidal and inhibitory 
serum is that bactericidal serum deposits greater quantities of both C3 and the C5b-9 
membrane attack complex on the Salmonellae than inhibitory serum. 
 
Exploration of the classes and sub-classes of antibodies raised to Salmonellae and the 
specific antigen targets of these antibodies is a natural progression of this thesis. The 
use and comparison of acute, convalescent and healthy bactericidal sera could provide 
details on the antibodies required for both immunity and protection. Polysaccharide 
antigens, such as OAg, are typically T-independent and immunisation of humans with 
several encapsulated bacteria results in a predominantly IgG2 anti-polysaccharide 
response (Siber et al., 1980). An exception is observed in young children under the age 
~2-3 years who can produce anti-polysaccharide antibodies in the IgG1 subclass (Morell 




et al., 1990). IgG2 deficiency is associated with decreased responses to infections with 
encapsulated bacteria and after immunisation with polysaccharide antigens (Siber et al., 
1980, Umetsu et al., 1985). As OAg is a major target of bactericidal antibodies, T-
independent responses could be central to development of immunity.  
 
Antibody responses and immunity against NTS disease naturally develop as African 
children age (MacLennan et al., 2008). Lack of specific antibodies early in life could be 
due to insufficient exposure to Salmonella antigens. It is also likely that immaturity of the 
infant immune system, particularly with regard to T-independent responses (Siegrist and 
Aspinall, 2009), is an important factor in the lack of anti-Salmonella antibodies in young 
children under ~2 years of age. To form effective protection in these children, a vaccine 
might have to produce a different response to the one naturally produced upon exposure 
to the pathogen. A proportion of children under 2 years old do have measurable titres of 
anti-Salmonella antibodies and bactericidal activity against Salmonella (MacLennan et 
al., 2008). Analysis of anti-Salmonella antibody sub-classes and antigen targets in this 
young antibody-producing population would help determine if a vaccine produces a 
different response in young children compared to older children and clarify what 
antibody repertoire constitutes an effective antibody response. For example, children 
immunised with an unconjugated meningococcal polysaccharide vaccine, develop an 
antibody response, but it is non-bactericidal (Plotkin, 2010). However, not all elements of 
the immune systems of African children function differently than adult immune systems. 
Phagocytes from young African children that lacked anti-Salmonella antibodies were just 
as effective at phagocytising and killing Salmonellae when given a source of anti-
Salmonella antibodies (Gondwe et al., 2010). Hence, generation of specific antibodies in 
these children, through vaccination, should enable mechanisms of both cell-free and 
cell-mediated immunity against NTS. This increases the likelihood that a vaccine that 




induces an antibody response will protect against invasive NTS disease in African 
children. 
 
It is feasible that both opsonising and bactericidal activities are effected by the same 
antibodies. Opsonic antibodies need to be bound by FCγ receptors on host immune 
cells and so need to bind to a location on the pathogen that is accessible. OAg is distal 
from the bacterial membrane on the outer ‘visible’ surface and so would be a clear 
antigen target for opsonising antibodies. Opsonisation of Salmonellae with antibodies 
alone failed to enhance phagocytosis and complement-fixation is required for both 
bactericidal and opsonic functions of antibodies against Salmonellae (Gondwe et al., 
2010). This means it is unlikely that significant opsonisation activity in the blood is 
mediated by antibody classes that do not fix complement well or at all, such as IgG4.  It 
is possible that many antibodies mediating both opsonisation and bactericidal activity 
are of the same sub-class, or even the very same antibodies. As antibodies are required 
for binding of C3 to smooth-form Salmonella (MacLennan et al., 2008) and complement 
is required for opsonisation of this type of bacteria, it is even possible that the principal 
opsonic effect is due to complement deposition, rather than direct opsonisation by the 
antibodies themselves. 
 
Almost all current vaccines work through antibodies in serum or on mucosa that block 
infection or bacteraemia (Plotkin, 2010). For this reason, the antibody response to 
Salmonella is essential to study. As well as quantity of response, the functional 
properties of antibodies in order to determine protection. It will also be helpful to 
determine useful correlates of protection for an NTS vaccine so that efficacy can be 
accurately determined. Many vaccine correlates and surrogates of protection are 
determined by measurement of antibodies. For three major bacteraemia causing 




pathogens Haemophilus influenzae type B, meningococci and pneumococci, serum 
bactericidal assays and opsonphagocytic assays are used for correlates of protection 
(Siber et al., 2007, Maslanka et al., 1998). Binding antibody titres, measured by ELISA, 
can also sometimes be useful as surrogates of protection (Kayhty et al., 1983). The 
manifestation of NTS disease in Africa and the susceptibility of Salmonellae to antibody-
dependent mechanisms of immunity imply these assays also function as useful 
correlates or surrogates of protection for a Salmonella vaccine. We have observed that 
serum containing binding antibodies, measured by flow cytometry, always have 
bactericidal activity against NTS. However, clear correlates of protection for vaccines 
against some intracellular bacterial diseases such as the Tuberculosis Bacille Calmette 
Guerin vaccine are not currently known (Fletcher, 2007). 
 
The work contained in this thesis and the continuation and extension of projects 
described, in classifying antibody responses and functionality, will play a key supportive 
role to the development of a vaccine against NTS for Africa. This thesis has particularly 
focussed on antibody-dependent complement-mediated immunity and as such, immunity 
against Salmonella in the blood. Study of possible antibody-mediated protection at the 
intestinal epithelium, the site of the initial pathogen: host contact, could further assist 
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Absent Bactericidal Activity of Mouse Serum against Invasive
African Nontyphoidal Salmonella Results from Impaired
Complement Function but Not a Lack of Antibody
Matthew K. Siggins,* Adam F. Cunningham,* Jennifer L. Marshall,* Jayne L. Chamberlain,*
Ian R. Henderson,* and Calman A. MacLennan*,†
Nontyphoidal strains of Salmonella are a major cause of fatal bacteremia in Africa. Developing a vaccine requires an improved
understanding of the relevant mechanisms of protective immunity, and the mouse model of Salmonella infection is useful for
studying immunity to Salmonella in vivo. It is important to appreciate the similarities and differences between immunity to
Salmonella in mice and men. Ab is important for protection against nontyphoidal Salmonella in both species, and we have
previously found an important role for Ab in cell-free complement-mediated bactericidal activity against Salmonella in Africans.
It is unclear whether this modality of immunity is relevant in the mouse model. C57BL/6, BALB/c, and C3H mice immunized with
heat-killed Salmonella Typhimurium strains D23580 (African invasive strain) and SL1344 and live-attenuated strain SL3261
produced a Salmonella-specific Ab response. Sera from these mice deposited reduced levels of C3 on Salmonella compared with
human sera and were unable to kill both wild-type and galE2 rough mutant of D23580, indicating absent cell-free killing via
classical and alternative complement pathways. Supplementing immune mouse sera with human complement enabled killing of
Salmonella, whereas addition of human anti-Salmonella Ab to immune mouse sera had no effect. These findings indicate that
mouse serum cannot effect cell-free complement-dependent killing of Salmonella, because of the reduced mouse complement
ability to kill these bacteria compared with human complement. This difference in Ab-dependent immunity to Salmonella in mice
and men must be considered when applying findings from the mouse model of Salmonella disease and vaccination response to
man. The Journal of Immunology, 2011, 186: 2365–2371.
N
ontyphoidal Salmonella (NTS) strains, in particular Sal-
monella enterica serovar Typhimurium, are emerging as
a major cause of fatal bacteremia among African chil-
dren (1–3) and HIV-infected adults (1, 4, 5). The minimum in-
cidence of NTS bacteremia is 175 out of 100,000 in Kenyan
children under 5 y of age (3), and the case-fatality rate exceeds
20% (2, 6). Partly because of the requirement for blood-culturing
facilities in the diagnosis of NTS bacteremia (2), the scale of the
problem caused by this disease has been unappreciated until re-
cently, and currently no vaccine is available. Increasing levels of
antibiotic resistance among African strains of NTS (1) and the
rapid demise of many children with NTS once they present to
hospital indicate that a vaccine is urgently needed. An improved
knowledge of the relevant protective mechanisms of immunity
against Salmonella is required for the development of an effective
vaccine against NTS, and this involves complementary studies
with human tissues and animal models of salmonellosis. Because
S. Typhimurium causes invasive disease in the mouse, this animal
provides a useful model for the study of NTS infections in vivo.
Salmonellae are adapted to survive within macrophages (7). It
has long been appreciated from mouse studies (8, 9) and more
recently for studies of patients with rare primary immunodefi-
ciencies (10, 11) that cell-mediated immunity is important for
protection against invasive Salmonella disease. From studying
NTS bacteremia in Malawi, we have recently shown that NTS
bacteremia particularly affects African children between 4 mo and
2 y of age, the period in which Ab levels to NTS are low or absent
(12). Ab can potentially protect against Salmonella disease in
several ways. First, Ab can protect in a cell-independent manner
through complement-dependent bactericidal activity. Second, it
can protect through a cell-dependent mechanism involving the
oxidative burst by opsonizing bacteria for uptake and killing by
phagocytic cells. In our studies on African children, we have
found evidence for an important role for both bactericidal (12) and
opsonic Ab (13) in protecting against NTS. Other ways in which
Ab can protect against Salmonella disease include Ab-dependent
cellular cytotoxicity and blockade of uptake by cells in the gas-
trointestinal tract.
A second major challenge in developing a vaccine against NTS
for Africa is to identify the key molecular targets of the protective
immune response against Salmonella. Because much of the as-
sessment of vaccine candidates needs to be performed in vivo, for
which animal models of infection are required, it is important to
understand the similarities and differences between the immune
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responses to Salmonella in mice and men. Studies of Salmonella
infections in mice have shown that blood Ab titers correlate with
protection against Salmonella (14). Ab has been shown to be im-
portant for protecting innately susceptible Nramps mouse strains
(15, 16), such as C57BL/6 and BALB/c, both in adoptive transfer
studies (17, 18) and in studies in T cell-impaired or -deficient mice
(19, 20). Recently, studies in C57BL/6 mice have indicated that
the outer membrane proteins (19), in particular OmpD (20), are
promising targets for vaccine development. Ab has previously
been shown to have an important role in opsonizing Salmonella
for phagocytosis and cellular killing in C57BL/6 mice (21).
However, its ability to kill Salmonella using the cell-independent
complement-mediated mechanism described in Africans is un-
certain, particularly in view of the recognized limited activity of
mouse complement (22, 23).
To address this question, we studied the bactericidal capacity of
serum, Ab, and complement from C57BL/6, BALBc, and C3H
mice immunized with heat-killed S. Typhimurium strains D23580
and SL1344 and live-attenuated strain SL3261.
Materials and Methods
Salmonella
S. Typhimurium D23580 is an invasive African strain of NTS isolated from
a bacteremic girl aged 26 mo who was admitted to Queen Elizabeth
Central Hospital in Blantyre, Malawi, in 2004 (12, 24). This strain is
sensitive to killing by human adult serum, undergoing a 1–3 log10 kill over
a 3-h time course (see Salmonella killing assays below). It is representative
of .90% of NTS strains isolated from bacteremic individuals in Malawi
since 2002. A rough galE2 mutant of D23580 that has truncated LPS
lacking O-Ag polysaccharide has previously been described (12). SL1344
is a laboratory strain of S. Typhimurium that has been used in many ex-
perimental studies. Both strains have been sequenced by the Sanger Core
Sequencing Facility at the Wellcome Trust Sanger Institute (24, 25).
SL3261 is an attenuated mutant of S. Typhimurium SL1344 with a deleted
aroA gene and was kindly provided by B.A.D. Stocker. For immunizations,
Salmonellae were grown in Luria-Bertani media to log phase, washed
twice with PBS, and heat-killed as required at 72˚C for 1 h. No exogenous
adjuvants were used for immunizations.
Mice
Animal studies had ethical and home office approval. C57BL/6, BALBc,
and C3H mice were age and sex matched, housed in pathogen-free con-
ditions, and used between 6 and 12 wk of age. Mice immunized with heat-
killed Salmonellae were given 107 bacteria/animal via the i.p. route at
day 0, boosted with the same dose of heat-killed bacteria at day 14, and
exsanguinated at day 28 by cardiac puncture. Those immunized with live
Salmonellae were given 5 3 105 bacteria i.p. at day 0 and exsanguinated at
day 35. Blood was allowed to clot for 60 min, immediately separated, and
frozen to preserve complement function. Aliquots of serum were stored at
280˚C and not subjected to freeze-thaw cycles.
Materials
Unless otherwise stated, materials were from Sigma-Aldrich. Human sera
were from African adults with anti-Salmonella Ab or were sera deficient in
anti-Salmonella Ab. When required, serum was heat-inactivated at 56˚C
for 30 min.
Hemolytic classical pathway complement function assay
Washed rabbit erythrocytes were resuspended in complement fixation di-
luent (CFD) (Oxoid) at 2% (v/v) and sensitized by incubation for 30 min at
room temperature with a 1:500 final dilution in CFD of mouse anti-rabbit
erythrocyte antiserum. Sensitized erythrocytes were washed, resuspended at
1% in CFD, aliquoted into the wells of a 96-well plate (50 ml/well), and
incubated at 37˚C for 30 min with 50 ml dilutions of mouse serum in CFD.
Zero and 100% lysis controls were included in all assays. Plates were
centrifuged, and complement activity was assessed by hemoglobin release
(absorbance at 415 nm). Percentage lysis for individual wells was calcu-
lated using the following formula: percent lysis = (A415[test] 2A415[min])/
(A415[max] 2 A415[min]) 3 100.
Anti-Salmonella Ab assays and complement deposition assays
These were performed by flow cytometry as described previously (12).
Briefly, 5 ml S. Typhimurium D23580 in log-growth phase was mixed with
45 ml 10% serum for Ab determination or undiluted serum for complement
deposition (final Salmonella concentration 2 3 108/ml). FITC-conjugated
anti-mouse IgG and IgM Ab (Sigma-Aldrich) and FITC-conjugated anti-
C3c Ab that binds both human and mouse C3 (DakoCytomation) were
used for detection prior to FACS analysis on an FACSCalibur instrument
(BD Biosciences).
Salmonella serum bactericidal assays
These were performed as described previously (12). Briefly, 5 ml viable S.
Typhimurium D23580 in log-growth phase was added to 45 ml undiluted
serum (final Salmonella concentration 1 3 106 CFU/ml) and incubated at
37˚C with the number of viable Salmonellae determined after 45, 90, and
180 min. When mouse serum was supplemented with human Ab or
complement, the mouse serum was mixed at a 1:1 ratio with either heat-
inactivated human immune serum (as a source of anti-Salmonella Ab) or
human serum lacking anti-Salmonella Ab (as a source of exogenous
complement). When mixed with Ab-deficient human serum, mouse serum
was diluted in PBS in a 10-fold dilution series to determine the minimum
concentration that could still effect Salmonella killing.
Confocal microscopy
Salmonellae incubated in serum and labeled with FITC-conjugated anti-C3
were fixed with acetone on Superfrost Plus charged microscope sides
(Leica Microsystems), mounted in Prolong-Gold DAPI (Invitrogen), and
viewed under an oil immersion 1003 objective lens with an Axiovert
100M confocal microscope (Zeiss).
Statistical analysis
Comparison of groups was performed using the Student t test.
Results
Immunization of mice with heat-killed African S. Typhimurium
strain D23580 induces a switched Ab response
Groups of six C57BL/6, BALBc, and C3H mice were primed and
boosted with heat-killed African S. Typhimurium D23580 or PBS
(negative control groups). Another two groups of six C57BL/6
mice were either primed and boosted with heat-killed labora-
tory strain S. Typhimurium SL1344 or immunized with the live-
attenuated vaccine strains SL3261. At 28 and 35 d, mice were
exsanguinated and serum assessed for Ab response to Salmonella.
Whereas no anti-Salmonella Ab was detected in serum from the
control groups, all mice immunized with Salmonella except two
produced IgG and IgMAb to Salmonella (Fig. 1A, 1B). Serum from
the two mice in which the immunizations had failed was discarded.
Anti-Salmonella Ab titers were similar regardless of whether the
Ab assay was performed using S. Typhimurium D23580, SL1344,
or SL3261 (Supplemental Fig. 1). Sera prepared from the mice
were shown to have intact complement function as demonstrated
by lytic activity against sensitized rabbit erythrocytes using a he-
moglobin release assay to assess classical pathway complement
activity (Fig. 1C). This demonstrated that the processing and
storage of the mouse sera had not adversely affected the quality of
the complement in these sera.
Sera from S. Typhimurium-immunized mice lack bactericidal
activity against wild-type S. Typhimurium
We next tested serum from the immunized mice for ability to kill
viable S. Typhimurium D23580 in the log-growth phase. Our
previous work with serum from African children has shown that, in
the presence of specific IgG or IgM Ab, human serum is capable of
Ab-dependent complement-mediated killing of D23580 (12). De-
spite the presence of anti-Salmonella Ab, sera from both immu-
nized and unimmunized C57BL/6 (Fig. 2A), BALB/c (Fig. 2B), and
C3H (Fig. 2C) mice were unable to kill wild-type D23580 in vitro
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over a 3-h time course, regardless of the immunization strategy
used. The concentration of viable Salmonellae increased by .1
log10 in this period. In contrast, African adult serum effected a 2
log10 kill over 3 h (Fig. 2D). The lack of killing of Salmonellae by
sera from all groups of mice compared with the killing of Salmo-
nellae by human serum was highly significant (Student t test, p ,
0.0001). These findings could result from the Ab induced following
immunization of mice with D23580 or SL1344 lacking inherent
bactericidal activity. This could occur if the Ab is unable to facil-
itate the deposition of complement membrane attack complex at
the Salmonella outer membrane. Alternatively, mouse complement
per se may lack the necessary bactericidal activity to kill Salmo-
nella, as suggested by early experiments on mouse complement
(22, 23).
Sera from S. Typhimurium-immunized mice also lack
bactericidal activity mediated through the alternative pathway
of complement against a galE2 rough mutant of
S. Typhimurium
To explore these possibilities, we repeated the serum killing assays
using a galE2 knockout mutant of D23580 that is unable to
synthesize the O-Ag polysaccharide of LPS (12). Previously, we
showed that this rough mutant is susceptible to killing by serum
from African children lacking Salmonella-specific Ab via alter-
native pathway complement activity (12). There was no difference
between the results from these experiments and those using wild-
type D23580. No Salmonella killing occurred with sera from
C57BL/6, BALB/c, and C3H mice immunized with D23580,
SL1344, and SL3261 or from unimmunized mice (Fig. 3A–C). By
contrast, African child serum lacking anti-Salmonella Ab was able
to effect a 3 log10 kill of S. Typhimurium D23580 (Fig. 3D).
Again, the lack of killing of Salmonellae by sera from all three
FIGURE 1. Ab response and classical pathway complement activity in
mouse sera following immunization with African and laboratory strains of
S. Typhimurium. Titers of anti-Salmonella Ab at 28 d after i.p. immuni-
zation with two doses of heat-killed Salmonellae (D23580 and SL1344)
and at 35 d after i.p. immunization with live-attenuated Salmonellae
(SL3261) and unimmunized (Control). Immunizations for heat-killed Sal-
monellae were with 107 heat-killed S. Typhimurium D23580 (African
strain) and SL1344 (laboratory strain). Immunizations for live-attenuated
SL3261 were with 5 3 105 Salmonellae. Groups of BALB/c, C3H, and
C57BL/6 mice received D23580 immunizations, with groups of C57BL/6
mice also receiving SL1344 and SL3261. A, IgG. B, IgM. Ab measured by
flow cytometric analysis of Ab-binding to fixed S. Typhimurium D23580.
Each point represents serum from one mouse. Horizontal bars indicate
median values. C, Lytic activity of mouse sera against rabbit erythrocytes
sensitized with mouse anti-rabbit erythrocyte antiserum, measured using
a hemoglobin release assay. Fresh C57BL/6 mice sera (diamonds); frozen
freshly thawed mice sera: BALB/c (inverted triangles), C3H (triangles),
and C57BL/6 (filled circles); and heat-inactivated C57BL/6 sera (empty
circles). Data are means of experiments with sera from six mice 6 SD.
FIGURE 2. Absence of killing of African wild-type S. Typhimurium
D23580 by mouse sera compared with human sera. In vitro serum bacte-
ricidal assay with 106 Salmonellae/ml at 45, 90, and 180 min time points
using sera from C57BL/6 (A), BALB/c (B), or C3H mice (C) immunized
with D23580 (squares) and unimmunized mice (circles). A also shows data
using sera from C57BL/6 mice immunized with SL1344 (triangles) and
SL3261 (inverted triangles). Data are means of experiments with sera from
three mice 6 SD. D, Killing of wild-type D23580 by control serum from
an African adult. Lack of killing of Salmonellae by sera from all groups of
mice compared with the killing of Salmonellae by human serum was
highly significant (Student t test, p , 0.0001).
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groups of mice compared with the killing by human serum was
highly significant (Student t test, p , 0.0001). These findings
strongly suggest that the lack of bactericidal activity is the result
of comparatively limited mouse complement function against
Salmonella, regardless of mouse species tested, the deficiency
affecting both classical (Ab-dependent) and alternative pathways.
Sera from S. Typhimurium-immunized mice deposit reduced
levels of C3 complement on Salmonella compared with human
sera
Because cleavage of C3 and deposition of C3b is the central event
in all complement activating pathways, we next looked at de-
position of C3 on the surface of wild-type S. Typhimurium D23580
by sera from mice immunized with Salmonellae using flow
cytometry. Whereas sera from unimmunized mice were unable to
deposit C3 on Salmonella, sera from C57BL/6, BALB/c, and C3H
mice immunized with D23580, SL1344, and SL3261 were able to
deposit C3 on the surface of D23580, though ∼1 log10 less than
the amount of C3 deposited by immune African serum (Student t
test, p , 0.0001) (Fig. 4A). Using confocal microscopy, qualita-
tively less C3 deposition was visualized on Salmonellae incubated
with mouse serum compared with human serum (Fig. 4B). These
data therefore indicate deficiency in C3 deposition on Salmonella
by mouse serum via the classical pathway relative to human im-
mune serum, but do not exclude the possibility of poor activity in
the terminal pathway of complement.
Mouse sera supplemented with human bactericidal
anti-Salmonella Ab do not kill S. Typhimurium D23580
To check whether the absence of killing of Salmonellae by mouse
serum was due to a lack of bactericidal Ab, we supplemented sera
from unimmunized C57BL/6, BALB/c, and C3H mice with heat-
inactivated serum from African adults containing Ab to Salmo-
nella. We had previously shown that sera from African children
that lack Ab to Salmonella become bactericidal when exogenous
anti-Salmonella Ab is added (12). Addition of human Ab did not
correct the inability of mouse sera to kill D23580, the absence of
killing of Salmonella being highly significant compared with the
FIGURE 3. Absence of killing of African rough galE2 mutant of
S. Typhimurium D23580 by mouse sera compared with human sera.
In vitro serum bactericidal assay with 106 Salmonellae/ml at 45, 90, and
180 min time points using sera from C57BL/6 (A), BALB/c (B), or C3H
mice (C) immunized with D23580 (squares) and unimmunized mice
(circles). A also shows data from C57BL/6 mice immunized with SL1344
(triangles) and SL3261 (inverted triangles). Data are means of experiments
with sera from three mice 6 SD. D, Killing of wild-type D23580 by
control serum from an African adult. Lack of killing of Salmonellae by
sera from all groups of mice compared with the killing of Salmonellae by
human serum was highly significant (Student t test, p , 0.0001).
FIGURE 4. Deposition of complement C3 on S. Typhimurium D23580
by mouse sera compared with human sera. A, Titers of C3 deposited on
S. Typhimurium D23580 following incubation in sera from BALB/c, C3H,
and C57BL/6 mice immunized with S. Typhimurium D23580, SL1344,
and SL3261 or unimmunized mice (Control) and immune human serum
(Immune) 6 heat inactivation (HI Immune) from a healthy African adult
and Ab-deficient human serum (Ab-def). Each point corresponds to one
experiment. Lines show median values for each group. Difference between
C3 deposition with immunized mice sera compared with immune human
sera was significant (Student t test, p , 0.0001). B, Confocal microscopy
imaging of C3 deposited on Salmonellae using FITC-conjugated anti-C3
Ab (green) following incubation in mouse and human sera. Salmonellae
are visualized using DAPI (blue). Human panels, Immune serum (Immune)
and heat-inactivated serum (Control). Mouse panels, Serum from C57BL/6
mice immunized with heat-killed D23580 (Immune) and unimmunized
(Control). PBS negative panels, Salmonellae incubated in PBS. All images
acquired with identical confocal microscope settings. Scale bars, 5 mm.
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killing by immune human serum (t test, p , 0.0001) (Fig. 5). This
finding suggests that lack of killing of Salmonellae by immune
mouse serum is not due to a lack of Ab function, further impli-
cating limited mouse complement function against Salmonella as
the reason for absent bactericidal activity.
Immune mouse sera supplemented with human complement
can kill S. Typhimurium D23580
To confirm that impaired mouse complement function rather than
impaired Ab function was the reason for absent killing of Sal-
monellae, we supplemented C57BL/6, BALB/c, and C3H mouse
serum with human complement by mixing mouse serum with
human serum lacking Ab to Salmonella. Mouse sera could now
kill and/or prevent the growth of Salmonella at 10- or 100-fold
dilutions with PBS (Fig. 6). This was statistically significant
compared with both the lack of killing by the anti-Salmonella Ab-
deficient human serum alone and immunized mouse serum alone
(Student t test, p , 0.0001 for serum from mice immunized with
heat-killed bacteria, and p, 0.05 for serum from mice immunized
with live-attenuated bacteria). This experiment confirms that ab-
sent killing of Salmonellae by mouse sera is the result of limited
mouse complement function against Salmonella and that the
mouse Ab against Salmonella has potential bactericidal activity
leading to complement-mediated killing of Salmonella, provided
a suitable source of exogenous complement is available.
Discussion
The main finding from this study is that although C57BL/6, BALB/
c, and C3H mice mount both an IgG and IgM Ab response to heat-
inactivated African invasive S. Typhimurium strain D23580 and
laboratory strain SL1344 and to live-attenuated S. Typhimurium
strain SL3261, serum from immunized mice lacks bactericidal
activity against Salmonella. The lack of killing appears to be due
to a lack of specific complement activity against Salmonella, be-
cause the serum is able to lyse erythrocytes in a standard hemo-
lytic assay. This contrasts with the 1–3 log10 killing of D23580,
which is effected by African adult and child serum containing
anti-Salmonella Ab. Serum from African children does not kill
Salmonella when it lacks specific Ab, and this was the basis for
previously describing bactericidal Ab in Africans as an effector of
humoral immunity against NTS (12).
S. Typhimurium D23580 was chosen for this study because it is
a typical invasive strain of NTS from Africa, is sensitive to killing
in human serum by bactericidal Ab in the presence of comple-
ment, and has been sequenced at the Wellcome Trust Sanger In-
stitute (24, 25). Experiments using S. Typhimurium laboratory
diarrhogenic strains SL1344 and SL3261 were included to dem-
onstrate that the lack of bactericidal activity was not restricted to
African invasive NTS and was independent of whether the im-
munization was with heat-killed wild-type or live-attenuated Sal-
monellae. C57BL/6 mice were chosen because mechanisms of
immunity to Salmonella have been studied extensively in these
mice (19–21), and the Ab response to vaccination with S. Typhi-
murium in C57BL/6 mice has been shown to protect against sub-
sequent infection with S. Typhimurium (19, 20). The experiments
were also performed with BALB/c and C3H mice to show that
FIGURE 5. Absence of killing of S. Typhimurium D23580 following
supplementation of mouse sera with human anti-Salmonella Ab. In vitro
serum bactericidal assay with 106 Salmonellae/ml at 45, 90, and 180
min time points using sera from C57BL/6 (A), BALB/c (B), or C3H-
unimmunized (C) mice all supplemented with heat-inactivated immune
human serum containing both anti-Salmonella IgG and IgM. Data are
means of experiments with sera from three mice6 SD. D, Killing of wild-
type D23580 by immune human serum (diamonds) and Ab-deficient hu-
man serum supplemented with heat-inactivated immune human serum
(diamonds with dashed line). Lack of killing by heat-inactivated human
control serum alone (hollow diamonds). The lack of killing of Salmonellae
by sera from all groups of mice compared with the killing of Salmonella by
human serum was highly significant (Student t test, p , 0.0001).
FIGURE 6. Killing of S. Typhimurium D23580 following supplemen-
tation of immune mouse sera with human complement. In vitro serum
bactericidal assay with 106 Salmonellae/ml at 45, 90, and 180 min time
points using sera from C57BL/6 (A), BALB/c (B), or C3H (C) mice im-
munized with D23580 (squares), SL1344 (triangles), and SL3261 (inverted
triangles), all supplemented with human complement. Sera from C57BL/6
and BALB/c mice immunized with heat-killed bacteria killed at a dilution
of 1:100. Sera from C3H bacteria immunized with heat-killed bacteria and
C57BL/6 mice immunized with live bacteria killed/prevented growth of
Salmonella at a dilution of 1:10. Data are means of experiments with sera
from three mice 6 SD. D, Lack of killing of wild-type D23580 by Ab-
deficient human serum (hollow diamonds), killing by control immune
human serum (diamonds), and Ab-deficient human serum supplemented
with heat-inactivated immune human serum as a source of Ab (diamonds
with dashed line). The killing of Salmonella by each mouse sera supple-
mented with human complement compared with the lack of killing of by
corresponding mouse serum alone (shown in Fig. 2) was statistically sig-
nificant (Student t test, p , 0.0001 for immunizations with heat-killed
bacteria, p , 0.05 for immunizations with live bacteria).
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deficiency in serum bactericidal activity in Salmonella is not re-
stricted to one inbred strain of mice. Our findings suggest that the
protective effect of mouse anti-Salmonella Ab is not mediated by
cell-independent bactericidal activity.
The galE2 rough mutant of S. Typhimurium D23580 is sensi-
tive to killing via the alternative pathway of complement by hu-
man serum lacking anti-Salmonella Ab (12). Absent killing of the
galE2 mutant by all mouse sera therefore implicates limited
complement function against Salmonella rather than absence of
bactericidal Ab itself as the reason for lack of killing with wild-type
D23580. Limited complement function in mouse serum was first
described .60 y ago (22). Indeed, our finding that serum from
immunized mice supplemented with human complement can effect
cell-free killing indicates that the Ab generated following immu-
nization with D23580, SL1344, and SL3261 is capable of direct-
ing complement-deposition to the Salmonella surface at locations
that enable membrane attack complex to kill the bacteria (12).
Our data suggest that complement from C57BL/6, BALB/c, and
C3H mice is defective in killing D23580 at multiple points in the
complement pathway. Because we have previously shown that
deposition of complement and killing of wild-type D23580 is Ab
dependent and does not proceed via alternative or mannose-binding
lectin pathways (12), the lower titers of C3 deposition on Sal-
monella seen with serum from immunized mice compared with
human serum indicate that classical pathway activity is reduced in
relation to that in human serum. The lack of killing of the D23580
galE2 mutant also indicates limited alternative pathway activity
and/or terminal pathway activity.
Nevertheless, functional classical pathway complement activity
was detected against sensitized rabbit erythrocytes in the hemo-
globin release assay used. We employed this assay to ensure that
the lack of bactericidal complement function against Salmonella
was not merely an artifact of suboptimal preparation and storage
of sera. These findings suggest that differences exist between
the susceptibility of erythrocytes and Salmonella to the lytic/
bactericidal effects of mouse complement, with Salmonella being
more resistant than erythrocytes. Complement that does not insert
into the Salmonella outer membrane can be shed from the surface
of S. Minnesota (26, 27), and various molecules on the Salmonella
surface, including those encoded by rck (28), traT (29), and pgtE
(30), confer some degree of resistance to complement-mediated
killing.
Such mechanisms are likely to raise the threshold of complement
deposition required for bactericidal activity against Salmonella
to proceed. Previously, we found that the rck gene is encoded in
the virulence plasmid of D23580 and that C9 is necessary for se-
rum bactericidal activity against D23580 (12). In contrast, several
studies on complement-mediated hemolysis have demonstrated
that this can proceed in the absence of C9 by limited perturbation
of the membrane by C8 (31–33).
With mouse complement lacking bactericidal activity against
Salmonella, it is likely that the protective effect of anti-Salmonella
Ab in C57BL/6, BALB/c, and C3H mice is mediated by opsoni-
zation facilitating phagocytosis, respiratory burst, and intracellular
killing of Salmonella by neutrophils, monocytes, and macro-
phages. The importance of anti-Salmonella Ab for these modali-
ties of cell-mediated immunity has been previously demonstrated
using serum and cells from C57BL/6 mice (21). Other work in
men and mice has indicated that opsonization of Salmonella with
C3 is required for optimal intracellular killing (13, 34–36), and
work with C1q-deficient mice has shown a role for the classical
pathway of complement in protecting against S. Typhimurium
(37). If C3 deposition on Salmonella is a requirement for such
killing, this suggests that the threshold level of C3 deposition
required for opsonization leading to intracellular killing of Sal-
monella is lower than the level required for bactericidal terminal
pathway complement activity.
Although Salmonellae are facultative intracellular bacteria, we
have previously identified that the high case-fatality rate among
young African children is associated with extracellular bacterial
growth unchecked by bactericidal Ab (12). Because our findings
indicate a lack of bactericidal activity in mouse serum against
Salmonella, this could contribute to the sensitivity of C57BL/6,
BALB/c, and C3H mice to infection with S. Typhimurium. Dif-
ferent mouse strains differ in their ability to handle infection with
Salmonella, and this may be due to a variety of reasons, including
differences in innate Nramp polymorphism-mediated genetic sus-
ceptibility of each strain to Salmonella and complement function.
Variations in complement function between strains can be complex.
For example, A/J mice are more effective at depositing C3b on
Salmonella than C57BL/6 mice but are deficient in the C5 com-
ponent of complement, hence preventing complement-mediated
bactericidal activity against Salmonella in such mice (36).
A positive outcome from the current study is the clear dem-
onstration of the bactericidal potential of Ab produced in mice
following immunization with Salmonella provided suitable ex-
ogenous complement is provided. We have been able to use this
finding to demonstrate that porins Omp F, C, and D are targets of
bactericidal Ab by immunizing mice with these porins and per-
forming bactericidal assays supplemented with human comple-
ment (38). Furthermore, this study suggests that the mouse model
underestimates the potency of Ab in protecting against Salmonella
infections. A consequence of this is that if immunizations with an
Ag offer Ab-mediated protection in the mouse, they may be more
likely to offer protection in humans.
In conclusion, Ab-mediated immunity against NTS in C57BL/6,
BALB/c, and C3Hmice and African children involves both distinct
and shared immunological mechanisms. Bactericidal Ab is able
to mediate cell-free complement-mediated killing of extracellular
bacteria in children, whereas Ab in mice appears incapable of this
modality of immunity. In contrast, both human and mouse Ab are
able to protect against Salmonella via opsonization in conjunction
with cell-mediated mechanisms.
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In the second to last sentence of the Abstract, the word “affect” should be “effect.” The correct sentence is: “These findings indicate that
mouse serum cannot effect cell-free complement-dependent killing of Salmonella, because of the reduced mouse complement ability to
kill these bacteria compared with human complement.”
In the Results section, in the second paragraph, line 11, the word “affected” should be “effected”. The correct sentence is: “In contrast,
African adult serum effected a 2 log10 kill over 3 h (Fig. 2D).”
In the Discussion section, in the first paragraph, line 10, “affected” should be “effected”. The correct sentence is: “This contrasts with
the 1–3 log10 killing of D23580, which is effected by African adult and child serum containing anti-Salmonella Ab.”
In the Discussion section, in the third paragraph, line 9, “affect” should be “effect.” The correct sentence is: “Indeed, our finding that
serum from immunized mice supplemented with human complement can effect cell-free killing indicates that the Ab generated following
immunization with D23580, SL1344, and SL3261 is capable of directing complement-deposition to the Salmonella surface at locations
that enable membrane attack complex to kill the bacteria (12).”
All instances of “Salmonella typhimurium” and “S. typhimurium” in the article should be changed to “Salmonella Typhimurium” and
“S. Typhimurium.” This change was requested by the authors at proof stage and was not made in production, with the exception of the first
page of the printed article (page 2365).
All of the above errors have been corrected in the online version, which now differs from the print version as originally published.
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